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1. INTRODUCTION 
Siddha System of Medicine is belived to be originated from lord shiva the 
supreme god of Tamil and also he is considered to be the principal siddhar.  Lord 
shiva preached this grateful science to shakthi, the goddess and the nanthi from them 
the siddha system was made available to common people by siddhars. 
Siddhars where those who were not only a physican but also a social 
reformers. They were well versed in the filed of medicine, natural science, alchemy, 
astrology etc., They give many excellent medicine which cure many non cureable 
diseases like diabetes, TB, HIV & Cancer. Siddhars were the persons who attained 
siddhi, that perfection and who had overcome death through these siddha Medicines.  
The truth is that throughout life we seem to swim in a sea of carcinogens and it 
is more by good fortune than by good management that some of us escape to die from 
other causes.                                                                                                                                                                                
- William boyd 
As rights said in this modern world the air we breathe, the food we eat and our 
life styles are all carcinogenic and are ultimately leading us by one way or other to 
dreadful disease cancer.Everyone in this world rich or poor, men or   woman, young 
or old, and even animals or prone to  affect by this disease and that could be 
prophylatically given against this disease. Also there is no medicine in the world that 
good completely cure this disease. 
The Currently available treatments for Cancer viz  Radiation, chemotherapy, 
Surgery are all of very Limited Value. The Surgical Procedures are useful only is very 
early stage and it is miserable that the disease is often detected in advanced stage.  
The Radiation technique and chemotherapy are useful only to prolong the survival 
period. 
In the pathetic Situation when scientist all over the world struggling to 
formulate a new medicine to combat the disease. In our Siddha system of medicine 
we had thousands of medicine with the indications to cure the disease. 
I selected yoniputru (cervix Cancer) as my dissertation topic because it is the 
most frequent of all genital tract cancer in women. 
Among various medicine in Siddha literature. I selected Rasa karpoora Kuligai 
as my dissertation  drug. Which Contains Mercurial Compounds (Pooram) that are 
used to cure almost all the diseases in Siddha. 
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We should be very careful while using Parpam, Chendooram, Kattu, 
Kalanugu, Chunnam, Guru, Kuligai etc. because these are prepared from metals, 
poisonous metalic salts. So, preparation of this type of internal medicine required high 
skilled work called suddhi. It is the important procedure which is meant purification 
of the raw drugs; it is the first step in medicine preparation.  
If the prepare medicine by using raw materials without suddhi It will produce 
immediate dangerous ill effects are delayed toxicity or both. So siddhars have 
concentrated very much in suddhi and recommended to many methods for each drug 
to purify them. 
Eventhough we are prepared the drugs after purification some times they 
produce some adverse effects. It may be due to improper purification, preparation or 
dosage. 
So majority of drugs prepared from mercurial substances are toxic unless other 
wise they are prove as safe by universely accepted toxicological screening methods. 
So it is essential to study about a drug regarding at what extend it is safe. 
As we are having advanced medical technology now a days there is a long gap 
between recent findings and traditional belives. It is time for us to establish our siddha 
system by breaking this interruption. So it is our duty to introduce the drug 
standardisation in universely acceptable method. 
A study on cancer is a life long work and with limited facilites and limited 
time this dissertation work is only a preliminary study, when compared to those well 
equipped brilliant team of researchers and scientist all over   the world spending 
crores of money and Conducting life long trails. This work of mine is simply a drop 
ina mighty ocean. But I have tried my best with all sincerity and dedication to study 
the action of the drug on the disease.  
By keeping all these facts in mine I enter in to this dissertation. 
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2.AIM& OBJECTIVES OF THE STUDY 
AIM:  
The aim of this present study is to scientifically validate traditional siddha 
medicineRasa karpoora kuligaifor its Anti-cancer, Anti-oxidant, Anti-inflammatory 
activities and also access safety profile of these drug according to OECD guidelines.  
OBJECTIVES:  
 The prime objective of these studies to collect various literatures which includes 
traditional siddha literatures basic modern science aspect of the test drug and the 
diseased view.  
 To prepare the drug according to siddha classical literature illustrations to 
standardize the drug by appropriate physico-chemical analysis.  
 To analyse the drug chemically for reduction of metals, minerals to access the safety 
profile of the drug by acute and sub-acute oral toxicity profiles of Rasa karpoora 
kuligai according to OECD guidelines.  
 To evaluate the anti-cancer activity of the test drug Rasa karpoora kuligai by invitro 
HeLa cell line method.  
 To access anti-oxidant activities of the test drug Rasa karpoora kuligai by using 
invitro dpph radical scavenging method. 
 To enumerate the anti-inflammatory activity of test drug Rasa karpoora kuligai by 
using carrageenan-induced paw edema method.  
 To evaluate exact bio-chemical content of Rasa karpoora kuligai by using various 
standard protocol. 
 To evaluate the mineral content of Rasa karpoora kuligai by various instrumental 
analysis.  
 To evaluate the efficacy of the drug Rasa karpoora kuligai by various analysis.  
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3. REVIEW OF THE LITERATURE 
3.1. RASA KARPOORAM (இரச கªர) 
3.1.1 GUNAPADAM ASPECT 
Rasakarpooram does not find a place in the list of 64 padanas but is 
considered as one among them by the medical practitioners. It’s prepared by the 
combination of rasam and salt. 
 
SYNONYMS: 
“¢ƫtைககைளெயலியைடvசனªர| 
தyவடதாலிநtகிªமதா|” 
- நாமதபநிகz 29 
 Durgai 
 Kalai 
 Aellidai 
 Sani 
 Pooram 
 Thettu 
 Vidathaali 
 Nacki 
 Buddimaatham  
 
RASA KARPOORA VAIPU MURAI: (Method of preparation) 
FIRST METHOD: 
 “தாென}றகªரெமா}²ெசாேவ} 
  சாதகமாதெரz£tகி 
 வாென}றசyt¬}²ப­~ைப 
  வளமாகெபா{திyநேவேக¶ 
 ேதென}றெசuக£காபதானy 
  திரமாகtள{ததிேலதவy 
 ஏென}றம²சyகவ{¢¬ 
  இயபாகெவ¸சீைலமz ெசேய 
 மzெச¢ெதாz¡²கைகய~பா 
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  வாகாக¬{த­ெமƬ{¢ைம|தா 
 மzெசதேமசytேளேக¶ 
  வாகாகஉைர{தி¯tெவைளெமத{ 
 மzெசதநªரuழாயைவ{¢ 
  வாகாகபணவைடதா}£tகிtெகாz” 
- Agasthiyar paripulanam 400. 
2 palam sootham placed in the mud pot in between 3 padi culinary 
salt(Nacl) and brick stone powder.Close the pot with another mud pot and seal with 7 
mud seelai . It is burnt for 90 kadikai after it is colled pooram is found deposited on 
the upper pot and the same is collected. 
SECOND METHOD: 
மயtக«²மிரதகªரxெசாேவா 
வயாதிெயலா|தƫ|¢ேபாவƬைசேக¶ 
மயtக«றஉ~©¶tvெசuக£¶ 
       வƬைசெபறவழி{ெத{¢ைவ{திடாேய    
ைவ{தேதாƫஇ¯வைக­|£ளாயாy 
ைம|தேனசytபாதிந­ 
ைவ{திவாஅதிைகையvதம~பா 
வாராடாகழxப{¢மாறம}றி 
ைவ{தuேகைகவாயெபா­மிy 
ம²சyெகாzyவாைய¬ 
ைவ{¢நேய¸சீைலமz ªசி 
     மாயபதªசி{¢அ~பேலறி 
அ~ேபறிகமலவ}னதின|தாெனா}² 
   அத}பறகடாtகின­|தா}¬}² 
எƬ{தாறிெய{¢~பாƫசyேமேல 
   ஏறிநிகªரஎ{¢ைவ{¢ 
10 kalanjuof sootham placed it mud pot in between the well powdered 
culinary salt and brickstone powder close the mud pot with 7mud seelai.then burnt it 
as deepackini kamalackini and kaadackini for 3 days respectively after it is cooled the 
pooram is found deposited on the upper pot and and the same is collected. 
THIRD METHOD: 
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Sulfur 67.2gm is melted in mud pot and mercuery 336gm is added to it and 
kinded well and there forms ablack colourd powder (kajali). Brickstone powder is 
placed up to half of the level of a pot culinary salt (Nacl) 650 gm is placed over it . 
Mercury sulfer camphor is placed over the salt and sealed with mud paste cloth . It 
burnt for 12 hour with kadackini after it is colled the mercurous chloride is found 
deposited on the upper pot and the same is collected. 
PROPERTIES: 
Colour  - White 
Appearance - Heavywhite rhombic crystals 
Potency - Hot 
Taste  - Salty, Pungent 
ACTION: 
 Laxative 
 Tonic 
 Antiseptic 
 Diuretic 
It is also an after excessive bile producer. 
 
THERAPEUTICAL EFFECTS: 
“இைடவாதைலெயƬைல}ம| 
ெதாைடவாைழவாதமாxேசாண – யைடயாேதா 
ெவாtரசகƫ~ªரெமா}ேறயனெவா¯த 
இtெவல{ேத¸நாள “. 
 “சசிவ}னக¯~ªர{தி 
    சாதி{தகயxவாச 
பசிகலிதாபேசாப 
    பº{திரபளைவட 
வசித¯கிராணேயா 
    வளரதிசாரேமக 
இசித¯மிசிºைல 
    யைவபலேராகேபாேம”. 
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 “திரzடவாதuடவாத 
த¯xச|நிபதி}¬}² 
ம¯zேட{¢மைரயா~© 
மzைடvைலகபாலவ 
பரuகிvைலபகிர|தி 
பtகைலயைவ«தேபா 
இ¯zடேமனெபா}னறமா 
இ¢ேவகபஇயபேர”. 
 
When calomel is taken along with jaggery for seven days, 
  It cures various types of throbbling pains,  
 Throbbling pain in the lumbar region, 
 Burning sensation, 
 Ulcer due to disorders of vatha humours, 
 Hepatomegaly,  
 Pyrexia, 
 Jaundice, 
 Basillary dysentery, 
 Dropsy, 
 Chronic ulcer, 
 Venereal diseases, 
 Indigestion, 
 Vomiting, 
 Diarrhoea, 
 Worm infestation, 
 Rheumatism, 
 Itching, 
 Constipation, 
 Scabies,etc., 
 
It is also effective in the treatment of head ache as explaind in the above tamil verses. 
In siddha system of medicine his compare to sanjeevi because it cures hard disease 
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like syphilis(kiranthi), uterine cancer(allgul putru), uterine ulcer(allgul ranam) and 
chronic non-healing ulcers. 
- AVN 4th vol  
PURIFICATION OF CALOMEL: 
FIRST METHOD: 
The poultice made of betel leaf(piper betel) and pepper (piper nigram) each 
8.75gm,is taken and dissolved in 1.3 litre of water calomel 35gm and tied with a cloth 
and immersed in  the liquid from the crops bar and heated. After the water is reduced 
to  ¾  of its volume the calomel is taken out washed with water and dried to get it in 
purified form. 
SECOND METHOD: 
Calomel 35 gm is consolidified in mother’s milk for 3 hours and again it is 
consolidified in garlic oil(thailam) for 9 hours.  It is taken out as purified. 
THIRD METHOD: 
Before mixing calomel in electuraries, it is consolidified with the juice of 
mukia madraspatana (musumusukku) and washed 
OTHER CANCER MEDICINES WHICH CONTAIN RASA KARPOORAM AS 
CHIEF INGREDIENT: 
1. CHANDA MAARUTHA CHENDOORAM: 
Dosage    :  ½ - 1 kundri 
Adjuvent    :   palm jaggary, tripala legium, panjadepakkini  
legium. 
Indication   :  Aruvagai putru (six types of cancer) 
Pavuthiram (fistula) 
Paarisavaayu (hemiplegia) 
        Mugavadham (facial palsy) 
2. VAAYU MAATHIRAI: 
Dosage   :   ½-1 maatirai 
Adjuvent   :  Palm jaggary, sukku paste. 
Indication   :   Uterine cancer (Allgul putru) 
        Penial cancer (Linga putru) 
        Necrotic ulcer (Ali ranam) 
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3. CHITHIRAMOOLA KULIGAI: 
Dosage  :  1 Melagu 
Adjuvent  :  Palm jiggery 
Indication  :  Uterine cancer (Yoni putru),  
Penile cancer (Linga putru),  
8 types of ulcers (Gunmam).      
4. KOOROSANAI  MELEGU: 
Dosage   :  3-5 kundri 
Adjuvantent   :  Sugar, palm jiggery 
Indication   :   Uterine cancer (allkul putru) 
Syphilis (kiranthi) 
Amenorrhoea (soodaka kattu) 
5. POORA KATTU 
Dosage   :  1-4 rice weight 
Adjuvantent  :  parangipattai legium, vaalmilaggu legium. 
Indication  :  Uterine cancer (allgul putru) 
Syphilis (kiranthi nooi) 
Urinary bladder ulcer (neerpai ranam) 
6. VETTAI MELEGU: 
Dosage  :  1/2 – 1 kundri 
Adjuvantent  :  palm jiggery, butter 
Indication  :  vettai (venelial diseases) 
Aan kurri pan (penear ulcer) 
Neerthaarai pun (ureter ulcer) 
7.  POORA CHUNNAM 
8.  CHITTATHE ENNAI 
9.  NAVA KIRAGA ENNAI  
10. VACHIRA KANDI MATUIRAI 
11. SHANMUGA CHENDOORAM 
12. PANJASOOTHA MELEGU 
13. KARPOORA MATHIRAI 
14. OONAN SUDAR THAILAM 
15. NAVA PAASAANA THILAM 
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SIGNS AND SYMPTOMS OF CALOMEL POISONING: 
Multiple red boils may appear on the face, ache formation, ulcers in the chest, 
mouth and tongue diarrhoea and dysentery, scrotal swelling and ulcer in the uvula.   
ANTIDOTE FOR POISONING: 
Nilapanai kilangu (curculigo orchides)         -  8.75gm 
Vallarai ver (centella asiatica root)             -  8.75gm 
Ponnankanni ver (alternatheria sessiles)       -  8.75gm 
Kanduparangi ver (clerodendrumserratum)   -  8.75gm  
All the above ingredients are mixed and boiled to make a decoction.  This 
decoction is used twice a day for two or three weeks with suitable diet restrictions. 
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3.1.2 GEOLOGICAL ASPECT 
MERCURY SUBCHLORIDE: 
 Mercury sub chloride is a chemical compound with the formula Hg2cl2. Also 
known as calomel (a mineral form rarely found in nature) 
 
IUPAC name   :   Dimercury dichloride 
Other name    :   Mercurous chloride 
Calomel 
Horn mercury 
Mercury (I) chloride 
Chemical formula  :  Hg2cl2 
Molar mass    :   472.09 g/mol 
Appearance    :   Heavywhite rhombic crystals 
Density    :   7.150 g/cm3 
Melting point    :   525°c 
Boiling point    :   383 °c 
Solubility in water   :   0.2 mg/100ml 
Solubility    :   Insoluble in ethanol, ether 
Refractive index   :   1.973 
LD50 median dose   :   210 mg/kg (rat, oral) 
 
OCCURRENCE: 
 Haria,  
 Obermoscuel,  
 Herowithz in Bavia and  
 Armaden in spain  
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PREPARATION OF MERCUROUS CHLORIDE:      
It is the most important mercurous compound.  In nature it occur as horn quick 
silver. It is prepared by 
1. HgSo4 + 2Nacl +Hg → Hg2cl2 + Na2So4 
Subliming a mixture of mercuric sulphate, mercury and sodium chloride in 
iron pot 
2.  Hgcl2 + Hg
∆
→Hg2cl2 
By heating an intimate mixture of Hg2cl2 and Hg in appropriate mixture 
proportions in iron pot. 
3.  Hg2 (NO3) + Nacl →Hg2cl2 + 2 NaNo3 
Hg2 (NO3) + 2Hcl →Hg2cl2 + 2HNO3 
By adding a soluble chloride, Eg  : Nacl or dill Hcl to the solution of  
Hg(NO3). 
4.  2Hgcl2 + 2H2O + SO2→Hg2cl2 + 2Hcl + 2H2SO4 
By reducing Hgcl2 solution with SO2 
ACTION: 
 Cathartic 
 Alterative 
 Diuretic  
 Antiseptic  
 Anthelmentic. 
INTERNAL USES: 
 Constipation,  
 Cholera,  
 Dysentery,  
 Cardiacdropsy, 
 Pleurisy,  
 Malign fever 
 Malaria,  
 Syphilis, 
 Gout, 
 Worms, 
 Cholelithiasis, 
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 Mitral insufficiency, 
 Eclampsia,  
 Gravidorum. 
EXTERNAL USES: 
 Small pox pitting, 
 Pruritus, 
 Diphtheria,  
 Syphilitic ulcer, 
 Myiasis, 
 Membraue croap, 
 Condylomata warts. 
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3.1.3 LATERAL RESEARCH 
Calomel was a mercurial compound used extencively by both union 
confederate doctors to treat wide variety of medical conditions. It came in two main 
forums. “Blue Pills” contained a mixture of mercury rose wate, licorice, powedered 
rose, honey and sugar. “Blue Mass” was a lump of Mercurous chloride from which 
dispensing doctors pinched of a place. Doses were never standard. 
In 19th centaury doctors feared constipation and dispensing calomel was one 
of the main methods of keeping the bowl open. However, strangely enough, calomel 
was also given to treat diarrhoea and dysentery. Many physicians seemed unaware 
that the doses of calomel and a related compound, tartar emetic, often caused worse 
problems that the original conditions. 
The large and frequent doses of mercury compounds cause excessive 
salivation often a pint to a quart a day. Many patients receiving these “heroic” doses, 
suffered from mercurial gangrene death of cheek and mouth tissue that often led to 
permanent facial deformities. Lose and lost teeth were common, as was death from 
mercury poisoning. 
In 16th centaury paracelsian and china physicians are used to treat malaria 
and yellow fever and a preparation called “worm chocolate” and “worm candy” was 
given to patients infested with helminthis. 
Toxic effects were soon noticed in individuals given large doses for long 
periods, in which excessive salivation, gum inflammation, loosening of teeth, gastro-
intestinal upset and an ashen appearance developed. They had troubling neurological 
symptom, such as arm and facial tremors, hyperfine, ataxia and erethism, unusual 
timidity and personality change. 
The toxic potential of calomel was highlighted in 1948. A Cincinnati 
paediatrician discovered that a common infantile and childhood illness called 
“Aerodynia” or “Pink disease” was caused by the white spread use of calomel in 
treating childhood teething and constipation. As late as 1950 acrodynia accounted for 
more than 3% of admissions to children ward’s in London hospitals. Official statistics 
record that 585 children died of pink disease between 1939 and 1948 in England and 
waves.   
 “Effect of dose not in proportion to size” well – triturated doses better 
than large coarse one. 
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3.2 ALLIUM SATIVUM –ெவைள~ªz 
3.2.1 GUNAPADAM ASPECT 
VELLAIPUNDU SYNONYMS: 
nts;Ss;sp jd;Dila tptuq;NfS 
Nkjpdpf;Fiw Nrhdh yR Nehyp\;Nlhk; 
ks;Ss;sp kJrpa nfe;jhq; Nfs; m];jkhk; 
kfhfe;Njha;Nfh Neu; epahF fpuQ;rNdh 
ks;Ss;sp jPgj;jpuf;fkhFQ; 
nrg;gpaNjhu; nts;Ss;sp;r; nraYkhNk. 
 
SYNONYMS: 
 Kuraisonalasu 
 Nolistoo 
 Madhusiya kaentharam  
 Kael astham 
 Maha kanthoo  
 Koonaerniyaa 
 Kiranchunoovaa 
 Depathirackam 
 Lasunam  
 Kaayam 
 Ulli 
 Pundu 
 Vellai pundu  
 Velvengayam 
VERNACULAR NAME 
Eng  :  garlic 
Tel  :  thella, gadda , velulli 
Mar  :  lohson 
Mal  :  vellulli 
Kan  :  bellulli 
Sans  :  lasuna 
Hind  :  lashan 
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HABITATE 
It s cultivated all over india. It s more pungent than onion nellakiri pundu is 
more popular. 
PARTS USED: 
Bulb and oil. 
 
ORGANOLEPTIC CHARACTERS: 
Colour - white 
Odour  - Garlic Odour 
Taste  - pungent (karppu) 
Character - Veppam 
Pirivu   - Pungent 
- Gunapadam Mooligai Vaguppu 
CHARACTERS: 
Taste - pungent, 
Potence Character-Hot potency 
Biotransformation-pungent (3) 
GENERAL CHARACTERS: 
re;jpNahL thje;jiyNehT jhspd;typ 
kd;dptU ePu;Nfhit td;rPj – kd;dNk 
a+s;Ss;spf; fhz;gh As%y Nuhf%k;Nghk; 
nts;Ss;spf; jd;dhy; ntUz;L 
 
 Garlic used for deafness chronic cough, asthma dysentery, headache, cyanicites, 
haemmoroids. 
 It also used for vadha diseases, kapha headache and oral diseases. 
 Garlic taken along with pepper and karichallai for stomach problems 
 1 to 2 drops of garlic juice droped into ear for ear diseases and deafness 
 garlic juice processed along with gingelly oil and used for ear diseases 
 20 to30 drops of garlic juice used 2 to 3 times per a day for chronic cough, asthma. 
 Garlic juice processed with mustard or coconut oil then it is externally used for body 
pain, pricking pain, whezzing, vadha diseases. 
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ACTIONS: 
 Carminative,  
 Stimulant, 
  Expectorant, 
 Anthelminthic, 
 Anti oxidant, 
 Stomachic, 
  Tonic, 
 Alterative, 
  Diuretic. 
AYURVEDIC AND SIDDHA USES: 
 Clove of garlic was known as ahome remedy in olden days in the east and is one of 
the most useful on account of it s prophylatic and curative properties. 
 The garlic oil capsules product the human body from the attacks of bacteria and 
bacillae in times of epidemics or when the danger of infection is prevalent and 
containing all the curative properties. 
 These capsules renew the blood cleanse if of all impurities regulate the digestion and 
remove all parasites in the intestines which might be injurious to health  
 The capsules recommented fof diseases of the lungs arterio-sclerosis high blood 
pressure gout rheumatism asthma chronic bronchial catarrh intestinal complaints loss 
of appetite constipation and worms. 
 The oil from seeds is prescribed internally as a febrifuge to prevent recurrence of the 
cold fits of intermittent fever  
 Externally it s used in paralytic and rheumatic affections as resolvent the garlic is 
applied to indolent tumours. 
 Internally garlic given with common saltin affection of the nervous system headache 
flatulence hysteria cough etc. 
 In emergency conditions it s applied like onion to the nose in cases of fainting  
 Externally the juice used as a rubefacient liniment acts very beneficially in infantile 
convulsions other nervous and spasmodic affections relax sorethroat inasthma general 
paralysis  facial paralysis gout sciatica  
 It s used for skin diseases including leprosy bruised garlic and onions are applied to 
the chest as poultice 
 When eaten in cold season it is said to ward off attacks of rheumatism and neuralgia  
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 Garlic produce copious dieresis and therefore it is used in dropsy and anasarca 
 Garlic juice mixed with 3-4parts ofordinary or distilled water has been used as a 
lotion for washing wounds and foul ulcers 
 Definite improvement in the condition of infected wounds was noticed with in 24 
hours after washing with this lotion and a very marked and decided improvement with 
in 48 hours not only was the prulent discharge markedly decreased but pain also 
considerably relived and in some cases in entirely disappeared no injury to the tissues 
could be noticed as a result of application of this solution. 
 
OTHER SIDDHA FORMULATIONS: 
1. KAALAMEGA NARAYANA CHENDOORAM: 
Dosage : 30-100mg 
Adjuvent : Thippili powder 
 Indications : Uterine cancer, Cheek cancer 
2. THAMIRA CHENDOORAM: 
Dosage : 30-45mg 
Adjuvent : Garlic juice 
Indications : Weakness 
3. PANCHA SOODHA MELUGU: 
Dosage : 50-100mg 
Adjuvent : Garlic juice 
Indications : Vadha diseases, five types of pain 
4. PASAANA PARPAM: 
Dosage : 1 milagalavu 
Adjuvent : Garlic juice 
Indications : Many diseases 
5. KANTHAGA MELUGU: 
Dosage : 2-3 Kundri 
Adjuvent : Garlic juice 
Indications : Leprosy, Diabetes insipidus 
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3.2.2 BOTANICAL ASPECTS: 
ALLIUM SATIVUM 
Taxonomy Classification 
Kingdom : Plantae 
Division : Angiosperms 
Class  : Monococs 
Order  : Asparagales 
Family  : Amaryllidaecae 
Subfamily : Allioideae 
Genus  : Allium 
Species : A.sativum 
 
Vernacular name 
Eng  : allium sativum 
Sans  : Lacuna, Ugragandua, Bhutagua, Mahusudra, Rosanam 
Hind&Bom : Lasan 
Sind  : Thum 
Per  : Sir 
Gug  : Lasan, Shutam 
Mah  : Lasan 
Tel  : Vellulli, Tellagadda 
Tam  : Vellapundu, Vallai Pundu, Ulli Pundu 
Mal  : Vellulli 
Can  : Bellulli 
Ben  : Rasan 
 
Parts used:  
Bulb and oil 
Distribution: 
 Garlic is among the oldest knowing horticultural crop.  In the old world 
Egyptian and Indian cultures refored to garlic 1000 years ago and there is clear 
historical evidence for it use by the Barsilonians 4500 years ago. 
 
 
20 
 
 Garlic grows wild only in Central Asia (Centered in Kgrgyzstan) today. 
Earlier in history garlic grew wild over a much larger region and, in fact, wild garlic 
may have occurred in an area from china to India to Egypt to the Ukraiue.  It’s 
cultivated all over the world in Spain, France, Egypt, Bulgaria, Hungary, USA, 
Mexico and Brazil. 
Botany: 
 Garlic is perennial of the lily family. It grows to a height of about 60 cm. It 
has short, flat upright leaves 15-30cm. The tall single flower stem bears spherical 
head of pale pinic or greenish- white blooms often mixed with tiny bulbis the 
subterranean white-skinned bulb or corn is subdivided into numerous “cloves”. 
Action: 
 Hot, 
 Stimulant, 
 Carminative,  
 Emmenagogue,  
 Antirheumatic,  
 Anthelmentic, 
 Alterative. 
Organoleptic properties: 
 The bulbs are pinkish-white color and are odoriferous. The size of the bulb 
varies in between 1.5-2.5 cm. 
Morphology \Macroscopical Characters: 
 The bulb grows at the base of a perennial plant with a erect flowering stem 
that grows 2-3 ff long. 
 The bulb is made up of several outer thin protective sheaths covering the inner 
sheathes.  The inner sheath covers the swollen leaves called as cloves. The 
mature bulb has around or more cloves in each bulb. 
 The cloves gave no symmetry except for a few present in the center. 
Microscopic characters: 
The bulbs are covered by an outer scale.  The outers scale is made up of an 
epidermis which encloses a mesophyll (devoid of chlorophyll), a ground tissue and 
below it is a layer of lower epidermal cells. 
The dry scales also contains about 2-3 layers of rectangular cells. 
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The rectangular cells may have many rhomboidal crystals of calcium oxalate 
The epidermal cells contain parenchymatous cells connected to several 
rectangular cells and vascular bundles made up of alternating xylem and phloem. 
The epidermal cells contain thick pitted walls. 
The lower epidermis consists of smaller rectangular cubical cells. 
Phytochemistry: 
Garlic bulbs are made up of numerous minerals, vitamins, carbohydrate, 
amino acids, volatile oils and other trace elements. 
Amongest all the members of the Allium species, garlic is said to have to the 
highest sulphur content. 
Volatile oils are present in about 0.1-0.5% concentration in garlic. These 
constitute of sulphur containing compounds like diallylsulphide, diallyltrisulphide, 
methylallyl sulphide, allyl propyl disulphide, allin, ajoene etc. 
When the garlic clove is crushed allin (s-allyl-1-cysteine sulpoxide) by the 
action of the enzyme allinase gets converted to 2-propene-2-sulfenic acid which in 
turn dimerizes to allicin (diallyl thio sulfinate) 
Allicin is responsible for the pungent odour of crushed garlic and also for zone 
of its pharmacological activities of garlic. 
Vitamins like vitB, VitA, VitC etc, 17 amino acids including  8 essential 
amino acids and minerals like Phosphorus, Calcium, Magnesium, Pottasium, Iron, 
Selenium, Germanium etc are present. 
Garlic medicinal uses 
In Hypercholesterolemia– Garlic has said to lower cholesterol levels. The 
proposed mechanism for this is that the diallyl disulphides and diallyl 
trisulphidespresent in garlic oil interfere with the factors normally responsible for 
lipid synthesis. Garlic can reduce the activity of the thiol group in the enzymes in the 
body. Garlic oil can also carry out oxidation of NADPH. Thus both the above 
activites interfere with normal lipid synthesis and blood lipid levels are reduced. 
These thiol containing enzymes are HMG-CoA reductase and coenzyme A which are 
essential enzymes for cholesterol biosynthesis. 
Other proposed mechanisms for reducing lipid levels are increased loss of bile 
salts in the feces. It has also been suggested that mobilization of these lipids into 
circulation can also reduce lipid levels. 
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As Antithrombotic agent– Ajoene (4, 5, 9-trithiadodeca-1, 6, 11-triene-9-
oxide) present in garlic is considered to inhibit platelet aggregation and is the most 
potent antithrombotic component of garlic.Methylallyltrisulphide present also acts 
as an antithrombotic agent. The suggested mechanism for this is the interference with 
thromboxane synthesis. 
It also shows fibrinolytic properties thereby helping in clot degradation. 
Antimicrobial properties– Garlic shows antimicrobial activity against 
various pathogens such as bacteria including resistant types, fungi, virus etc. It is 
active against both gram positive and gram negative bacteria and strains of 
Mycobacterium. These effects are seen due to ajoene present in garlic. Allicin also 
shows the antimicrobial properties by inhibiting thiol containing enzymes thereby 
affecting protein, DNA, RNA synthesis. 
Due to the antifungal properties, garlic has been proposed for the treatment of 
oral and vaginal candidiasis. 
Garlic is active against various viruses such as herpes simplex virus type I and 
II, Infulenza B virus, parainfluenza virus, cytomegalovirus, human rhinovirus type 2 
etc. 
Chemoprotective properties– Animal studies have shown that garlic has 
positive effects against hepatoxins. The reaction of allicin in garlic with the 
sulfhydryl groups contribute to the inhibitory effect. Sulfhydryl groups concentration 
is high in rapidly dividing cells. 
Immunity– Immunity is increased due to a number of factors on consumption 
of garlic. Selenium andgermanium present in garlic are said to be responsible for 
immunologic activities. Enhanced phagocytosis, increased killer cell activity, 
lymphocyte proliferation, increased production of cytokines and reduction of immune 
suppresion are the suggested mechanisms via which garlic increases immunity. 
Antioxidant properties– Allicin present in garlic is responsible for the 
increase of catalase and glutathione peroxidase enzymes which are two important 
antioxidant  enzymes in the body. The other sulphur compounds may also show 
potential antioxidant properties by inhibiting lipid peroxidation in the liver and 
preventing a reaction which is considered to be one of the main features of aging in 
liver cells. 
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3.2.3 LATERAL RESEARCH 
Anti-carcinogenic activity: 
 Garlic also helps to reduce the risk of cancer due to its carcinogenic properties. 
It helps to prevent cancerous compounds from forming and developing into 
tumours. It also inhibits the growth of tumours that have already formed. 
 This DADS and s-allyl cysteine (SAC) decrease the incidence of colon and 
mammary cancer. 
Anticarcinogenic and antitumerogenic 
 Several epidemological studies have shown that garlic consumption is 
correlated to reduced cancer risk. 
 Individuals consuming about 20 gm of garlic per day have been reported to 
show a 13 times reduced stomach cancer mortality rate then individuals 
consuming less than 1 gm per day according to studies conducted  on 
population of different regions of contries like China , Italy and United States. 
 In lowa women’s health study the results showed the garlic is significantly 
associated with decreased colon cancer risk and reported to decrease the risk 
of gastric cancer. 
 Animal and in vitro studies have demonstrated that various garlic constituents 
inhibit the growth of different forms of cancer cells such as skin, mouth, 
mammary, lung, uterine, oesophagus,stomach and colon tumours,. 
 In fact, tumours that have already formed can be reduced by 50-70% by 
increasing garlic intake  
 Several compounds are involved in garlic possible to anticancer effects. Garlic 
contains allyl sulphur and other compounds that slow down and prevent the 
growth of tumour cells. Allyl sulfer compounds, which occur naturally in 
garlic and onions, make cells vulnerable to strees created by products of cell 
division. Because cancer cells divide very quickly, they generate more 
sterssors than most normal cells. Thus cancer cells are damaged by the 
presence of allyl sulphur compounds to much greater extent than normal cells. 
 The chemistry of garlic is complicated as a result; the quality of garlic 
products depends on the manufacturing process.  Peeling garlic and processing 
garlic into pill or powder can increase the number and valiety of active 
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compounds. Peeling garlic releases an enzyme called allinase and starts a 
series of chemical reaction that produce diallyl disulfide (DADS)  
 In garlic powder s-allyl cysteine (SAC) (or) dialkyldisulfide (DADS) decrease 
the incidence of colon cancer and mammary tumours. 
 SAC and s-propyl cysteine inhibit the invitro formation of N-Nitroso 
morphoine (NMOR) a know carcinogen. 
 Garlic and onion have been reported as anticarcinogenic food due to their 
ability to detoxify the xenobiotics. 
 Dially Disulphide (DAD) isolated from garlic is reported to inhibit the 
activation of Nitrosamine, than reducing the probability of the development of 
cancer of the stomach. 
 Garlic can inhibit the progression of existing cancer. It is more effective 
against N-Nitroso induced cancer. 
 Garlic contains number of sulphur compounds including diallylsulfide. This 
compound inhibits tumour metabolism and enhances the immune response. 
Anti-Microbial Activity: 
 Garlic has been embloyed for centuries as a traditional herbal medicine to treat 
infectious diseases. 
 Studies with garlic extract confirmed its antiviral activity against influenza-B 
and herpes simplex viruses. 
 Garlic juice showed Antibiotic activity against Mycobacterium tuberculosis, 
Staphyllococcus aureus, Brucella abortus and Escuerichia coli. 
 Garlic extract was found to be capable of inhibiting 22 isolates of the fungus. 
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3.3. PIPER BETEL (ெவறிைல) 
3.3.1. GUNAPADAM ASPECT 
VETRILLAI SYNONYMS 
ntw;wpiyap;d; Ngu;jidNa tpsk;gf;NfS 
Ntz;oaNjhu; jhk;Gy khjhthFk; 
Rpj;jpiyahQ; rhjfyl;Rkp ahFk; 
jhk;G+yf; rz;zp ey ehfty;yp 
xj;jpiyNthk; Gyf;fd;dpahFk; 
cWgy;Yf; fofpjhd; Njfuf;rpfahk; 
ej;jiy ehfj;ij R+uzkhf;fp 
eyq;fpaNjhu; ntw;wpiyapd; ehkkhNk 
Synonyms: 
 Saathaga lakshmi 
 Thamboola madha 
 Nagavalli 
 Lomalaga kanni 
 Thaeka rakshini  
 Palluckalaggi  
 Nagatthai chooranamaacki 
 Thamboolam  
 Thamboola valli  
 Thirayal  
 Mellilai  
 Vellilai  
 Melladagu  
Vernacular names: 
        Telugu   :  Tamalapaku 
        Kannada   :  Vilaya 
        Duk  :  Thambole 
        Bengali   :  Pan 
        Hindi   :  Paan 
        Sanskrit  :  Tambula and nagavalli  
     Gujarathi   :  Naagarvel na paan 
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Types: 
Vetrillai  :  Migundha manamum, kaaramum, nivamum illatuattu  
Kammaru vettrilai :  Karuppu niramum, karppum udayatu 
Karpoora vettrilai :  Karpoora manamum siru kaaramumudaiyatuu 
habitate: 
 In India it’s cultivated in hot areas and saduppu nilam.  It’s a type of climber. 
It’s cultivated for its leaf. 
Parts used: 
 Leaf 
Properties: 
Taste (suvai)   :  vurviruppu, pungent (karppu) 
Quality (thanmai)  :  veppam (hot) 
Pirivu (postdigstive effect)  :  pungent (karppu) 
Action:  
 Stimulant, 
 carminative  
 astringent,  
 aphrodisiac,  
 antiseptic,  
 febrifuge,  
 stomachic, 
 galactagogue, 
 sialogogue. 
General properties: 
Iak; mWq;fhd; mjd; rhuq; nfhz;lf;fhw; 
igar; raj;jpak;Nghk; ige;njhbNa! – nka;naz; 
fbapd; Fzk; NghFk; fhuntw;wp iyf;Fg; 
gbAKj; njhlkpijg; ghu; 
 
vl;bnyhd;W fpl;bdP Nuw;wq; rpNuhghu 
khl;b tpLrd;dp khe;jNkhL – ehl;bw; 
gupa Fuf;fk;ky; gz;bAg;gp rk;Ngh 
kupafk; khW ntw;wpiy 
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 Juice of betel leaf curesIyyam, saytthiyam, kanaakkadi, muppini, uteriaria. 
 Betel leaf juice cures cynacites, head ache, stomach pain, sorethroat, muppini, 
maantuam vaetriuppisam. 
Therapeutic uses: 
 For sore throat and thondaiyaddaippu betel leaf is taken along with saambrani 
pathangam. 
 Paarsurakkam, paalkatti udayavum betel leaf anaill vaatti adukkadukaai 
mulaill vaithu kattalaam. 
 Tualai paluvukku muckilum, kaathu kutthalacku kaathilum vetrilai juice 
2.3drops. 
 Betel leaf juice give along with ginger juice for lung disorders. 
 Its externally used for fire wound. 
 Vetrilaiyai ennaiyil nanaithu, vilakil vatti maarbin mel poda, eramal, 
moochumuttal kadinaswasam, kuzhanthaigalukundaagam erumal vilagum 
 Koorosani taken along with betel juice for duspnoea, cough and koolaikattu. 
 Mercury purified by betel juice. 
 Fresh leaves are generally used for chewing, in the form of packets made with 
the addition of hurnt like catecha or gambler and pieces of areca(betel) nut in 
any state of maturing and tobacco. 
 Those who can afford, add also cardamoms, nut megs, cloves, camphor and 
aromatics. 
 They sweeten the breath, improve the voice and remove from mouth. 
 Also they increase the salivary secretion. The ancient Hindu writers’ 
recommented betel leaves to be chewed early in the morning after meals. 
Siddha and ayruvedic uses: 
It is useful in bronchitis, asthma, catarrh, cough, leprosy, skin diseases, filarial 
dipsia, alcuolism, syncope, otalgia, fever, halitorsis impotencym rewmatism, 
dyspepsia, indigestion in children, pnaryngitis, laryngitis, obesity,conjutivitis, night 
blindness, glandular swelling oil of betel has been used in the treatment of various 
respiratory cattarrns and as a local application either by gargle or by ingalation in 
diphtheria.  It has carminative properties oil shows marked irritant action on skin and 
mucous membrave. It has an antispasmodic action on involuntary muscle tissue, 
inhibiting excessive peristalitic movements of intestinals.  
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OTHER SIDDHA FORMULATIONS: 
1. ABRAHA PARPAM: 
Dosage  : 100-200mg 
Adjuvent  : Honey 
Indication  : Diabetes Mellitus and Diabetes Insipidus  
2. POORNA CHANTHROTHAYAM: 
Dosage  : 100-200mg 
Adjuvent   : Betel Leaf juice or Karpoorathi chooranam 
Indication  : Tuberculosis, Dysentry, Fever 
3. KASTHURI MATHIRI: 
Dosage  : 1-2 pills 
Adjuvent  : Betel Leaf juice or Honey 
Indication  : Heart proplems, intermittent fever, fits 
4. SAANTHA SANTHROTHAYAM: 
Dosage  : 1-2 pills 
Adjuvent  : Betel Leaf juice or Honey 
Indication  : Liver diseases, constipation 
5. SAMBARANI POO MATHIRAI: 
Dosage  : 1 pill 
Adjuvent  : Betel Leaf or Pepper powder 
Indication  : Dysmennorhea, Amennorhe 
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3.3.2 BOTANICAL ASPECT   
PIPER BETEL 
BOTANICAL ASPECT 
Botanical name :  Piper betel 
Taxonomy classification: 
Kingdom   :  Plantae 
Division   :  Angiospermae 
Class    :  Magnoliidae 
Order    :  Piperals 
Family   :  Piperaceae 
Genus    :  Piper 
Species  :  Betel 
Botanical name : Piper betel 
Vernacular name: 
English   :  betel pepper 
Ayurvedha   :  tambula, nagavallari nagini, tambulavalli,  saptashiva,      
Siddha   :  vertillai, naga valli, kanmaru vetrillai  
Unani    :  pan, tambool 
Telegu   :  tamala paku, tamula paku 
Marathi   :  pan, nagvel vidyachepan 
Kannada   :  veelyade ele 
Common Indian name :  paan / pan 
Distribution: 
 A native of java, it is cultivated in india in assam, west Bengal, bihar,uttar 
pradesh, madya pradesh , maharastra, karnadaka, tamilnadu and kerala. 
Botanical discribtion: 
 Perennial, creeping herbs, stems semiwoods climbing by short adventitious root 
leaves bradly ovate, slightly cordate, acuminate (or) acute entire, globroas, 
pentiolata, mace spikes dense, cylindrical, female spikes 2.5-5 cm long pendulous 
fruits rarely produced often sunk in the  fleshy spike, forming nodule like 
structure. 
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Parts used: 
 Whole plant and leaf 
Pharmacognosy: 
 Leaves coriaccous, 10-18 by 5-12.5 cm broadly ovale acuminate, glabrous, 5-9 
nerved the suprabasai nerves usually alternate base sligntly cordate (or) 
usually rounded more (or) oblique, pentioles 1.3-2.5 cm. 
 Microscopically leaves shows a dorsiventral structure. The cutice is hot 
striated, the hypodermis contains secretorycells, while the power epidermis 
bears cni to multicelluular hairs and ansiolytic stomata.  The pentiole shows a 
discontinuous collencymas zone below the epidermis. Mucilage canals at the 
center, vascular bundles graded in size arranged in arcs and multicellular hairs. 
Chemical constituents(phytochemical): 
 Vitamin A &C, thiamine, ribatiavin nicotinic acid, glucose, fructose, maltose, 
sucrose malic acid, obalic acid, amino acids viz leucine phenylalanine, 
alanine, arginive, thrioniue, serineaspartic acid, glutamic acid, methioninive, 
valiue, thyrosine, asparagines, glucine, protine, ornithiue and α- amino butyric 
acid and β and α sitosterois, hentriacontane, pentatriacontane, n-triacontanol 
and stearic acid stigmasterol allylpyrocatechol, chevibetol acetate and 
allylpylrocatecol aiacetate, eugenol,carvacrol, chavicol, allylcatecol, 
chavibetol cineoue, estragol, eugenol hutuyl ether, P- Cunene, caryophylleve, 
candinene, α- terpinene and unidentified sequiterpenes, tocopuerol, eugenol, hydroxyl chavicol and mixture of two unideutified compounds β sitostercois, diosgenin (roots). 
Pharmacological activities: 
 Fungicidal 
 Hematicidal 
 Anti-baterial 
 Anti-fungal 
 Hypotensive 
 Cardiac and respiratory depresent 
 Anti- miotic 
 Mild anti infertility 
 Anthementic 
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 Anti tuberculous 
 Anti-microbial 
 Cardiotonic 
 Stomach muscle retaxant 
Action and uses: 
 When leaf is chewed, the mild anti – infective content in the leaf. Fresuen breath and cleanse mouth.  Its constituents directly enter the blood via buccal mulosa as this is a direct way of entry into blood stream, it is the best way to deliver drugs into the blood stream during sickness. 
 The leaf contain several polsypuenois that not only figuts microbes, but also act as pain relivers and anti inflammatory agent.  Recent studies have shown that the leaf contains tdnnis, sugar, diastage and an essential oil. 
 A particular phenol called chavical p;resent in it has power ful antiseptic painful are for temporary relief.  Betel leaves posses good diuretic properties.  Therflre it can be mixed with dilute milk and consumed by sweetening as it helps ease urination. 
 The betel leaf also beneficial in treating nervous pains an debility.  The juice of the leaves, when consumed by adding a teaspoon of honey, twice a day act a good tonic. 
 Betel leaves has been in use since ancient times for healing wounds.  Ayurveda has hrougly belived in this property of the leaf.  The juices of the leaves applied locally on the wound after which the betel leaf is wrapped around and bandaged.  The wound is sure to heal with in a day or two. 
 The paste of three paan leaves is taken with one gram rock salt with hot water.  Thrice daily for filarial(shlee puta)the leaves juice is taken orally for indigestion and stomach disorders. 
 The oral intake of leaves decreases cough and reducing swerling of throat and throat irritatation. 
 Betel leaf juice is taken with honey for dry cough.It also helps in reducing difficulty in breathing for people suffering from asthma.  Some apply mustard oil to the leave of the betel plant, warm it and keep it on the chest to bring relief from asthma  
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 Betel leaves are used for treating head ache and also to reduce the pain associated with arthritis.  The juice from the leaves can be mixed with any hot oil (like coconut oil)and applied topically to treat lower back pain.  The juice of the leaves is also used to relive headache. 
 The leaves of the betel can increase alertness and mental functions in humans.  Taking the juice of betel leaves with honey can help in curing nervous exhaustion. 
 In Indonesia herbal tea made using betel leaves help in freeing the body from the unpleasant odor of sweating and menstrual. The herb also help in treating bad breath, intestinal worms, scanty urination, inflammation of testis, low breast milk production, diabetes, constipation palpitation, wounds ulcers and other skin inflammatory conditions. 
 Dosage:For oral intake ayurvedic pharmacopeia of india recommended 10-20 ml juice of fresh leaves. 
 In an animal study using betel leaves it was found that low dose of the herb can decrease  T4 levels and increase T3 levels. 
 Also recent studies have shown that the leaf contains components that have chemo- preventive and anti-cancer properties.  
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3.3.3 LATERAL RESEARCH 
Anti oxidant property:  The is reported das gupta and de(2004) evaluated the antioxidant activities of 
aqueous extract of the piper betel leaves by invitro methods. 
 DPPH radicals scacenging activity  
 Superoxide scavenging activity  
 Hydroxyl radical scavenging activity 
Finally the piper betelShowed very high antioxidant activity. 
 Wong et al (2006) investicated the antioxidant properties of 25 edible trophical 
plants  including pip;er betel using DPPH and FRAP assays.  Total phenolic 
content was also estimated.  Piper betel showed very high antioxidant activity. 
  (rathee et al 2006) chevibetol, allylpyrocatechol and their respective glucosides 
were isolated from leaves.  Among the isolated compounds allylpyrocatechol 
showed the best results in all the invitro exp;eriments.  It could prevent  
Fe(II)induced lpo of liposoues and rat brain homogenates as well as gamma ray 
induced damage of PBR 322 plasmid DNA more efficient then chevibetol. 
 Maniguha et al (2009) evaluated the antioxidant of piper betel leaves.  Etuanolic 
extract of piper betel leaf showed strough antioxidant activities like reducing 
power DPPH radical, sup;eroxide anion scavenging and deoxyribose degradation 
actiovities when compared with different standard such as ascorbic acid, DMSO 
and BHI . 
-PULLLIAN HERBAL ANTI OXIDANTS 2012 
 
ANTICANCER PROPERTY: 
 The leaf constituents, hydroxyl chavicol and β carotene were found to reduce the 
number of papilomas per mouse  
 Also the constituents, β carotene and α tocophenol are reported to significantly 
inhibit DMBA inducved skin tumour formation by 83-86 and 86% in swigs mice 
and 92.94 89% in male swigs bare mice respectively. 
 While hydroxyl chavicol showed 90% ingibition in swigs bare mice. 
 The constituent eugenol shows minimal protection in both the strains of mice. 
 The leaf extract of betel quid when administered simultaneously while mutagenic 
tobacco specific N nitrosamines (present in the extract of chewed tobacco) viz  N- 
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nitrosonornicotive (NNN) and 4 uretagenic affects and reduce the tumour 
incidence in mice. 
 The leaf extract is reported to exhibit antitumor activity in 7, 12, dimethyl benzene 
and antnraceve (DMBA) treated wistar rats. 
Anti microbial: 
 The betel leaf oil posses strong antibacterial activity against the gram positive 
bacteria bacillus subtills , bacillus pumillus staphylococcus aurous, salmonella 
typhi, vibrio cholera and several other pathogenic microorganisms. 
 The essential oil was also found to be more effective against tape worms(taenia 
solium) and hook worms( bunostomum trigonocephalum) than the synthetic 
anthelmentics, piperzive phosphate and hexyl resorcihol.   
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3.4. MILAGU (மிள) 
3.4.1. GUNAPADAM ASPECT: 
MILAGU SYNONYMS: 
 kpsfpDlg; Ngh;jidNa tpsk;gf;NfS 
  Kjph;e;J epd;w jpiu Nghf;fp khprpahFk; 
 tsfpDl tyrKkh jPl;rzkhFk; 
  kfj;jhdJ td;khQ; rpahkkhFQ; 
 FsfpDl %\;zkhk; rj;Jt Ne\q; 
  Nfhyf khQ;ruJe; jdpAkhFk; 
 tsfpDl thjj;ij aWf;Ffpd;w  
  kfj;jhd kpsFf;F ehkkhNk 
     - Bogar Nigandu 1200 
Thiraipokki 
Marisi 
Valasam 
Thetsanam 
Thuranam 
Seyamam 
Mooshnam 
Sathuvanesam 
 Kolagam 
 Sarathunthini 
 Vadha Arukki 
-Gunapadam Mooligai Vaguppu 
 nrhy;ypaNjhh; mUl;lndd;Wk; ,jw;Fg; NgU 
  nrhw;nghpa kjq;fd; vd;Wk; NgUz;lhFk; 
 my;ypa Njhh; kiyj;jpUf;f ndd;Wk; NgU 
  m\;lkhrhjp nad;Wk; ,jw;Fg; NgU 
 fy;ypaNjhh; fj;jphpr ndd;Wk; NgU 
  fUj;Jul ndd;Wk; Neh;tse;jh ndd;Wk; 
 ky;saNjhh; nfe;jf ndd;wpjw;Fg; NgU 
  trdpj;Njhk; kpsfpdpl mjPjg; NgNu. 
- Panchakaviya Nigandu 
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 Arutan 
 Mathengan 
 Malaithirukkan 
 Astamasathi 
 Kathirisan 
 Karvuthurudan  
 Nerrvalandan 
 Kanthakan 
Properties:  
 Taste  : Pitter, Pungent  
 Character  : Veppam 
 Class  : Pangent 
 used part : Seed 
 Action  :  
 Acrid 
 Carminative 
 Stimulant 
 Antiperiodic 
 Resolvent  
 Rubefacient 
 Antivatha 
 Atidode. 
Vernacular Names: 
 Tamil  : Milagu 
 Eng  : Pepper 
 Jehegu  : Miriyalu 
 Malayam : Kurumilagu 
 Kannadam : Menasy  
 Sanskrit : Maricha 
 Hindi  :  Kali mirich 
 Persian : Filfliaisiah 
 Bengoli : Glomorich, Morich, Kalamorich 
 Gujarathi : Kalimori 
 Urdu  : Fulfil Sioyah, Kalimirich 
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General Characters: 
 ‘rPjRuk; ghz;L rpNy\;kq; fpuhzp%yk; 
  thjk; mUrpgpj;jk; kh%yk; XJrd;dp 
 ahrk; mg];khuk; mld;Nkfk; fhrk; ,it  
  ehrk; fwpkpsfp dhy;” 
 
 ‘NfhZfpd;w gq;ftyp Fa;aNuh fk;thjk; 
 Nrhzpjq;f Oj;jpw;Fs; Njhd;Wk; Neha; - fhzhpa 
  fhJNeha; khjh; Fd;kq; fhkhiy ke;jk; vd;wPh; 
  VJNeha; fha; ,Uf;fpy; <q;F. 
It cures the Malarial Fever, Anemia, diarrhoea, piles, ulcer, Flattulance, 
Anorexia, Diabeties, cough, hemeplegia, vaginal disease, Neck and Nasal disorders, 
Jaundice, pitham, vatham, vedhasonitha Noi, and Sanni. 
Therapeutic uses 
 It is prescribed in cholareae, dyspepsia, flatulance, aliments. 
 An infusion of black paper Forms a useful stimulant gargle in relaxed sore - 
throat and hoarseness dependent thereon and in tootheache  also. 
 Piperine is given with much benefit in aguee, gonorrhoea, haemorrhoids etc in 
doses of 3 to 10 grains. 
 In Intermittent fever black pepper in doses of about a drachm is recommended to 
be given with the juice of leaves of ocimum sanctum or jeucas linifoha. 
 The drug is also used in scorpion bite. 
 
OTHER SIDDHA FORMULATIONS: 
1. Milagu thiravagam 
Dosage :  Kasu eadai 
Indication : Peptic ulcer, Indigestion, Anorexia 
2. Milagu Legium 
Dosage :  Punnai kai alavu 
Indication : Peptic ulcer, Vaivu, Diarrhoea. 
3. Karuvepilai vadagam 
Dosage :  Illanthai vithai alavu 
Indication : Anorexia, Diarrhoea, Discentry. 
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4. Kanthaga Chooranam 
Dosage :  Verugadi alavu 
Indication : Peptic ulcer, Indigestion, Constipation. 
5. Sowbagiya sundi Chooranam 
Dosage :  Verugadi alavu 
Indication : Peptic ulcer, Indigestion, Diarrhoea. 
6. Pirandai Vadagam 
Dosage :  I Manthai vithai alavu 
Indication : Peptic ulcer, Vomitting, Anorexia 
7. Thirikadgu Kirutham 
Dosage :  1 Spoon 
Indication : Piles, Diarrhoea. 
8. Pirandai Chooranam 
Dosage :  Verugadi alavu 
Indication : Peptic ulcer, Vomitting, piles, Abdominel, disorders. 
9. Thirikadugu thiravagam 
Dosage :  5 Drops 
Indication : Peptic ulcer, Bronchial Asthma. 
10. Muppirandai Chooranam 
Dosage :  Verugadi alavu 
Indication : Peptic ulcer, Indigestion, Piles.  
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3.4.2. BOTANICAL ASPECTS 
MILAGU (PIPER NIGRUM) 
Taxonomical Classification: 
Kingdom  : Plantae  
  Subkingdom  : Tracheobionta  
Superdivision : Spermatophyta  
Division  : Magnoliophyta  
Class   : Magnoliopsida  
Subclass  : Magnoliidae 
Order  : Piperales 
Family  : Piperaceae  
Genus  : Piper L.  
Species  : Piper nigrum L.  
Common name:  
 Black pepper, white pepper, green pepper, peppercorn, Madagascar pepper 
(English); pippali (Sanskrit); kali mirch (Hindi, Urdu); milagu (Tamil) 
Synonym:  
 Muldera multinervis Miq. 
Habitat:  
 Montane tropical evergreen forest. 
Geography and distribution 
 Black pepper is native to the Western Ghats of Kerala State in India, where it 
grows wild in the mountains. 
 It is cultivated all over the tropics as a commercial crop. Vietnam, Indonesia, 
Brazil and India are the major producers. 
DESCRIPTION 
Overview: 
  A climber that grows to a height or length of 10 m or more. Once the main 
stem is established it grows many side shoots to create a bushy column. 
 The plants form short roots, called adventitious roots, which connect to 
surrounding supports. 
 
 
 
40 
 
Leaves: 
 Almond-shaped, tapering towards the tip, dark green and shiny above, paler 
green below, arranged alternately on the stems. 
Flowers:  
 Borne in clusters along flowering stalks known as spikes. 50–150 whitish to 
yellow-green flowers are produced on a spike. 
Fruits:  
 Round, berry-like, up to 6 mm in diameter, green at first but turning red as 
they ripen, each containing a single seed. 50–60 fruits are borne on each spike. 
 Fruits are picked when green and immature to produce green pepper; when 
fully grown but still green and shiny to produce black pepper; and when slightly riper 
to produce white pepper (for which the fruits are also soaked to remove the fleshy 
outer layer). 
Other pepper plants 
Uses 
Food 
 The fruits of Piper nigrum are used to make black pepper. This hotly pungent 
spice is one of the earliest known and most widely used spices in the world today. It is 
used as flavouring, particularly for savoury foods, meat dishes, sauces and snack 
foods. It is also used as a table condiment. 
 Black pepper, white pepper and green peppercorns are all produced 
from Piper nigrum fruits, but are harvested at different times and are processed 
differently. 
 India is a key producer of black pepper and exports much of what is grown. 
Peppercorns from Malabar and Tellicherry in Kerala, India, are particularly prized for 
their flavour and pungency. 
 Black pepper is also used to produce pepper oil and oleoresin, which are 
frequently used in the production of convenience foods and sometimes also for 
perfumery. 
 Of lesser importance is the use of preserved immature green pepper or fresh 
pepper fruits, which are eaten more like a vegetable. 
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Black peppercorns 
 Black peppercorns feature as remedies in Ayurveda, Siddha and Unani 
medicine in South Asia. They are most frequently used as an appetizer and to treat 
problems associated with the digestive system, particularly to eradicate parasitic 
worms. Some traditional uses of black pepper are supported by scientific evidence. 
 In Siddha medicine, black pepper has been used to aid digestion, improve 
appetite, treat coughs, colds, breathing and heart problems, colic, diabetes, anaemia 
and piles. Stomach ailments such as dyspepsia, flatulence, constipation and diarrhoea 
are all treated with black pepper, which may be mixed with other substances such as 
castor oil, cow's urine or ghee. 
 Black pepper has been prepared in tablet form as a remedy for cholera and 
syphilis, sometimes combined with other substances. It has also been used in tooth 
powder for toothache, and an infusion of black pepper has been suggested as a 
remedy for sore throat and hoarseness. Black pepper may be chewed to reduce throat 
inflammation. 
 Externally, it has been applied as a paste to boils and to treat hair loss and 
some skin diseases. Oil of pepper is reputed to alleviate itching. A mixture of sesame 
oil and powdered black pepper has been recommended for application to areas 
affected by paralysis. A mixture of black pepper and honey is regarded as a remedy 
for night blindness. Black pepper has been given by inhalation to comatose patients. It 
is also believed to be useful against hepatitis, urinary and reproductive disorders. In 
Ayurveda and Siddha medicine, a paste made using white pepper is applied to treat 
some eye diseases. 
Phytochemical constitutents : 
   Black pepper contains about 3% essential oil, whose aroma is dominated 
(max. 80%) by monoterpenes hydrocarbons: sabinene, beta-pinene, limonene, 
furthermore terpinene, alpha-pinene, myrcene, delta3-carene and monoterpene 
derivatives (borneol, carvone, carvacrol, 1,8-cineol, linalool). Sesquiterpenes make up 
about 20% of the essential oil: beta-caryophyllene, humulene,beta-bisabolone and 
caryophyllene oxide and ketone. Phenylether (eugenol, myristicin, safrole) are found 
in traces. Loss of monoterpenes due to bad storage conditions (especially for ground 
pepper) should be avoided.  
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Pharmacological activity: 
 Constituents: Black pepper has been found to contain piperine1, alkamides9, 
piptigrine7, wisanine7, dipiperamide D10, and dipiperamide E10. 
 Acetylcholinesterase inhibitory activity: In an in vitro study, an extract of Piper 
nigrum L. seeds showed 50-65% inhibitory activity on acetylcholinesterase.2 
 Antibacterial effects: In an in vitro study using 12 different genera of bacterial 
populations isolated from the oral cavity of 200 individuals, an aqueous decoction of 
black pepper (Piper nigrum L.) exhibited 75% antibacterial activity as compared to 
aqueous decoction of bay leaf (53.4%) and aqueous decoction of aniseed (18.1%), at 
the concentration of 10mL/disc.4 
 Anti-inflammatory effects: Based on animal study, a polyherbal formulation (Aller-
7/NR-A2) containing extracts from seven medicinal plants including Phyllanthus 
emblica, Terminalia chebula, Terminalia bellerica, Albizia lebbeck, Piper 
nigrum, Zingiber officinale, and Piper longum demonstrated 31.3% inhibition against 
carrageenan-induced acute inflammation in Wistar Albino rats, while ibuprofen (50 
mg/kg orally) exerted 68.1% inhibition.3 Aller-7 also exhibited a dose-dependent 
(150-350mg/kg) anti-inflammatory effect against Freund's adjuvant-induced arthritis 
in Wistar Albino rats; an approximately 63% inhibitory effect was observed at a dose 
of 350mg/kg. 
 Antilarval activity: Piptigrine, isolated from the dried ground seeds of Piper 
nigrum Linn., exhibited toxicity of 15.0ppm against fourth instar larvae of Aedes 
aegypti Liston.7 
 Antioxidant effects: Based on animal study, a polyherbal formulation (Aller-7/NR-
A2) containing extracts from seven medicinal plants including Phyllanthus 
emblica, Terminalia chebula, Terminalia bellerica, Albizia lebbeck, Piper 
nigrum, Zingiber officinale, and Piper longumexhibited concentration-dependent 
scavenging activities toward biochemically generated hydroxyl radicals 
(IC50 741.73mcg/mL); superoxide anion (IC50 24.65mcg/mL by phenazine 
methosulfate-nicotinamide adenine dinucleotide [PMS-NADH] assay and 
IC504.27mcg/mL by riboflavin/nitroblue tetrazolium [NBT] light assay), nitric oxide 
(IC50 16.34mcg/mL); 1,1-diphenyl-2-picryl hydrazyl (DPPH) radical 
(IC50 5.62mcg/mL); and 2,2-azinobis-ethyl-benzothiozoline-sulphonic acid 
diammonium salt (ABTS) radical (IC50 7.35mcg/mL).5Aller-7 inhibited free radical-
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induced hemolysis in the concentration range of 20-80mcg/mL. Aller-7 also 
significantly inhibited nitric oxide release from lipopolysaccharide-stimulated murine 
macrophages. 
 Cytochrome P (CYP) 450 effects: In in vitro studies, constituents isolated 
from Piper nigrum, including piperine and dipiperamides D and E, potently inhibited 
some CYP450 metabolic pathways, including CYP2D69 and CYP3A48,10. 
 Gastrointestinal effects: In a clinical study of intestinal peristalsis in 16 healthy 
volunteers, consumption of 1.5g of black pepper in capsules increased the orocecal 
transit time from 90 ± 51 minutes to 122 ± 88 minutes (p=0.09).11 In an in vitro study, 
piperine inhibited digoxin and cyclosporine A transport in Caco-2 cells with 
IC50 values of 15.5 and 74.1mcM, respectively.8 The bactericidal and anti-adhesive 
properties of black pepper have also been investigated against Helicobacter pylori, 
however, aqueous extracts did not show bactericidal effect on any of the isolates.6 
 Neural effects: In an in vitro study using whole-cell patch-clamp electrophysiology, 
piperine, a pungent alkaloid found in black pepper, had similar agonist effects on the 
human vanilloid receptor TRPV1 as capsaicin.1 However, piperine could induce 
greater receptor desensitization and exhibit a greater efficacy than capsaicin. 
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3.4.3. LATERAL RESEARCH : 
 Black pepper (Piper nigrum L.) native of south India popularly known as” 
king of spices”. Pepper is mostly used in the curry recipes as masalas and also as 
ingredient in the prescriptions of folk medicine, Ayurveda and traditional medicinal 
systems. The spicy tang of pepper is due to the presence of piperamides which are the 
pungent bioactive alkaloids accumulate in the skin and seeds of the fruit. Among them 
piperine is the major chemical constituent responsible for the bitter taste of the black 
pepper. 
In the present study piperine was evaluated for its antimicrobial activity 
against Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, 
Escherichia coli, Alternaria alternata, Aspergillus niger, Aspergillus flavus and 
Fusarium oxysporum. The antibacterial activity was measured by agar well diffusion 
method and antifungal activity by poisoned food technique. Piperine showed 
antimicrobial activity against all tested bacteria with zone of inhibition ranged from 8-
18mm. maximum zone of inhibition was against Gram positive bacteria 
Staphylococcus aureus (18mm) and minimum against Gram negative bacteria 
Escherichia coli (8mm). Piperine showed maximum antifungal activity towards 
Fusarium oxysporum (14mm) and very least effect against Aspergillus niger (38mm). 
The results showed significant activity of piperine and suggesting its use as natural 
antimicrobial agent.  
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3.5. BREAST MILK 
3.5.1. GUNAPADAM ASPECT 
jd;dpahnkd; Nwhjpr; rUtNjh \q;fSk; Nghk; 
cd;dpa jhgnkhopAq;fhz; - rd;dpNahL 
thjRuk; gpj;jRuk; td;fgr; Rue;jzpAq; 
Nfhjpy; tYikAz;lhq; $W 
 
,UNjhrk;Nghf;Fk; kpfw; fpupr;re; jPu;f;Fk; 
mUe;J kUe;jp dDghdk; - nghUe;Jk; 
mQ;rdj;jpw; foF kzy; twl;rp ePq;fptpLk; 
gQ;rpdb khju; Kiyg;ghy;. 
 
Breast milk is an ideal diet for children as it contains all the nutrients essential 
for the growth of children and is easily digestible. Children feed on breast milk will 
rarely contract infectious diseases. 
Mother’s, while giving breast milk to their babies, and also bestows best 
qualities such as kindness, affection, bondness and knowledge. 
Mother’s milk is prescribed as best adjuvant for certain diseases. For chronic 
constipation caused in delirium and fever cases, breast milk is considered as best 
medicine. 
Milk is ground with borne camphor, saffron flower, Cloves and stem of betel 
leaf. A cloth soaked in this milk is applied over the body and head for the control of 
fever and headache. 
 Breast milk soaked in a cloth and applied over the abdomen, cures dysuria and 
constipation especially in children. 
 Breast milk is also instilled as eye drops for eye diseases. 
 Breast milk is used to purify cinnabar, rasa chendooram, sub-chloride of 
mercury etc. It is also useful for grinding the drugs like chandamaarutha chendooram 
and kasturi pills. It is also added in the preparation of saranaathi thailam. 
 Breast milk and ginger juice are taken one part and equal quantity of gingerly 
oil is mixed, boiled and used as a hair oil for curing the headache caused by cold. 
  
 
 
46 
 
3.5.2. SCIENTIFIC ASPECT 
The team of researcher isolated the key compound - a protein called alpha-
lactalbumin.Subsequent tests showed the compound becomes lethal only when 
exposed to acid, as it is in the stomach, so the scientists mixed it with oleic acid, 
which is found in babies' stomachs, to form a compound they call HAMLET (human 
alphalactalbumin made lethal to tumour cells).  
The Swedish team, led by Professor Catharina Svanborg, have shown that 
HAMLET attacks cancer cells, causing apoptosis - a form of cell suicide - in 40 kinds 
of tumour. 
Studies with rats showed that after just seven weeks a highly invasive brain 
cancer called glioblastoma was seven times smaller in those treated with HAMLET.  
The product has also been made into a cream and tested on warts (which share the 
same growth properties as tumours) and found to reduce their size by 75 per cent in 
20 volunteers.  
DIABETES & PARKINSON'S  
Breast milk could be a new, and easier, source of stem cells. Stem cells are 
one of the most exciting discoveries in medicine, thanks to their remarkable ability to 
develop into many different cell types in the body, serving as a sort of internal repair 
system.  
Stem cells are already being used to treat leukaemia and could soon help treat 
eye conditions.  
Scientists are also researching their potential in the longer term for treating 
conditions such as spinal injuries, diabetes and Parkinson's disease.  
A molecular biologist at Perth University, Australia, has discovered stem cells 
in breast milk.  
Dr Mark Cregan and his team cultured the cells of human breast milk and 
found the result was positive for a stem cell marker called nestin. 
'These cells have all the physical characteristics of stem cells,' he says. 'What 
we will do next is to see if they behave like stem cells.'  
If so, this promises to provide researchers with an ethical and easier means of 
harvesting stem cells for researching treatments. Indeed, Dr Cregan believes this 
development could be possible within five years.  
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DIARRHOEA  
Chronic diarrhoea kills up to 2.2 million people worldwide every year, mostly 
children in developing countries. Scientists are looking at whether breast milk could 
help treat it.  
One approach is based on indigestible sugars known as oligosaccharides, 
many of which occur only in human milk. These sugars protect a baby from 
pathogens to which the mother has never been exposed.  
It's thought oligosaccharides might be used to boost elderly people's weakened 
natural protection against pathogens. They could also be used after a course of strong 
antibiotics by helping re-colonise the digestive tract with beneficial bacteria. So far, 
scientists have been able to genetically engineer mice to produce oligosaccharides in 
their milk and are working on bioengineering bacteria to produce human 
oligosaccharides to put into baby formula milk (to protect bottle-fed babies) or as 
supplements for adults.  
Other compounds found in breast milk, called lysozyme and lactoferrin, have 
been tested on children with diarrhoea and have been shown to not only be an 
effective treatment, but to offer some sort of protection against future bouts.  
ARTHRITIS  
Breast milk contains lactoferrin, which helps prevent babies' immune systems 
from overreacting.  
This is being looked as a potential treatment for auto-immune conditions, such 
as rheumatoid arthritis, multiple sclerosis and septic shock.  
In Italy, studies are under way to see if a breast milk molecule called 
glyerophosphocholine (GPC) can improve mental function in people with dementia or 
victims of stroke and traumatic brain injury.  
In many separate trials, GPC appears to improve memory, attention and 
orientation in people with various forms of dementia, including Alzheimer's.  
It works like a brain nutrient, feeding the most energetically needy cells of our 
body, such as the brain cells.  
ACNE  
A science student at the University of California recently discovered that the 
lauric acid in breast milk reduces irritation and spots, and has developed an acne 
cream that is undergoing clinical trials. 
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The cream uses tiny gold particles to carry lauric acid into pores where its 
anti-microbial properties fight bacteria. 
As breast milk is difficult to source, researchers are working to develop new 
sources for its healthgiving compounds.  
The compounds lysozyme and lactoferrin are harvested for research from a 
specific variety of rice, and the milk from genetically engineered goats and cows.  
Though some of these beneficial compounds are found in milk from other 
animals, others occur only in human milk, and the nonhuman versions are less potent 
when given to humans. 
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3.5.3. LATERAL RESEARCH 
The benefits of breast milk are well known, but why breastfeeding protects 
against various forms of cancer remains a mystery. This study found high levels of 
cancer-fighting TNF-related apoptosis inducing ligand (TRAIL) in human milk, 
which might be one source of breast milk’s anticancer activity. Researchers took 
samples of colostrum, the first milk available to newborns, and of mature breast milk 
from new mothers. Researchers then obtained samples of blood from healthy women, 
and various ready-to-feed infant formulas. The colostrum, mature breast milk, blood 
and formula were then all tested to measure their level of TRAIL. The researchers 
found that colostrum and breast milk contained 400- and 100-fold, respectively, 
higher levels of TRAIL than blood. No TRAIL was detected in the formula. 
“The important role of breastfeeding in the prevention of certain childhood 
cancers, such as lymphoblastic leukemia, Hodgkin’s disease, and neuroblastoma, has 
been previously demonstrated,” wrote the authors. “However, endogenous soluble 
TRAIL represents a strong candidate to explain the overall biological effect of 
breastfeeding against cancer.” 
Background: TNF-related apoptosis inducing ligand (TRAIL) is a pleiotropic 
cytokine, which plays a key role in the immune system as well as in controlling the 
balance of apoptosis and proliferation in various organs and tissues. 
Objective: To investigate the presence and levels of soluble TRAIL in human 
colostrum and milk. 
Methods: The levels of soluble human TRAIL were measured in human 
colostrum (day 2 after delivery) and breast milk (day 5 after delivery). The presence 
of TRAIL was also measured in infant formula. 
Results: Levels of soluble TRAIL in the colostrum and mature human milk 
were, respectively, at least 400 and 100 fold higher than those detected in human 
serum. No TRAIL was detected in formula. 
Conclusion: Human soluble TRAIL is present at extremely high levels in human 
colostrum and human milk and might have a significant role in mediating the anti-
cancer activity of human milk. 
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3.6.DISEASE REVIEW 
3.6.1. SIDDHA ASPECT: 
©² வ¯ வழி 
ciugj dope;j czTfS z;zy; 
tiugL Gyhy; kPd; tof;fj; Jz;zy; 
GzHr;rp kpFjypd; ntg;g kPWjy; 
ntg;g epiyfs; NtWgLgtiu 
mbf;fb GzHjy; xOf;F NehAwy; 
clyof;NfYjy; mZf;fs; GFjy; 
vDkpit gpwTk; gytifg;gl;l 
Gw;WNeha;f; fbg;gilahFk;. 
- khd;KUfpak; vd;Wk; jkpo; kUj;JtE}y; 
 
©றி} «றி 
Gw;Wj; Njhd;wple; jpdT Njhd;wy; 
mt;tplk; Giugl;nldj; Njhd;wpLjy; 
jirfope; jfty; jsHr;rp Njhd;wy; 
cly;epiy NtWgl; nld;dj; Njhd;wy; 
Gw;Wk; cWg;gpd; njhopy; Fiwe;jpLjy; 
 Mw;wy; nfLjy; cWg;G Nehjy; 
rptj;jy; fLj;jy; Fj;jy; gpwTk; 
 Gw;WNehapd; Kd;dkhFk; 
©றி} றிண 
rpWf rpWfr; Nrtw; g+g;Nghy 
$He;J jpuz;L kop jir tsHjy; 
gpzpAw; wplKk; maYk; euk;Gk; 
kpfTk; Nehjy; jiraope; jpLjy; 
euk;G Kjypa mupf;fg;gLjy; 
FUjpAk; gOg;G Njhd;wy; xOfy; 
clk;G nkypjy; jLkhw; waHr;rp 
vDkpit gpwTk; Gw;wpd; FwpNa 
 
 
GiuNjhd;WjYk; jir jpiwj; jplYk; 
 cl;rij jpusYk; FUjpnahOfYk; 
vspjpw; wPuhg; Gz; Njhd;wplYk; 
FUf;fs; Nghyj; jirNkw; nwhd;wYk; 
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czT whik njhlHe;j Njhd;wYk; 
mbf;fb apUky; Fuyil Njhd;wYk; 
Gs;spfs; Njhd;wYk; epwk; NtWgLjYk; 
ePq;fhj; jsHr;rp aaHr;rp Njhd;wYk; 
Flw;gpzp njhlHe;j Njhd;wYk; gpwTk; 
Gw;WNeha;f;Fk; Kd;dkhjypd; 
Kw;gl TzHe;J Nghjy; khNk 
 
அ©றி} ண 
my;Fy; thapD kfe;J kUfpDk; 
 Nrtw;g+g;Nghy; moprij tsHjy; 
Nehjy; Fj;jy; rPo;kpf nthOfy; 
FUjp ntspg;gly; jireuk; gopjy; 
Giugly; vDkpit ngz;Fwpg; Gw;wpd; 
Fwpnad nkhopg newpgwp GytH 
 
த¯, தரா ேநாtறி 
Gw;W Nehaidj;Jk; nghUe;jg; Ngzpd; 
 mupjpw; wPHtd thFnkd;g 
mWitapw; rpw;rpy mfy;tJ khFk; 
 kpf;f jsHr;rp nkypT ePH Ntl;if 
nghwpfspd; Mw;wyopjy; kaf;fk; 
 fha;r;ry; Njhd;wy; tpf;fnyLj;jy; 
czT nry;yhik cz;lj whik 
 vDkpit gpwTe; jPuhf; FwpAk; 
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3.6.2. MODERN ASPECT:  
INTRODUCTION  
Cervical cancer is a cancer arising from the cervix. It is due to the abnormal 
growth of cells that have the ability to invade or spread to other parts of the 
body. Early on, typically no symptoms are seen. Later symptoms may include 
abnormal vaginal bleeding, pelvic pain, or pain during sexual intercourse. While 
bleeding after sex may not be serious, it may also indicate the presence of cervical 
cancer.  
Human papillomavirus (HPV) infection appears to be involved in the 
development of more than 90% of cases; most people who have had HPV infections, 
however, do not develop cervical cancer. Other risk factors include smoking, a weak 
immune system,birth control pills, starting sex at a young age, and having many 
sexual partners, but these are less important. Cervical cancer typically develops 
from precancerous changes over 10 to 20 years. About 90% of cervical cancer cases 
are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are 
other types. Diagnosis is typically by cervical screening followed by 
a biopsy. Medical imaging is then done to determine whether or not the cancer has 
spread.  
HPV vaccines protect against between two and seven high-risk strains of this 
family of viruses and may prevent up to 90% of cervical cancers. As a risk of cancer 
still exists, guidelines recommend continuing regular Pap smears. Other methods of 
prevention include: having few or no sexual partners and the use 
of condoms. Cervical cancer screening using the Pap smear oracetic acid can identify 
precancerous changes which when treated can prevent the development of 
cancer. Treatment of cervical cancer may consist of some combination 
of surgery, chemotherapy, and radiotherapy. Five year survival rates in the United 
States are 68%. Outcomes, hever, depend very much on how early the cancer is 
detected.[8] 
Worldwide, cervical cancer is both the fourth-most common cause of cancer 
and the fourth-most common cause of death from cancer in women. In 2012, an 
estimated 528,000 cases of cervical cancer occurred, with 266,000 deaths. This is 
about 8% of the total cases and total deaths from cancer. About 70% of cervical 
cancers occur in developing countries. In low-income countries, it is the most 
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common cause of cancer death. In developed countries, the widespread use of cervical 
screening programs has dramatically reduced rates of cervical cancer. In medical 
research, the most famous cell line known as HeLa was developed from cervical 
cancer cells of a woman named Henrietta Lacks.  
Signs and symptoms 
The early stages of cervical cancer may be completely free of 
symptoms. Vaginal bleeding, contact bleeding (one most common form being 
bleeding after sexual intercourse), or (rarely) a vaginal mass may indicate the 
presence of malignancy. Also, moderate pain during sexual intercourse and vaginal 
discharge are symptoms of cervical cancer. In advanced disease, metastases may be 
present in the abdomen, lungs, or elsewhere. 
Symptoms of advanced cervical cancer may include: loss of appetite, weight 
loss, fatigue, pelvic pain, back pain, leg pain, swollen legs, heavy vaginal bleeding, 
bone fractures, and/or (rarely) leakage of urine or feces from the vagina. Bleeding 
after douching or after a pelvic exam is a common symptom of cervical cancer.  
Causes 
Infection with some types of HPV is the greatest risk factor for cervical 
cancer, followed by smoking. HIV infection is also a risk factor. Not all of the causes 
of cervical cancer are known, however, and several other contributing factors have 
been implicated.  
Human papillomavirus 
Human papillomavirus types 16 and 18 are the cause of 75% of cervical 
cancer cases globally, while 31 and 45 are the causes of another 10%. 
Women who have many sexual partners (or who have sex with men who have had 
many other partners) have a greater risk. 
  Of the 150-200 types of HPV known, 15 are classified as high-risk types (16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), three as probable high-risk 
(26, 53, and 66), and 12 as low-risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 
CP6108).  
Genital warts, which are a form of benign tumor of epithelial cells, are also 
caused by various strains of HPV. However, these serotypes are usually not related to 
cervical cancer. It is common to have multiple strains at the same time, including 
those that can cause cervical cancer along with those that cause warts. 
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Infection with HPV is generally believed to be required for cervical cancer to 
occur.  
Smoking 
Cigarette smoking, both active and passive, increases the risk of cervical 
cancer. Among HPV-infected women, current and former smokers have roughly two 
to three times the incidence of invasive cancer. Passive smoking is also associated 
with increased risk, but to a lesser extent. Smoking has also been linked to the 
development of cervical cancer. Smoking can increase the risk in women a few 
different ways, which can be by direct and indirect methods of inducing cervical 
cancer. A direct way of contracting this cancer is a smoker has a higher chance 
of CIN3 occurring which has the potential of forming cervical cancer. When CIN3 
lesions lead to cancer, most of them have the assistance of the HPV virus, but that is 
not always the case, which is why it can be considered a direct link to cervical 
cancer.Heavy smoking and long-term smoking seem to have more of a risk of getting 
the CIN3 lesions than lighter smoking or not smoking at all. Although smoking has 
been linked to cervical cancer, it aids in the development of HPV which is the leading 
cause of this type of cancer. Also, not only does it aid in the development of HPV, but 
also if the woman is already HPV-positive, she is at an even greater likelihood of 
contracting cervical cancer.  
Oral contraceptives 
Long-term use of oral contraceptives is associated with increased risk of 
cervical cancer. Women who have used oral contraceptives for 5 to 9 years have 
about three times the incidence of invasive cancer, and those who used them for 10 
years or longer have about four times the risk.  
Multiple pregnancies 
Having many pregnancies is associated with an increased risk of cervical 
cancer. Among HPV-infected women, those who have had seven or more full-term 
pregnancies have around four times the risk of cancer compared with women with no 
pregnancies, and two to three times the risk of women who have had one or two full-
term pregnancies.  
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Diagnosis 
Biopsy 
The Pap smear can be used as a screening test, but is false negative in up to 
50% of cases of cervical cancer. Confirmation of the diagnosis of cervical cancer or 
precancer requires a biopsy of the cervix. This is often done through colposcopy, a 
magnified visual inspection of the cervix aided by using a dilute acetic 
acid (e.g. vinegar) solution to highlight abnormal cells on the surface of the cervix. 
Medical devices used for biopsy of the cervix include punch forceps, SpiraBrush 
CX, SoftBiopsy, or Soft-ECC. 
Colposcopic impression, the estimate of disease severity based on the visual 
inspection, forms part of the diagnosis. 
Further diagnostic and treatment procedures are loop electrical excision 
procedure and conization, in which the inner lining of the cervix is removed to be 
examined pathologically. These are carried out if the biopsy confirms severe cervical 
intraepithelial neoplasia. 
This large squamous carcinoma (bottom of picture) has obliterated the cervix 
and invaded the lower uterine segment. The uterus also has a roundleiomyoma up 
higher. 
Often before the biopsy, the doctor asks for medical imaging to rule out other 
causes of woman's symptoms. Imaging modalities such as ultrasound, CT scan and 
MRI have been used to look for alternating disease, spread of tumor and effect on 
adjacent structures. Typically, they appear as heterogeneous mass in the cervix.  
Precancerous lesions 
Cervical intraepithelial neoplasia, the potential precursor to cervical cancer, is 
often diagnosed on examination of cervical biopsies by a pathologist. For 
premalignant dysplastic changes, cervical intraepithelial neoplasia grading is used. 
The naming and histologic classification of cervical carcinoma precursor 
lesions has changed many times over the 20th century. TheWorld Health 
Organization classification system was descriptive of the lesions, naming them mild, 
moderate, or severe dysplasia orcarcinoma in situ (CIS). The term, cervical 
intraepithelial neoplasia (CIN) was developed to place emphasis on the spectrum of 
abnormality in these lesions, and to help standardise treatment. It classifies mild 
dysplasia as CIN1, moderate dysplasia as CIN2, and severe dysplasia and CIS as 
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CIN3. More recently, CIN2 and CIN3 have been combined into CIN2/3. These results 
are what a pathologist might report from a biopsy. 
These should not be confused with the Bethesda system terms for Pap smear 
(cytopathology) results. Among the Bethesda results: Low-grade Squamous 
Intraepithelial Lesion (LSIL) and High-grade Squamous Intraepithelial Lesion 
(HSIL). An LSIL Pap may correspond to CIN1, and HSIL may correspond to CIN2 
and CIN3, however they are results of different tests, and the Pap smear results need 
not match the histologic findings. 
Cancer subtypes 
Histologic subtypes of invasive cervical carcinoma include the 
following: Though squamous cell carcinoma is the cervical cancer with the most 
incidence, the incidence of adenocarcinoma of the cervix has been increasing in 
recent decades.  
 squamous cell carcinoma (about 80-85%) 
 adenocarcinoma (about 15% of cervical cancers) 
 adenosquamous carcinoma 
 small cell carcinoma 
 neuroendocrine tumour 
 glassy cell carcinoma 
 villoglandular adenocarcinoma 
Noncarcinoma malignancies which can rarely occur in the cervix 
include melanoma and lymphoma. The FIGO stage does not incorporatelymph 
node involvement in contrast to the TNM staging for most other cancers. 
For cases treated surgically, information obtained from the pathologist can be 
used in assigning a separate pathologic stage, but is not to replace the original clinical 
stage. 
Staging 
Cervical cancer is staged by the International Federation of Gynecology and 
Obstetrics (FIGO) staging system, which is based on clinical examination, rather than 
surgical findings. It allows only these diagnostic tests to be used in determining the 
stage: palpation, inspection,colposcopy, endocervical curettage,  hysteroscopy, 
 cystoscopy,  proctoscopy, intravenous urography, and X-ray examination of the lungs 
and skeleton, and cervical conization. 
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Prevention  
Screening 
Checking the cervix by the Papanicolaou test, or Pap smear, for cervical 
cancer has been credited with dramatically reducing the number of cases of and 
mortality from cervical cancer in developed countries. Pap smear screening every 3–5 
years with appropriate follow-up can reduce cervical cancer incidence up to 
80%. Abnormal results may suggest the presence of precancerous changes, allowing 
examination and possible preventive treatment. The treatment of low-grade lesions 
may adversely affect subsequent fertility and pregnancy. Personal invitations 
encouraging women to get screened are effective at increasing the likelihood they will 
do so. Educational materials also help increase the likelihood women will go for 
screening, but they are not as effective as invitations.  
According to the 2010 European guidelines, the age at which to start screening 
ranges between 20 and 30 years of age, "but preferentially not before age 25 or 30 
years", and depends on burden of the disease in the population and the available 
resources.  
In the United States, screening is recommended to begin at age 21, regardless 
of age at which a woman began having sex or other risk factors. Pap tests should be 
done every three years between the ages of 21 and 65. In women over the age of 65, 
screening may be discontinued if no abnormal screening results were seen within the 
previous 10 years and no history of CIN 2 or higher exists. HPV vaccination status 
does not change screening rates. Screening can occur every 5 years between ages 30 
and 65 when a combination of cervical cytology screening and HPV testing is used 
and this is preferred. However, it is acceptable to screen this age group with a Pap 
smear alone every 3 years. Screening is not beneficial before age 25 as the rate of 
disease is low. Screening is not beneficial in women older than 60 years if they have a 
history of negative results.  
Liquid-based cytology is another potential screening method. Although it was 
probably intended to improve on the accuracy of the Pap test, its main advantage has 
been to reduce the number of inadequate smears from around 9% to around 1%. This 
reduces the need to recall women for a further smear. The United States Preventive 
Services Task Force supports screening every 5 years in those who are between 30 
and 65 years when cytology is used in combination with HPV testing.  
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Pap smears have not been as effective in developing countries. This is in part 
because many of these countries have an impoverished health care infrastructure, too 
few trained and skilled professionals to obtain and interepret Pap smears, uninformed 
women who get lost to follow-up, and a lengthy turn-around time to get results. These 
realities have resulted in the investigation of cervical screening approaches that use 
fewer resources and offer rapid results such as visual inspection with acetic acid or 
HPV DNA testing.  
Barrier protection 
Barrier protection and/or spermicidal gel use during sexual intercourse 
decreases cancer risk. Condoms offer protection against cervical cancer. Evidence on 
whether condoms protect against HPV infection is mixed, but they may protect 
against genital warts and the precursors to cervical cancer. They also provide 
protection against other STIs, such as HIV and Chlamydia, which are associated with 
greater risks of developing cervical cancer. 
Condoms may also be useful in treating potentially precancerous changes in 
the cervix. Exposure to semen appears to increase the risk of precancerous changes 
(CIN 3), and use of condoms helps to cause these changes to regress and helps clear 
HPV. One study suggests that prostaglandin in semen may fuel the growth of cervical 
and uterine tumors and that affected women may benefit from the use of condoms.  
Abstinence also prevents HPV infection.  
Vaccination 
Two HPV vaccines (Gardasil and Cervarix) reduce the risk of cancerous or 
precancerous changes of the cervix and perineum by about 93% and 62%, 
respectively. The vaccines are between 92% and 100% effective against HPV 16 and 
18 up to at least 8 years.  
HPV vaccines are typically given to age 9 to 26 as the vaccine is only 
effective if given before infection occurs. The vaccines have been shown to be 
effective for at least 4 to 6 years, and they are believed to be effective for 
longer; however, the duration of effectiveness and whether a booster will be needed is 
unknown. The high cost of this vaccine has been a cause for concern. Several 
countries have considered (or are considering) programs to fund HPV vaccination. 
Since 2010, young women in Japan have been eligible to receive the cervical cancer 
vaccination for free. In June 2013, the Japanese Ministry of Health, Labor and 
Welfaremandated that, before administering the vaccine, medical institutions must 
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inform women that the Ministry does not recommend it. However, the vaccine is still 
available at no cost to Japanese women who choose to accept the vaccination.  
Nutrition 
Vitamin A is associated with a lower risk[61] as are vitamin B12, vitamin 
C, vitamin E, and beta-carotene.[62] 
Treatment 
The treatment of cervical cancer varies worldwide, largely due to access to 
surgeons skilled in radical pelvic surgery, and the emergence of "fertility-sparing 
therapy" in developed nations. Because cervical cancers are radiosensitive, radiation 
may be used in all stages where surgical options do not exist. 
Microinvasive cancer (stage IA) may be treated by hysterectomy (removal of 
the whole uterus including part of the vagina For stage IA2, the lymph nodes are 
removed, as well. Alternatives include local surgical procedures such as a loop 
electrical excision procedure or cone biopsy. For 1A1 disease, a cone biopsy (cervical 
conization) is considered curative. 
If a cone biopsy does not produce clear margins (findings on biopsy showing 
that the tumor is surrounded by cancer free tissue, suggesting all of the tumor is 
removed), one more possible treatment option for women who want to preserve their 
fertility is a trachelectomy. This attempts to surgically remove the cancer while 
preserving the ovaries and uterus, providing for a more conservative operation than a 
hysterectomy. It is a viable option for those in stage I cervical cancer which has not 
spread; however, it is not yet considered a standard of care, as few doctors are skilled 
in this procedure. Even the most experienced surgeon cannot promise that a 
trachelectomy can be performed until after surgical microscopic examination, as the 
extent of the spread of cancer is unknown. If the surgeon is not able to 
microscopically confirm clear margins of cervical tissue once the woman is under 
general anesthesia in the operating room, a hysterectomy may still be needed. This 
can only be done during the same operation if the woman has given prior consent. 
Due to the possible risk of cancer spread to the lymph nodes in stage 1b cancers and 
some stage 1a cancers, the surgeon may also need to remove some lymph nodes from 
around the uterus for pathologic evaluation. 
A radical trachelectomy can be performed abdominally or vaginally and 
opinions are conflicting as to which is better. A radical abdominal trachelectomy with 
lymphadenectomy usually only requires a two- to three-day hospital stay, and most 
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women recover very quickly (about six weeks). Complications are uncommon, 
although women who are able to conceive after surgery are susceptible to preterm 
labor and possible late miscarriage. Wait at least one year is generally recommended 
before attempting to become pregnant after surgery. Recurrence in the residual cervix 
is very rare if the cancer has been cleared with the trachelectomy. Yet, women are 
recommended to practice vigilant prevention and follow-up care including Pap 
screenings/colposcopy, with biopsies of the remaining lower uterine segment as 
needed (every 3–4 months for at least 5 years) to monitor for any recurrence in 
addition to minimizing any new exposures to HPV through safe sex practices until 
one is actively trying to conceive. 
Early stages (IB1 and IIA less than 4 cm) can be treated with radical 
hysterectomy with removal of the lymph nodes or radiation therapy. Radiation 
therapy is given as external beam radiotherapy to the pelvis 
and brachytherapy (internal radiation). Women treated with surgery who have high-
risk features found on pathologic examination are given radiation therapy with or 
without chemotherapy to reduce the risk of relapse. 
Brachytherapy for cervical cancer 
Larger early-stage tumors (IB2 and IIA more than 4 cm) may be treated with 
radiation therapy and cisplatin-based chemotherapy, hysterectomy (which then 
usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by 
hysterectomy. When cisplatin is present, it is thought to be the most active single 
agent in periodic diseases.  
Advanced-stage tumors (IIB-IVA) are treated with radiation therapy and 
cisplatin-based chemotherapy. On June 15, 2006, the US Food and Drug 
Administration approved the use of a combination of two chemotherapy 
drugs, hycamtin and cisplatin, for women with late-stage (IVB) cervical cancer 
treatment. Combination treatment has significant risk of neutropenia, anemia, 
and thrombocytopenia side effects. 
For surgery to be curative, the entire cancer must be removed with no cancer 
found at the margins of the removed tissue on examination under a microscope. This 
procedure is known as exenteration 
Prognosis 
Prognosis depends on the stage of the cancer. The chance of a survival rate 
around 100% is high for women with microscopic forms of cervical cancer. With 
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treatment, the five-year relative survival rate for the earliest stage of invasive cervical 
cancer is 92%, and the overall (all stages combined) five-year survival rate is about 
72%. These statistics may be improved when applied to women newly diagnosed, 
bearing in mind that these outcomes may be partly based on the state of treatment five 
years ago when the women studied were first diagnosed. With treatment, 80 to 90% of 
women with stage I cancer and 60 to 75% of those with stage II cancer are alive 5 
years after diagnosis. Survival rates decrease to 30 to 40% for women with stage III 
cancer and 15% or fewer of those with stage IV cancer 5 years after diagnosis.  
According to the International Federation of Gynecology and Obstetrics, 
survival improves when radiotherapy is combined with cisplatin-based chemotherapy.  
As the cancer metastasizes to other parts of the body, prognosis drops 
dramatically because treatment of local lesions is generally more effective than 
whole-body treatments such as chemotherapy. 
Interval evaluation of the woman after therapy is imperative. Recurrent 
cervical cancer detected at its earliest stages might be successfully treated with 
surgery, radiation, chemotherapy, or a combination of the three. About 35% of 
women with invasive cervical cancer have persistent or recurrent disease after 
treatment.  
Average years of potential life lost from cervical cancer are 25.3. Around 
4,600 women were projected to die in 2001 in the US of cervical cancer, and the 
annual incidence was 13,000 in 2002 in the US, as calculated by SEER. Thus, the 
ratio of deaths to incidence is about 35.4%. 
Regular screening has meant that precancerous changes and early-stage 
cervical cancers have been detected and treated early. Figures suggest that cervical 
screening is saving 5,000 lives each year in the UK by preventing cervical 
cancer. About 1,000 women per year die of cervical cancer in the UK. All of 
the Nordic countries have cervical cancer-screening programs in place. Pap smear was 
integrated into clinical practice in the Nordic countries in the 1960s.  
Epidemiology 
Worldwide 
Worldwide, cervical cancer is both the fourth-most common cause of cancer 
and deaths from cancer in women. In 2012, 528,000 cases of cervical cancer were 
estimated to have occurred, with 266,000 deaths. It is the second-most common cause 
of female-specific cancer after breast cancer, accounting for around 8% of both total 
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cancer cases and total cancer deaths in women. About 80% of cervical cancers occur 
in developing countries.  
United States 
An estimated 12,900 new cervical cancers and 4,100 cervical cancer deaths 
will occur in the United States in 2015. In the United States, it is the eight-most 
common cancer of women. The median age at diagnosis is 48. Hispanic women are 
significantly more likely to be diagnosed with cervical cancer than the general 
population. In 1998, about 12,800 women were diagnosed in the US and about 4,800 
died. In 2014, an estimated 12,360 new cases were expected to be diagnosed, and 
about 4,020 were expected to die of cervical cancer. Among cancers of the female 
reproductive tract it is less common than endometrial cancer and ovarian cancer. The 
rates of new cases in the United States was 7 per 100,000 women in 2004. Cervical 
cancer deaths decreased by approximately 74% in the last 50 years, largely due to 
widespread Pap smear screening. The annual direct medical cost of cervical cancer 
prevention and treatment prior to introduction of the HPV vaccine was estimated at $6 
billion.  
EU 
In the European Union, about 34,000 new cases per year and over 16,000 
deaths due to cervical cancer occurred in 2004.  
UK 
Cervical cancer is the 12th-most common cancer in women in the UK (around 
3,100 women were diagnosed with the disease in 2011), and accounts for 1% of 
cancer deaths (around 920 died in 2012). With a 42% reduction from 1988-1997, the 
NHS-implemented screening programme has been highly successful, screening the 
highest-risk age group (25–49 years) every 3 years, and those ages 50–64 every 5 
years. 
Canada 
In Canada, an estimated 1,300 women will have been diagnosed with cervical 
cancer in 2008 and 380 will have died.  
Australia 
Australia had 734 cases of cervical cancer (2005). The number of women 
diagnosed with cervical cancer has dropped on average by 4.5% each year since 
organised screening began in 1991 (1991–2005). Regular twice-yearly Pap tests can 
 
 
63 
 
reduce the incidence of cervical cancer up to 90% in Australia, and save 1,200 
Australian women from dying from the disease each year.  
India 
In India, the number of people with cervical cancer is rising, but overall the 
age-adjusted rates are decreasing. Usage of condoms in the female population has 
improved the survival of women with cancers of the cervix.  
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4. MATERIALS AND METHODS 
4.1. Preparation of the drug 
Drug selection 
 In this dissertation of “Rasa Karpoora Kuligai” has been selected from the classical 
siddha literature,”Gunapadam Thathu Jeeva Vaguppu.. 
Ingredients of the drug are, 
1. Purified Pooram   - 21gm 
    (Calomel/Hydrargyrum subchloride) 
2. Betel Leaves   - 168gm 
    (Piper betle) 
3. Pepper     - 126gm 
    (Piper nigrum) 
4. Garlic    - 84gm 
    (Allium sativum) 
5. Betel leaf juice   - q/s 
6. mother s milk                         -          q/s 
 
Collection of the drugs: 
 All the raw materials were obtained from country drug shop, Tirunelveli and 
Nagercoil districts. 
Identification and Authentication: 
All raw drugs were identified and Authenticated by the experts of Gunapadam 
(pharmacology) and Medicinal Botany departments, in Government Siddha Medical 
College Palayamkottai, Tirunelveli. 
            The specimen samples of the identified raw drugs were presented in the 
laboratory of PG Gunapadam for future references.  
Purification of raw drugs: 
Calomel: 
 The poultice made of betel leaf and pepper each 8.75gm is taken and dissolved 
in 1.3 litre of water. Calomel 35gm tied with a cloth and immersed in the liquid from 
the cross bar without touching the bottom of the vessels and heated. After the water is 
reduced to ¾ of its volume, the calomel is taken out, washed with water and dried to 
get it in purified form. 
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Pepper: 
 Soak pepper in the juice of Utthamani and dry it in sunlight till the juice dries 
up compeletely. 
Garlic: 
Peel the skin of garlic. 
Betel Leaves: 
Remove the stalk and midrib of betel leaves. 
PREPARATIONS OF THE DRUG 
(Rasa Karpoora Kuligai) 
 Ingredients of the drug are, 
1. Purified Pooram   - 21gm 
    (Calomel/Hydrargyrum subchloride) 
2. Betel Leaves   - 168gm 
    (Piper betle) 
3. Pepper     - 126gm 
    (Piper nigrum) 
4. Garlic    - 84gm 
    (Allium sativum) 
5. Betel leaf juice   - q/s 
Process: 
Calomel 21gm is soaked in mother’s milk for three days. Garlic 84gm, 
pepper 126gm, and betel leaves 168gm are triturated with betel leaves juice for 15 
hours (5 samam) and then rolled into pills like a unarmed night shade (sundai). Then 
it is dried in shade and preserve get the kuligai for further use. 
Preservation of drug: It is stored in an air tight glass container. 
Administration of the drug: 
Form of the drug : Kuligai 
Route   : Enteral (oral) 
Dosage  : One pill twice a day for seven days  
Adjuvant  : Boiled and Cooled water. 
Shelf Life  : 5 years 
Indications: 
 Scabies, syphilis, Cervical cancer, Penile cancer, Chronic ulcers and Pit wound. 
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4.2. PHARMACEUTICAL REVIEW 
4.2.1. SIDDHA ASPECT OF THE FORMULATION 
khj;jpiu: 
khj;jpiu ghfk;: 
fy;f jputpaq;fisj; jdpahfNtDk;> gw;gnre;J}uq;fSld; Nrh;j;NjDk; 
[yk;> f\hak;> %yifr;rhW ,itfSld; VNjDk; xd;wpy; ed;F 
cwthFk;gbmiuj;J Fwpg;gpl;l mstpd;gb khj;jpiu nra;tjhFk;. 
miug;G tpjp 
khj;jpiu nra;tjw;fhf epakpf;fg;gl;l fy;fq;fis jdpj;jdpahfr; 
#uzpj;J mstpd;gb fy;tj;jpy; ,l;L girAz;lhf;f $ba jputpankhd;wpdhy; 
eidAk;gb gprwpf; fy;tj;jpd; fPo;f;ifapy; itj;J nfhz;L nfhQ;rq; 
nfhQ;rkhff; fy;tj;jpd; Nky;ifapy; VWk;gbj; js;sp miuf;f Ntz;Lk; ,g;gb 
fPo;f;ifapy; ,Ue;j ruf;ifnay;yhk; NkNywpa gpd; kPz;Lk; gbg;gbahf 
fPo;iff;FtUk;gb js;spjs;sp miuj;jy; Ntz;Lk; ,q;qdk; Fwpj;j fhyk; 
tiuapy; miug;gpd; eph;j;Njh\khd khj;jpiuahFk;. 
khj;jpiu jpul;Lk; ghfk; 
miuf;Fk; NghJ> ruf;F fy;tj;jpy; rpwpJk; gw;whky; FotpAld; Gus 
Ntz;LtJkd;wp mJ Fotpf;Fk; fy;tj;jpw;Fk; rk;ge;jkpy;yhky; ,Uf;f 
Ntz;Lkட 
thirid jputpaq;fs; Nrh;f;Fk; fhyk; 
f];J}hp> NfhNuhrid> mk;gh;> Fq;Fkg;G+> gr;irf; fw;G+uk;> 
Kjyhditfis khj;jpiu jpul;l 1 ehopiff;F Kd; Nrh;j;jiug;gJ 
ed;Wmq;qd Kbj;j khj;jpiufis epoYyh;j;jp clNd fy;fhh;f; 
rPrhtpy;gjdQ;nra;jy; Ntz;Lk;. 
miug;gpd; Kd; gpd; Nrh;f;f Ntz;Ltd  
gpuNahfj;jpy; miug;gjw;F vJ fbdkhdNjh mjid fy;tj;jpy; ,l;L 
miuj;J> mJ gf;Ftkhdgpd; kw;witfisg; gbg;gbahf xd;wd; gpd; 
xd;whfr;Nrh;j;J miuj;jy; Ntz;Lk;. thsk; Kjypa gUg;gpdq;fs; NrUk; 
nghOJkhj;jpiu jpul;l 1 rhkj;jpw;F Kd; Nrh;j;jy; Ntz;Lk;. Vnddpy; 
jhsfj;ijNghd;w fbd ruf;Fld; kj;jpkkhd ruf;F 
rk;ge;jg;gbd; jhsfk; vspjpy;miuglhJ. 
thsk; Kjyait ePz;l miug;gpw;F gpd; khj;jpiu nra;J tUk;NghJ> 
mjdpypUe;J ijyk; ntspg;gLk; mjdhy; mjd; td;ik FiwAk; 
 
 
 
4.2.2. MODERN ASPECT OF THE FORMULATION 
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Tablet (Pill)-Kuligai 
A tablet is a pharmaceutical dosage form it otherwise called as caplet. 
Medicinal tablets are called as "pills". Originally "pills" referred specifically to a soft 
mass rolled into a ball shape, rather than a compressed powder. (wikipedia. org). 
As per Indian Pharmacopeia 2007 defined the Tablets are solid dosage forms 
each containing a unit dose of one or more medicaments. They are anticipated for oral 
route. A tablet consists an active medicament with excipients which are in powder 
form are compressed or pressed into a solid dosage form. About two third drugs 
prescribed are in solid dosage form and tablets include half of them. 
Classification: 
As per IP2007 tablets are majorly classified into following categories (Indian 
pharmacopoeia 2007) 
1. Uncoated Tablets: 
This type of tablets contains single layer or more than one layer tablet 
consisting of active ingredient with the excipients, no additional cover is applied on to 
it after the compression. 
2. Coated Tablets: 
Coated types of tablets have an additional coating layer on it after the tablet 
was compressed, the coating layer of tablets formed with sugar, gums, resins, inactive 
or insoluble fillers, plasticisers, polyhydric alcohols, waxes. 
3. Dispersible Tablets: 
These are the film coated or uncoated tablets because a uniform dispersion 
when suspended in water 
4. Effervescent Tablets: 
These type of tablets which are uncoated and are planned to be dissolved and 
produce an dispersion before they are administered the dissolution is achieved by the 
reaction between an organic acid and bicarbonate which produce CO2, thus produced 
CO2 will disintegrate the tablet so which dissolves in the solution to produce an 
suspension which was rapidly absorbed. 
5. Modified-release Tablets: 
These types of tablets are the coated or uncoated tablets which are designed in 
such a way that the rate or location of the active ingredient released is modified. It 
includes enteric coated tablets, prolong release tablet or delay release tablet. 
A) Enteric-coated Tablets: 
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These are also called as gastro resistant tablets as they resistant to the gastric 
juices; these are formulated by coating the tablet with anionic polymer of 
methylacrylic acid and their esters or by coating with cellulose acetyl pthylate. 
Ex: erythromycin, NSAIDS 
B) Prolonged- release Tablets: 
These types are otherwise called as sustain release tablets or extended release 
tablets was formulated in such a way that the active ingredient is released for a 
prolong duration of time and is available in systemic circulation after administration. 
C) Delayed-release Tablets: 
This dosage form was planned to release the drug after some time delay or 
after the tablet has passed one part of the GIT into another. All enteric coated tablets 
are type of delayed action tablet but all delayed action of tablets was not enteric or not 
intended to produce enteric action. 
6. Soluble Tablets: 
These are coated or uncoated tablets which are planned to dissolve in water 
before they are administered. 
7. Tablets for Use in the Mouth: 
These are the tablet formulations which are planned to be show local action in 
the buccal cavity. These include buccal tablet, Sublingual Tablets and Troche or 
lozenges.Buccal tablets are placed in between the cheek and gingival. Sublingual 
tablets are placed below the tongue Eg: glyceryl trinitrate. 
8. Tablets for other routes of administration: 
These include implantable tablets and vaginal tablet. These are inserted in to 
the rectum or vagina for their local or systemic action. 
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4.2.3.ADVERSE EFFECT OF CHEMOTHERAPHY 
CHEMOTHERAPHY DRUGS USED IN GYNAECOLOGIGIC CANCER 
Cycle Non Specific Agents : 
Alkylating Agents : Alkylating agents prevent cell division primarily by cross 
linking strands of DNA.  Because of continued synthesis of their cell constituents, 
such as RNA and Protein, growth is unbalanced and the cell dies.  Activity of 
Alkylating agents does not depend on DNA synthesis in the target cells. 
TABLE : 1 
Drug Dose and Route of 
Administration 
Acute side 
effects 
Toxicity 
Cyclophosphamide 500-1500 mg/m2 
single dose IV 
Nausea, 
Vomiting 
Bone Marrow 
Depression 
Alopecia 
Cystitis 
Chlorambucil 
(Leukeran) 
0.1-0.2 mg/kg/day 
PO 
Nausea, 
Vomiting 
Bone Marrow 
Depression 
Melphalan 0.2 mg/kg/day PO 
for 4 days 
every 4 - 6 weeks 
Nausea, 
Vomiting 
Bone Marrow 
Depression 
Thiotepa 0.2 mg/kg/day for 5 
days 
None Bone Marrow 
Depression 
Ifosfamide 7-10g/m2 IV over 3-
5 daysevery 3 - 4 
weeks 
Nausea, 
Vomiting 
Bone Marrow 
Depression 
Alopecia 
Cystitis 
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Cycle Specific Agents  
Antimetabolites : Antimetabolites act by inhibiting essential metabolic 
processes that are required for DNA and RNA synthesis. 
TABLE : 2 
Drug Dose and Route of 
Administration 
Acute side effects Toxicity 
5-Fluorouracil 
(5-Fu) 
12mg/kg/day IV for 
4 days 
Occasional 
Nausea, Vomiting 
Bone Marrow 
Depression 
Diarrhoea, Stomatitis 
Alopecia 
Methotrexate 1.5 mg/kg IV for  
5 days 
None Bone Marrow 
Depression 
Megaloblastic 
Anaemia, 
Diarrhoea, Stomatitis 
Alopecia, Hepatic 
fibrosis, Vasculitis, 
Pulmonary fibrosis 
Cytarabine 200mg/m2 daily for  
5 days by 
continuous infusion 
Nausea, Vomiting Bone Marrow 
Depression 
Megaloblastosis, 
Leucopenia, 
Thrombocytopenia 
Gemcitabine 800-1000mg/m2 IV 
weekly every  
3 weeks 
Mild Nausea, 
Vomiting 
Malaise,  
Maculopopular 
Rash 
Bone Marrow 
Depression 
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Antibiotics : 
Several cytotoxic Antibiotic have come into use for chemotherapy of certain 
neoplasms. Those used in gynaecological cancers are given in table. 
TABLE : 3 
Drug Dose and Route of 
Administration 
Acute side 
effects 
Toxicity 
Actinomycin D 
(Dactinomycin) 
15mg/kg/day IV Pain on focal 
infiltration with 
skin Necrosis, 
Nausea and 
Vomiting, 
Cramps and 
Diarrhoea 
Bone Marrow 
Depression 
Stomatitis, Erythema, 
Hyperpigmentation and 
Desquamation in area of 
Previous irritation 
Mitomycin C 0.05 mg/kg/day IV 
for 6 days then 
alternate days until 
a 50 mg total dose 
Nausea and 
Vomiting  
Local 
inflammation 
and Ulceration if 
extra vasated 
Neutropenia, 
Thrombocytopenia, Oral 
Ulceration, Diarrhoea 
Bleomycin 10-20mg/m2 IV Fever Chills, 
Nausea, 
Vomiting, Local 
pain and 
Phlebitis 
Hyperpigmentation of 
skin, Pal Phemonitis 
with dyspnoea, fibrosis, 
especially with more 
than 400mg total dose 
 
Doxorubicin  
(Adriamycin) 
60-100 mg/m2 IV 
every 3 weeks 
Nausea, 
Vomiting, Fever 
local Phlebitis, 
Necrosis if extra 
vasated, red 
urine 
Bone Marrow 
Depression, 
Alopecia, Cardiac 
Toxicity, related to 
Cumulative dose 
Atrophy of myocardia if 
a total dose of 450-500 
kg/mg is exceeded 
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Plant Alkaloids : 
The plant alkaloids arrest cells in Metaphase by binding the microtubular 
protein used in the formation of the mitotic spindle. 
TABLE : 4 
Drug Dose and Route of 
Administration 
Acute side effects Toxicity 
Vinblastine 
(Velban) 
0.10-0.15 mg/kg/1 
week IV 
Severe prolonged 
inflammation if 
extra vasated, 
Nausea, 
Vomiting, 
Headache, 
Parasthesias 
Bone Marrow 
Depression 
Alopecia, Muscle 
Weakness, Pheripheral 
Neuropathy, Mental 
depression and Stomatitis 
Vincristine  
(Oncovin) 
0.4-1.4 mg/m2 IV 
weekly 
Local 
inflammation if 
extra vasated 
Parasthesias, Weakness 
loss of reflexes, 
Constipation hoarseness, 
foot drop, Marrow 
toxicity, anaemia, 
alopecia 
Etoposide (VP-
16) 
100 mg/m2 IV day 
1:3:5 repeat in  
4 weeks 
Nausea and 
Vomiting 
Leucopenia, 
Thrombocytopenia, 
Alopecia, Headache, 
Fever, Occasional 
Hypotension 
Pacilitaxel 
(Taxol) 
170-250 mg/m2 IV 
every 3 - 4 weeks 
Allergic reaction 
Nausea, Vomiting 
Bone Marrow 
Depression 
Severe allergic like 
reactions with facial 
erythema, dyspnoea, 
Tachycardia, 
Hypotension, 
Cardiotoxicity, Alopecia, 
Stomatitis, Fatique 
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Miscellaneous Chemotherapy Drugs : 
Certain Neoplastic agents are available that do not clearly fit into any of the 
above categories. 
TABLE : 5 
Drug Dose and Route 
of 
Administration 
Acute side 
effects 
Toxicity 
Cisplantin 
(Cisdiamminedichloro 
Platinum) 
50-100 mg/m2 
IV every 3 
weeks 
Nausea and 
Vomiting 
Renal damage, 
Moderate 
myelosuppresion, 
Neurotoxicity, severe 
renal damage can be 
avoided by not 
exceeding a total dose 
of 500 mg/m2 in any 
treatment course 
Carboplatin 
(Paraplatin) 
250-400 mg/m2 
IV by 24 hr. 
continuous 
infusion every  
2-4 weeks 
Mild Nausea 
and Vomiting 
Bone Marrow 
Depression 
esp. Thrombocytopenia 
Hydroxyurea 80mg/kg PO 
every 3 days 
Anorexia and 
Nausea 
Bone Marrow 
Depression 
MegaloblasticAnaemia, 
Stomatitis, Diarrhoea, 
Alopecia 
Hexamethyl 
Melamine 
4-12 mg/kg/day 
PO in divided 
doses 
Nausea and 
Vomiting 
Bone Marrow 
Depression 
Neurotoxicity both 
central and Peripheral 
Hycomptamine 
(Topotecan) 
1.5 mg/m2 daily 
for 5 days 
Maculopopular 
Pruritic 
exanthema 
Bone Marrow 
Depression 
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Medroxy Progesterone 
Acetate (MPA) 
400-800 
mg/week IM 
None Liver function 
Abnormalities alopecia 
and hypersensitivity 
reactions 
Tamoxifen 10-20 mg PO 
twice daily 
Nausea Hot flashes, Pruritis 
Vulvae, Occasional 
Vaginal bleeding 
Leuprolide 1mg/day 
Subcutaneously 
Nausea Hot flashes 
 
DRUG TOXICITY : 
 The mechanism of toxicity is similar to the one producing the desired 
cytotoxic effect chemotherapeutic agents can damage even organs with limited cell 
proliferation.  Chemotherapeutic agents must be used at doses that produce some 
degree of Toxicity to normal tissue in orders to be effective. 
HAEMATOLOGIC TOXICITY : 
 The most common haematologic adverse effects include myelosuppression, 
manifested primarily as Leucopenia, thrombocytopenia and anaemia.  The majority of 
chemotherapeutic agents produce myelosuppression.  Most of these produce a 
maximum drop in leucocyte and platelet counts between day 7 and day 14 following 
drug administration, with recovery completed between day 21 and day 28. 
DERMATOLOGIC TOXICITY : 
EXTRAVASION INJURY : 
 The administration of chemotherapy generally involves the use of veins 
located between the dermis and the subcutaneous fat of the upper extremity.  
Extravasion of certain cytotoxic drugs into this space can cause a full thickness of 
skin and in areas with little subcutaneous fat, damage to Nerves, tendons and Muscles 
as well. 
RADIATION ENHANCEMENT EFFECTS : 
 Certain cytotoxic drugs have the capacity to cause damage to previously 
irradiated tissue.  Particularly skin and mucous membrane. Drugs commonly 
associated with this type of reaction include Actinomycin D, Doxorubicin, 5-
Fluorouracil, and Hydroxyurea.  The reaction assumes the form of an erythema 
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followed by dry desquamation with occasional ulceration.  Management ranges from 
topical steroids and cool soaks for mild to moderate reactions, to surgical debridement 
for more severe reactions associated with ulceration. 
ALOPECIA : 
 Hair loss associated with chemotherapy is a result of the effect of cyrotoxic 
agents on the rapidly proliferating tissue of the hair follicle.  Inhibition of the 
activities of the growth cycle results in a failure to maintain the size of the root and 
the diameter of the shaft of the hair.  The resultant thinner shaft is more susceptible to 
breakage with consequent loss of hair. 
GASTRO INTESTIONAL EFFECTS : 
 Nausea and Vomiting secondary to chemotherapy are mediated through the 
vomiting centre in the medulla stimulation of this center arises from the 
chemoreceptor trigger zone, which lies close to the vomiting centre, (or) from stimuli 
transmitted from the cerebral cortex, gastrointestinal tract, heart and vestibular 
apparatus. 
MUCOSITIS : 
 The term mucositis refers to the effect of certain chemotherapeutic agents on 
the epithelial lining of the gastrointestinal tract and includes stomatitis, cheilosis, 
glossitis, esophagitis and oral ulceration. 
DIARRHOEA AND CONSTIPATION : 
 Diarrhoea, particularly bloody diarrhoea may be associated with those agents 
that produce mucositis, and is usually associated with severe mucositis in other 
portion of the gastrointestinal tract.  In patients with protracted diarrhoea, the 
possibility of pseudomembranous colitis need to be ruled out. 
 Constipation is most often seen in patients receiving vinca alkaloids, 
particularly vincristine as a consequence of automatic neuropathy.  The problem 
usually occurs within 3 days of drug administration.  Management is conservative, 
with resolution expected over a 2 week period. 
HEPATOTOXICITY : 
 Hepatotoxicity is uncommon mild elevations in transaminase alkaline 
phophatase and bilirubin are seen with many agents, but rarely the condition is severe.  
The management of all these reported hepatotoxicities requires the cessation of the 
affording agent when the liver abnormality is detected. 
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CARDIAC EFFECTS : 
 The principal chemotherapeutic agents associated with cardiotoxic effects are 
the anthracyclineantitumour antibiotics. i.e. daunrubicine and doxorubicin.  The 
arrghythmias and electro cardiographic changes may occur during or immediately 
after drug administration.  Cardiomyopathy is directly related to the cumulative total 
drug dose with doxorubicin at total doses higher than 550 mg/m2, the incidence of 
cardiomyopathy associated with intractable congestive heart failure reaches 30%. 
PULMONARY EFFECTS : 
 Pulmonary toxicity secondary to chemotherapy takes the form of a diffuse 
interstitial pneumonitis, which may eventually develop into pulmonary fibrosis.  The 
drug first associated with these complications is bleomycin, onset is heralded by a dry 
cough dysphoea and fine bibasilar rales.  Other drugs associated with a similar picture 
are Mitomycin C, the nitrosoureas, busulfan, and Methotrexate. 
GENITOURINARY EFFECTS : 
RENAL EFFECTS : 
 The drugs that most commonly produce direct renal toxicity include 
cisplantin, mitomycin C, mithramycin, methotrexate, and the nitrosources.  The most 
prominent of these agents producing renal toxicity is cisplantin.  The frequency of 
nephrotoxicity can be reduced by the induction and continuation of a urine flow in 
excess of 100ml/hr. prior to, during and for several hours after the drug 
administration. 
BLADDER EFFECTS : 
 Significant toxicity to the lining of the urinary bladder has been reported with 
cyclophosphamide and the related compound ifosfamide. The urotoxicity of 
ifostamide, characterized by haemorrhagic cystitis, is due to the toxic metabolites 4 
hydroxyifosfamide and acrolein. 
GONADAL EFFECTS : 
 There have been no large scale detailed studies of drug effects on gonodal 
function.  The reported effects are testicular atrophy, failure of spermatogenesis, and 
amenorrhoea.  These agents mustard type alkylating agents, busulfan, the vinca 
alkaloids belomycin, hydroxyurea and procarbazine. 
NEUROLOGICAL EFFECTS : 
 Acute encephalopathic syndrome  have been reported with a variety of 
different chemotherapeutic agents.  Management requires the cessation of the drug 
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and supportive care of the patient, pheripheral neuropathies are generally manifestated 
by both sensory and motor components, and are dose related.  Pheripheral neuropathy 
is the principal non-haematologic dose limiting side effect of paclitaxel.  The 
incidence of neuropathy is dose depent.  Amifostine appears to have a neuroprotective 
activity. 
EVALUATION OF NEW AGENTS : 
 A number of trials are necessary to demonstrate the use of a new agent in 
regular medical practice.  These trials are define as follows : 
Phase 1 : 
 These trials are designed to test new drugs at various doses to evaluate toxicity 
and determine the tolerance to a particular agent. 
Phase 2 : 
 These attempt to determine the therapeutic effectiveness as well as the extent 
of toxicity of the particular agent at doses expected to be effective against specific 
tumour types. 
Phase 3 : 
 These are designed to compare the drug to treatment currently in use.  They 
are prospective randomised double blind trails. 
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4.3. STANDARDIZATION OF DRUG: 
 The standardization of drug is essential to exhibit the purity and quality and 
quantity of drug.  This is basically done by biochemical, physiochemical, 
phytochemical and instrumental analysis. 
 The physiochemical analysis have been done at Aravindh herbal labs (p) ltd, 
Rajapalayam, Biochemical analysis were done at Govt Siddha Medical College 
Palayamkottai and microbiological analysis were done at inbiotics, William hospitial 
campus ms road, Nagerkovil,And the instrumental analysis was done at Indian 
Institute of Technology (IIT),Chennai-36  . 
Organoleptic character 
 The organoleptic characters of the sample drug were evaluated.1gm of the test 
drug was taken and the colour, texture, particle size and other morphology were 
viewed by naked eye under sunlight. Then the result is noted 
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4.3.1. PHYSICO CHEMICAL ANALYSIS 
 Physicochemical studies of the trial drug have been done according to the 
WHO guidelines. 
Determination of Ash Values: 
Total Ash: 
3g is accurately weighed and incinerated in a crucible dish at a temperature 
not exceed 450oC until free from carbon. It is then cooled and weighed. The % w/w of 
ash with reference to the air-dried powder is calculated 
Water Soluble Ash: 
The total ash is obtained as the above method for preparation of total ash. The 
ash is boiled for 5minutes with 25ml water. The insoluble ashes is collected using 
filter paper and washed with hot water and then transferred to the silica crucible then 
ignite for 15minutes at temperature not exceeding 450oC. The silica crucible and 
residue are weighed until constant weight is attained for determination of weight of 
insoluble ash. The weight of the water soluble ash is determined by substracting the 
weight of insoluble ash from the weight of total ash. 
Acid insoluble Ash: 
The total ash is obtained as the above method for preparation of total ash. The 
ash is boiled for 5minutes with 25ml 10% Hcl. The insoluble ashes is collected using 
filter paper and washed with hot water and then transferred to the silica crucible then 
ignite for 15minutes at temperature not exceeding 450oC. The silica crucible and 
residue are weighed until constant weight is attained.  
Determination of Extractive Value: 
Alcohol Soluble Extractive Value: 
3g of test drug powder is weighed and macerated with 100ml of ethanol in a 
closed container for 24 hours. The resulting solution is shaken continuously for 6 
hours and allowed to stand and soak for 18 hours. The solution is filtered and 
evaporated of the filtrate in a flat bottomed shallow dish and dried at 105oC then 
cooled and weighed. 
Water soluble Extractive value: 
3g of test drug powder is weighed and macerated with chloroform and water, 
respectively, at 80oC for 24 hrs. The resulting solution is shaken continuously for 6 
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hours and allowed to stand and soak for 24 hrs then filtered. The solution from both 
chloroform and water respectively is filtered and evaporated of the filtrate in a flat 
bottomed shallow dish and dried at 105oC then cooled and weighed. 
Loss on Drying: 
The powdered drug is dried in the oven at 100- 105°C to constant weight. The 
result was noted. 
THIN LAYER CHROMATOGRAPHY 
Thin-layer chromatography(TLC) is a chromatographic technique that is 
useful for separating organic compounds. Because of the simplicity and rapidity of 
TLC, it is often used to monitor the progress of organic reactions and to check the 
purity of products.TLC is a simple, quick and inexpensive procedure that gives how 
many components are in a mixture.TLC is also used to support the identity of a 
compound in a mixture when the Rf of a compound is compared with the Rf of a 
known compound(preferably both run on the same TLC plate).Chromatography 
works on the principle that different compounds will have different solubilities and 
adsorbtion to the two phases between which they are to be partitioned. As the solvent 
rises by capillary action up through the adsorbent, differential partitioning occurs 
between the components of the mixture dissolved in the solvent stationary adsorbent 
phase. The more strongly a given component of a mixture is adsorbed on to the 
stationary phase, the less time it will spend in the mobile phase and the more slowly it 
will migrate up the plate. 
The following are some common uses of Thin-Layer 
Chromatography 
1. To determine the number of components in a mixture. 
2. To determine the identity of two substances. 
3. To monitor the progress of a reaction. 
4. To determine the effectiveness of a purification. 
Apparatus 
              Flat glass plates of appropriate dimensions which allow the application at 
specified points of the necessary quantities of the solution being examined and 
appropriate reference solutions and which allow accommodation of the specified 
migration path-length. The plates are prepared as described below; alternatively, 
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commercially prepared plates may be used.An aligning tray or a flat surface on which 
the plates can be aligned and rested when the coating substance is applied. 
               The adsorbent or coating substance consisting of finely divided adsorbent 
materials, normally 5 μm to 40 μm in diameter, is suitable for chromatography. It can 
be applied directly to the plate or can be bonded to the plate by means of Plaster of 
Paris (Hydrated Calcium Sulphate) or with any other suitable binders. The adsorbent 
may contain fluorescing material to help in visualising spots that absorb ultra-violet 
light.A spreader which, when moved over the glass plate, will apply a uniform layer 
of adsorbent of desired thickness over the entire surface of the plate.A storage rack to 
support the plates during drying and transportation. 
                A developing chamber that can accommodate one or more plates and can be 
properly closed and sealed. The chamber is fitted with a plate support rack that 
supports the plates, back to back, with lid of the chamber in place.Graduated micro-
pipettes capable of delivering microlitre quantities say 10 μl and less.  
                A reagent sprayer that will emit a fine spray and will not itself be attacked 
by the reagent.An ultra-violet light, suitable for observation at short (254 nm) and 
long (365 nm) ultra-violet wavelengths. 
Preparation of plates: 
Unless otherwise specified in the monograph, the plates are prepared in the 
following manner. Prepare a suspension of the coating substance in accordance with 
the instructions of the supplier and, using the spreading device designed for the 
purpose, spread a uniform layer of the suspension, 0.25 to 0.30 mm thick, on a flat 
glass plate 20 cm long. Allow the coated plates to dry in air, heat at 100º to 105º for at 
least 1 hour (except in the case of plates prepared with cellulose when heating for 10 
minutes is normally sufficient) and allow to cool, protected from moisture. Store the 
plates protected from moisture and use within 3 days of preparation. At the time of 
use, dry the plates again, if necessary, as prescribed in the monographs 
Method 
Unless unsaturated conditions are prescribed, prepare the tank by lining the 
walls with sheets of filter paper; pour into the tank, saturating the filter paper in the 
process, sufficient of themobile phase to form a layer of solvent 5 to 10 mm deep, 
close the tank and allow to stand for 1 hour at room temperature. Remove a narrow 
strip of the coating substance, about 5 mm wide, from the vertical sides of the plate. 
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Apply the solutions being examined in the form of circular spots about 2 to 6 mm in 
diameter, or in the form of bands (10 to 20 mm x 2 to 6 mm unless otherwise 
specified) on a line parallel with, and 20 mm from, one end of the plate, and not 
nearer than 20 mm to the sides; the spots should be 15 mm apart. If necessary, the 
solutions may be applied in portions, drying between applications. Mark the sides of 
the plate 15 cm, or the distance specified in the monograph, from the starting line. 
Allow the solvent to evaporate and place the plate in the tank, ensuring that it is as 
nearly vertical as possible and that the spots or bands are above the level of the mobile 
phase. Close the tank and allow to stand at room temperature, until the mobile phase 
has ascended to the marked line. Remove the plate and dry and visualise as directed in 
the monograph; where a spraying technique is prescribed it is essential that the 
reagent be evenly applied as a fine spray. 
For two-dimensional chromatography dry the plate after the first development 
and carry out the second development in a direction perpendicular to the first. 
When the method prescribed in the monograph specified ‘protected from light’ 
or ‘in subdued light’ it is intended that the entire procedure is carried out under these 
conditions. 
Visualisation 
The phrases ultra-violet light (254 nm) and ultra-violet light (365 nm) indicate 
that the plate should be examined under an ultra-violet light having a maximum 
output at about 254 or at about 365 nm, as the case may be. 
The term secondary spot means any spot other than the principal spot. 
Similarly, a secondary band is any band other than the principal band. 
Rf. Value 
Measure and record the distance of each spot from the point of its application 
and calculate the Rf. value by dividing the distance travelled by the spots by the 
distance travelled by the front of the mobile phase. 
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MICROBIAL LIMIT TESTS: 
DETERMINATION OF TOTAL AEROBIC MICROBIAL COUNT: 
Dissolve 10 g or dilute 10 ml of the preparation being examined, unless 
otherwise specified, in buffered sodium chloride-peptone solution Ph 7.0 or any other 
suitable medium shown to have no antimicrobial activity under the conditions of test 
and adjust the volume to 100 ml with the same medium. If necessary, adjust the pH to 
about 7. 
Membrane filtration: 
 Use membrane filters 50 mm in diameter and having anominal pore size not 
greater than 0.45 μm the effectiveness of which in retainingbacteria has been 
established for the type of preparation being examined. Sterilise andassemble the 
filtration apparatus described under tests for sterility. 
Transfer 10 ml or a quantity of each dilution containing 1 g of the preparation 
being examined to each of two membrane filters and filter immediately. If necessary, 
dilute the pretreated preparation so that a colony count of 10 to 100 may be expected. 
Wash each membrane by filtering through it three or more successive quantities, each 
of about 100 ml, of a suitable liquid such as buffered sodium chloride-peptone 
solution pH 7.0. For fatty substances add to the liquid polysorbate 20 or polysorbate 
80. Transfer one of the membrane filters, intended for the enumeration of bacteria, to 
the surface of a plate of casein soyabean digest agar and the other, intended for the 
enumeration of fungi, to the surface of a plate of Sabouraud dextrose agar with 
antibiotics. 
Incubate the plates for 5 days, unless a more reliable count is obtained in 
shorter time, at 30º to 35º in the test for bacteria and 20º to 25º in the test for fungi. 
Count the number of colonies that are formed. Calculate the number of micro-
organisms per g or per ml of the preparation being examined, if necessary counting 
bacteria and fungi separately. 
Plate count: For bacteria: 
Using Petri dishes 9 to 10 cm in diameter, add to each dish a mixture of 1 ml 
of the pretreated preparation and about 15 ml of liquefied casein soyabean digest agar 
at not more than 45º. Alternatively, spread the pretreated preparation on the surface of 
the solidified medium in a Petri dish of the same diameter. If necessary, dilute the 
pretreated preparation as described above so that a colony count of not more than 300 
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may be expected. Prepare at least two such Petri dishes using the same dilution and 
incubate at 30º to 35º for 5 days, unless a more reliable count 
is obtained in a shorter time. Count the number of colonies that are formed. Calculate 
the results using plates with the greatest number of colonies but taking 300 colonies 
per plate as the maximum consistent with good evaluation. 
For fungi: 
 Proceed as described in the test for bacteria but use Sabouraud dextrose agar 
with antibiotics in place of casein soyabean digest agar and incubate the plates at 20º 
to 25º for 5 days, unless a more reliable count is obtained in a shorter time. Calculate 
the results using plates with not more than 100 colonies. 
TESTS FOR SPECIFIED MICRO-ORGANISMS: 
Pretreatment of the sample being examined – Proceed as described under the 
test for total aerobic microbial count but using lactose broth or any other suitable 
medium shown to have no antimicrobial activity under the conditions of test in place 
of buffered sodium chloride-peptone solution pH 7.0. 
ESCHERICHIA COLI: 
 Place the prescribed quantity in a sterile screw-capped container, add 50 ml of 
nutrient broth, shake, allow to stand for 1 hour (4 hours for gelatin) and shake again. 
Loosen the cap and incubate at 37º for 18 to 24 hours. 
Primary test: 
 Add 1.0 ml of the enrichment culture to a tube containing 5 ml of MacConkey 
broth. Incubate in a water-bath at 36º to 38º for 48 hours. If the contents of the tube 
show acid and gas carry out the secondary test. 
Secondary test:  
 Add 0.1 ml of the contents of the tubes containing (a) 5 ml of MacConkey 
broth, and (b) 5 ml of peptone water. Incubate in a water-bath at 43.5º to 44.5º for 24 
hours and examine tube (a) for acid and gas and tube (b) for indole. To test for indole, 
add 0.5 ml of Kovac’s reagent, shake well and allow to stand for 1 minute; if a red 
colour is produced in the reagent layer indole is present. The presence of acid and gas 
and of indole in the secondary test indicates the presence of Escherichia coli. 
Carry out a control test by repeating the primary and secondary tests adding 
1.0 ml of the enrichment culture and a volume of broth containing 10 to 50 
Escherichia coli (NCTC 9002) organisms, prepared from a 24-hour culture in nutrient 
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broth, to 5 ml of MacConkey broth. The test is not valid unless the results indicate 
that the control contains Escherichia coli. 
SALMONELLA : 
 Transfer a quantity of the pretreated preparation being examined containing 1 
g or 1 ml of the product to 100 ml of nutrient broth in a sterile screwcapped jar, shake, 
allow to stand for 4 hours and shake again. Loosen the cap and incubate at 35º to 37º 
for 24 hours. 
Primary test: 
Add 1.0 ml of the enrichment culture to each of the two tubes containing (a) 
10 ml of selenite F broth and (b) tetrathionate-bile-brilliant green broth and incubate 
at 36º to 38º for 48 hours. From each of these two cultures subculture on at least two 
of the following four agar media: bismuth sulphate agar, brilliant green agar, 
desoxycholatecitrate agar and xylose-lysine-desoxycholate agar. Incubate the plates at 
36º to 38º for 18 to 24 hours. Upon examination, if none of the colonies conforms to 
the description given in Table 2, the sample meets the requirements of the test for the 
absence of the genus Salmonella. 
If any colonies conforming to the description in Table 2 are produced, carry 
out the secondary test. 
Secondary test:  
Subculture any colonies showing the characteristics given in Table 2 in triple 
sugar-iron agar by first inoculating the surface of the slope and then making a stab 
culture with the same inoculating needle, and at the same time inoculate a tube of urea 
broth. Incubate at 36º to 38º for 18 to 24 hours. The formation of acid and gas in the 
stab culture (with or without concomitant blackening) and the absence of acidity from 
the surface growth in the triple sugar iron agar, together with the absence of a red 
colour in the urea broth, indicates the presence of salmonellae. If acid but no gas is 
produced in the sub culture, the identity of the organisms should beconfirmed by 
agglutination tests.  
Carry out the control test by repeating the primary and secondary tests using 
1.0 ml of the enrichment culture and a volume of broth containing 10 to 50 
Salmonella abony (NCTC 6017) organisms, prepared from a 24-hour culture in 
nutrient broth, for the inoculation of the tubes (a) and (b). The test is not valid unless 
the results indicate that the control contains Salmonella. 
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Table no: 6 – Test for Salmonella 
Medium Description of colony 
Bismuth Sulphite agar Black or green 
Brilliant green agar Small, transparent and colourless, or opaque, 
pinkish or white (frequently surrounded by a 
pink or red zone) 
Deoxycholate – Citrate agar Colourless and opaque, with or without black 
centers 
Xylose-lysine-desoxy-cholate agar  Red with or without black centres 
 
PSEUDOMONAS AERUGINOSA : 
 Pretreat the preparation being examined as described above and inoculate 100 
ml of fluid soyabean-casein digest medium with a quantity of the solution, 
suspensionor emulsion thus obtained containing 1 g or 1 ml of the preparation being 
examined. Mix and incubate at 35º to 37º for 24 to 48 hours. Examine the medium for 
growth and if growth is present, streak a portion of the medium onthe surface of 
cetrimide agar medium, each plated on Petri dishes. Cover and incubate at 35º to 37º 
for 18 to 24 hours. If, upon examination, none of the plates contains colonies having 
the characteristics listed in Table 3 for the media used, the sample meets the 
requirement for freedom from Pseudomonas aeruginosa. If any colonies conforming 
to the description in Table 3 are produced, carry out the oxidase and pigment tests. 
Streak representative suspect colonies from the agar surface of cetrimide agar 
on the surfaces of pseudomonas agar medium for detection of fluorescein and 
pseudomonas agar medium for detection of pyocyanin contained in Petri dishes. 
Cover and invert the inoculated media and incubate at 33º to 37º for not less than 3 
days. Examine the streaked surfaces under ultra-violet light. Examine the plates to 
determine whether colonies conforming to the description in Table 3 are present. 
If growth of suspect colonies occurs, place 2 or 3 drops of a freshly prepared 
1% w/v solution of N,N,N1,N1-tetramethyl-4-phenylenediamine dihydrochloride on 
filter paper and smear with the colony; if there is no development of a pink colour, 
changing to purple, the sample meets the requirements of the test for the absence of 
Pseudomonas aeruginosa. 
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Table no: 7- Tests for Pseudomonas aeruginosa 
Medium Characteristic 
colonical 
morphology 
Fluorescence 
in UV light  
Oxidase 
test 
Gram stain 
Cetrimde agar Generally 
greenish 
Greenish Positive Negative rods 
Pseudomonas agar 
medium for dedection 
of fluorescein 
Generally 
colourless to 
yellowish 
Yellowish Positive Negative rods 
Pseudomonas agar 
medium for dedection 
of pyocyanin 
Generally 
greenish 
Blue Positive Negative rods 
 
STAPHYLOCOCCUS AUREUS:  
Proceed as described under Pseudomonas aeruginosa. If, upon examination of 
the incubated plates, none of them contains colonies having the characteristics listed 
in Table 4 for the media used, the sample meets the requirements for the absence of 
Staphylococcus aureus. If growth occurs, carry out the coagulase test. Transfer 
representative suspect colonies from the agar surface of any of the media listed in 
Table 4 to individual tubes, each containing 0.5 ml of mammalian, preferably rabbit 
or horse, plasma with or without additives. Incubate in water-bath at 37º examining 
the tubes at 3 hours and subsequently at suitable intervals up to 24 hours. If no 
coagulation in any degree is observed, the sample meets the requirements of the test 
for the absence of Staphylococcus aureus. 
Table no:8 – Tests for Staphylococcus aureus 
Selective medium Characteristic colonical morphology Gram stain 
Vogel-Johnson agar Black surrounded by yellow zones Positive cocci (in clusters) 
Mannitol-salt agar Yellow colonies with yellow zones Positive cocci (in clusters) 
Baired-Parker agar Black, shiny, surrounded by clear zones 
of 2 to 5 mm 
Positive cocci (in clusters) 
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4.3.2. BIO CHEMICAL ANALYSIS: 
Preliminary Basic and Acidic radical studies: 
Preparation of the extract: 
5gms of the test drug is weighed accurately and placed in a 250ml clean beaker.  Then 
50ml of distilled water is added and dissolved well.  Then it is boiled well for about 
10 minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is made 
up to 100ml with distilled water. This preparation is used for the qualitative analysis 
of acidic/ basic radicals and biochemical constituents in it.  
QUALITATIVE ANALYSIS FOR BASIC RADICALS: 
Test for Calcium: 
 2ml of the above prepared extract is taken in a clean test tube. To this add 2ml 
of 4% Ammonium oxalate solution. Formation of white precipitate indicates the 
presence of calcium. 
Test for Iron (Ferric): 
 The extract is acidified with glacial acetic acid and potassium ferro cyanide. 
Formation of blue colour indicates the presence of ferric iron. 
Test for Iron (Ferrous): 
 The extract is treated with concentrated Nitric acid and ammonium thio-
cyanate solution. Formation of blood red colour indicates the presence of ferrous iron. 
Test for Zinc: 
 The extract is treated with potassium ferro-cyanide. Formation of white 
precipitate indicates the presence of zinc. 
QUALITATIVE ANALYSIS FOR ACIDIC RADICALS: 
Test for Sulphate: 
 2ml of extract is added to 5% barium chloride solution. Formation of white 
precipitate indicates the presence of sulphate. 
Test for Chloride: 
 The extract is treated with silver nitrate solution. Formation of white 
precipitate indicates the presence of chloride. 
Test for Phosphate: 
 The extract is treated with ammonium molybdate and concentrated nitric acid. 
Formation of yellow precipitate indicates the presence of phosphate. 
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Test for Carbonate: 
 On treating the extract with concentrated hydrochloric acid giving brisk 
effervescence indicates the presence of carbonate. 
Test for starch: 
 The extract is added with weak iodine solution. Formation of blue colour 
indicates the presence of starch. 
Test for albumin: 
 The extract is treated with Esbach`s reagent. Formation of yellow precipitate 
indicates the presence of albumin. 
Test for tannic acid: 
 The extract is treated with ferric chloride. Formation of bluish black 
precipitate indicates the presence of tannic acid. 
Test for unsaturation: 
 The extract is treated with potassium permanganate solution. The dis-
colourization of potassium permanganate indicates the presence of unsaturated 
compounds. 
Test for the reducing sugar: 
 5ml of Benedict`s qualitative solution is taken in a test tube and allowed to 
boil for 2 minutes and added 8-10 drops of the extract and again boil it for 2 minutes. 
Any colour change indicates the presence of reducing sugar. 
Test for amino acid: 
 One or two drops of the extract is placed on a filter paper and dried it well. 
After drying, 1% Ninhydrin is sprayed over the same and dried it well. Formation of 
violet colour indicates the presence of amino acid. 
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4.3.3. INSTRUMENTAL ANALYSI 
             SEM (SCANNING ELECTRON MICROSCOPE) 
                                             SEM INSTRUMENT 
 
                  SEM - SCANNING ELECTRON MICROSCOPE 
 
 
 
 
 
 
 
 
 
                                           
 
MECHANISM 
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In scanning electron microscope high-energy electron beam is focused through 
a probe towards the sample material. Variety of signals was produced on interaction 
with the surface of the sample. This results in the emission of electrons or photons and 
it is collected by a appropriate detector.  
The types of signal produced by a scanning electron microscope include  
 Secondary electrons 
 back scattered electrons 
 characteristic x-rays, light 
 specimen current 
 Transmitted electrons. 
 This gives the information about the sample and it includes external morphology, 
texture, its crystalline structure, chemical composition and it displays the shape of the 
sample. 
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 FT-IR(Fourier Transform Infrared Spectroscopy): 
                                            
                                               FTIR INSTRUMENT 
 
                                
                                               
                             FTIR MECHANISM 
Model   :  Spectrum one: FT-IR Spectrometer 
Scan Range   :   MIR 450-4000 cm-1 
Resolution   :   1.0 cm-1 
Sample required :   50 mg, solid or liquid. 
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It is the preferred method of infrared spectroscopy. FT-IR is an important and 
more advanced technique. It is used to identify the functional group, to determine the 
quality and consistency of the sample material and can determine the amount of 
compounds present in the sample. It is an excellent tool for quantitative analysis. 
In FT-IR infrared is passed from a source through a sample. This infrared is 
absorbed by the sample according to the chemical properties and some are 
transmitted. The spectrum that appears denotes the molecular absorption and 
transmission. It forms the molecular fingerprint of the sample. Like the finger print 
there is no two unique molecular structures producing the same infrared spectrum. It 
is recorded as the wavelength and the peaks seen in the spectrum indicates the amount 
of material present.  
FT-IR is the most advanced and the major advantage is its 
 Speed 
 Sensitivity 
 Mechanical simplicity 
 Internally calibrated     
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ICP-OES (INDUCTIVELY COUPLED PLASMA OPTIC EMISSION 
SPECTROMETRY) 
 
ICP-OES (INDUCTIVELY COUPLED PLASMA OPTIC EMISSION 
SPECTROMETRY) 
Manufacturer :     Perkin Elmer 
Model     :       Optima 5300 DV ICP-OES Inductively Coupled Plasma      
Spectrometer (ICP) 
Principle : 
An aqueous sample is converted to aerosols via a nebulizer. The aerosols are 
transported to the inductively coupled plasma which is a high temperature zone 
(8,000– 10,000ºC). The analysts are heated (excited)to different (atomic and/or ionic) 
states and produce characteristic optical emissions (lights). These releases are 
separated based on their respective wavelengths and their strengths are measured 
(spectrometry). The intensities are proportional to the concentrations of analyses in 
the aqueous sample. The quantification is an external multipoint linear standardization 
by comparing the emission intensity of an unknown sample with that of a standard 
sample. Multi-element calibration standard solutions are prepared from single- and 
multi element primary standard solutions. With respect to other kinds of analysis 
where chemical speciation is relevant (such as the concentration of ferrous iron or 
ferric iron), only total essential concentration is analysed by ICP-OES. 
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Application: 
        The analysis of major and minor elements in solution samples. 
Objectives: 
 Determine elemental concentrations of different metals. 
 Learn principles and operation of the ICP-OES instrument 
 Develop and put on a method for the ICP-OES sample analysis 
 Enhance the instrumental conditions for the analysis of different elements 
 probes the outer electronic structure of atoms 
Mechanism:  
In plasma emission spectroscopy (OES), a sample solution is presented into 
the core of inductively coupled argon plasma (ICP), which generates temperature of 
approximately 8000°C. At this temperature all elements become thermally excited 
and emit light at their characteristic wavelengths. This light is collected by the 
spectrometer and passes through a diffraction grating that serves to resolve the light 
into a spectrum of its essential wavelengths. Within the spectrometer, this deflected 
light is then collected by wavelength and amplified to yield an strength of  
measurement that can be converted to an elemental concentration by comparison with 
standardizationvalues 
The Inductively Coupled Plasma Optical Emission Spectrometric (ICP-OES) 
analysis was done in Saif, IIT Madras, and Chennai-36 using Perkin Elmer Optima 
5300 DV. 
Sample preparation: 
Inductively Coupled Plasma Spectroscopy techniques are the so-called "wet" 
sampling methods whereby samples are introduced in liquid form for analysis. 
100 mg “Rasa karpoora kuligai” was occupied in a clean, dry test tube. To 
this, 3 ml Nitric acid was added and mixed well and allowedfor few minutes untill the 
reactions were completed. And then, 25 ml of Refined water, was added to prepare 
digested solution.  
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4.4. TOXICOLOGICAL STUDIES 
PRECLINICAL TOXICITY STUDIES OF RASA KARPOORA KULIGAI ON 
WISTAR ALBINO RATS 
4.4.1. ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO 
EVALUATE TOXICITY PROFILE OF MKC 
OBJECTIVES 
The aim of this Study is to evaluate the toxicity of the test substance mavilingu 
kasaya chooranam, when administered orally to Female Wister Rats with different 
doses, so as to provide a rational base for the evaluation of the toxicological risk to 
man and indicate potential target organs. 
Guidelines followed: 
 (a)  OECD Guidelines No. 423, 
Study Design and Controls: 
1) Female Wister Rats in controlled age and body weight were selected. 
2) The test drug RKK  was administered at 5 mg/kg, 10 mg/kg,300 mg/kg, 1000 
mg/kg, and  2000  mg/kg body weight of animal as suspension along with water. 
3) The results were recorded on day 0, with single oral dosing period of 14 days.  
EXPERIMENTAL PROCEDURE 
1. ANIMALS  
1.1 Supply 
A total of 15 Female Wister Rats with an approximate age of 6 weeks and 
purchased from M/s.Venkateshwara Enterprises  Pvt. Ltd, Bangalore. On their arrival 
a sample of animals was chosen at random and weighed to ensure compliance with 
the age requested. The mean weights of Female Wister Rats were 100-150 g 
respectively.  The animals were housed in metabolic cages (55 x 32.7 x 19 cm), with 
sawdust litter, in such a way that each cage contained a maximum of 3 animals of the 
same sex. 
All animals underwent a period of 20 days of observation and acclimatization 
between the date of arrival and the start of treatment. During the course of this period, 
the animals were inspected by a veterinary surgeon to ensure that they fulfilled the 
health requirements necessary for initiation of the Study. 
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1.2. Housing 
The Female Wister Rats were housed in metabolic cages (55 x 32.7 x 19 cm), 
placed on racks. From the week before initiation of the treatment, each cage contained 
a maximum of  3 rats of the same sex and treatment group. 
Each cage was identified by a card, color coded according to the dose level. 
This card stated the cage number, number and sex of the animals it contained, Study 
number, test substance code, administration route, dose level and Study Director's 
name, date of the arrival of the animals and initiation of treatment. 
The temperature and relative humidity were continuously monitored. Lighting 
was controlled to supply 12 hours of light (7:00 to 19:00 hours) and 12 hours of dark 
for each 24-hour period. 
The cages corresponding to each experimental group were distributed on racks 
in such a manner that external factors, such as environmental conditions, were 
balanced as far as possible. 
2.DIET 
All the rats had free access to a pelleted rat diet. The diet was analyzed by the   
manufacturer to check its composition and to detect possible contaminants. 
2.1. Water 
The water was offered ad libitum in bottles.  
 
3. Numbering and Identification 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
 
                              Table no-9 Numbering and Identification 
 
 
                            
 
 
                 
 
                                    
Group No         Animal Marking 
1 Head 
2 Body 
3 Tail 
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Table no 10 Numbering and Identification 
Cage No Group No Animal Marking Sex 
1 I H,B,T Female 
2 II H,B,T Female 
3 III H,B,T Female 
4 IV H,B,T Female 
5 V H,B,T Female 
 
The group no., cage no., sex of the animal and animal no. were identified as 
indicated below using cage label and body marking on the animals 
3. ADMINISTRATION ROUTE AND PROCEDURE 
          The test substance was administered orally. The Female Wister Rats belonging 
to the control group were treated with the vehicle (Water) at the same administration 
volume as the rest of the treatment groups. 
3.1. Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
drug was administered orally as single dose using a needle fitted onto a disposable 
syringe of approximate size at the following different doses. 
Table no -11 Doses 
GROUP DOSE 
GROUP DOSE 
Group-I 5  mg/kg 
Group-II 50  mg/kg 
Group-III 300  mg/kg 
Group-IV 1000  mg/kg 
Group-V 2000  mg/kg 
 
The test item was administered as single dose. After single dose administration 
period, all animals were observed for  14days. 
Dose Preparation 
               RASA KARPOORA KULIGAI  was added in distilled water and completely 
dissolved to form oral for administration. The dose was prepared of a required 
concentration before dosing by dissolving, in distilled water. It was mixed well. The 
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preparation for different doses was vary in concentrations to allow a constant dosage 
volume. 
3.2. Administration 
The test item was administered orally to each Female Wister rats as single 
dose using a needle fitted onto a disposable syringe of appropriate size at the 
following different doses. The concentration was adjusted according to its body 
weight. The volume was not exceeding 10 ml/kg bodyweight. Variability in test 
volume was minimized by adjusting the concentration to ensure a constant volume at 
all dose levels. 
3.3.Observation period 
All animals were observed for any abnormal clinical signs and behavioral 
changes. The appearance, change and disappearance of these clinical signs, if any, 
were recorded for approximately 1.0, 3.0 and 4.0 hours post-dose on day of dosing 
and once daily thereafter for14 days. Animals in pain or showing severe signs of 
distress were humanely killed. The cageside observation was included changes in 
skin, fur, eyes and mucous membranes, occurrence of secretions and excretions. 
Autonomic activity like lacrimation,  piloerection, pupil size and unusual respiratory 
pattern, changes in gait, posture, response to handling, presence of clonic or tonic 
movements, stereotypes like excessive grooming and repetitive circling or bizarre 
behavior like self-mutilation, walking backwards etc were observed. At the 14th day, 
sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive 
stimuli) was conducted. Auditory stimuli responses were measured by clicker sound 
from approximately 30 cm to the rats; visual stimuli response were measured with the 
help of shining pen light in the eye of rats and placing a blunt object near to the eye of 
rats. Response to proprioceptive stimuli was measured by placing anterior/dorsal 
surface of animals paw to the table edge. The responses of reactions for these three 
exercises were normal in animals belonging to both the controls as well as drug 
treatment dose groups. 
3.4.Mortality and Morbidity 
All animals were observed daily once for mortality and morbidity at 
approximately 1.0, 3.0 and 4.0 hours post dose on day of dosing and twice daily 
(morning and afternoon) thereafter for 14 days 
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4.4.2 Sub-Acute Toxicity Study in Wister rats to Evaluate Toxicity Profile of 
RASA KARPOORA KULIGAI 
1. Objective 
The objective of this ‘Sub-Acute Toxicity Study of MKC ON Wister Rats’ 
was to assess the toxicological profile of the test item when treated as a single dose 
daily. Animals should be observed for 28 days after the drug administration. This 
study provides information on the possible health hazards likely to arise from 
exposure over a relatively limited period of time.  
2. Test Guideline Followed 
      OECD 407 Method - Sub-Acute Toxic Class Method (Repeated Dose 28-Day 
Oral Toxicity Study in Rodents) 
3. Test Item Detail 
Name: RASA KARPOORA KULIGAI 
4.Test System Detail 
The study was conducted on 5 male 5 female Wister rats for each group. 
These   animals were selected because of the recommended rodent species for oral 
studies as per followed guideline and availability of Animals 8-12 weeks old male and 
female rats were selected after physical and behavioral examination. The body weight 
range was fallen within ± 20% of the mean body weight at the time of Randomization 
and grouping. The rats were housed in standard laboratory condition in Polypropylene 
cages, provided with food and water adlibitum in the Animal at M/s. Sree 
Venkateshwara Enterprises Pvt. Ltd, Bangalore. The experimental protocol was 
approved by Institutional Animal Ethical Committee as per the guidance of 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Environment and Forest, government of India. 
5.  Acclimatization 
The animals were selected after veterinary examination by the veterinarian. 
All the selected animals were kept under acclimatization for a week. 
6.Randomization & grouping 
One day before the initiation of treatment (days 0- last day of acclimatization), 
the selected animals were randomly grouped into three different groups containing 
minimum 5 male and 5 female animals per group.  
 
 
 
 
101 
 
7.Numbering and Identification 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
                            Table no-11 Numbering and Identification 
 
 Cage 
No  
Group No 
C0NCENTRATION/DOSE 
Animal Marking Sex 
1 1. CONTROL H,B,T,HB,NM                  
H,B,T,HB, NM 
Male 
Female 
2 2. LOW DOSE OF  RKK 
200mg/kg 
H,B,T,HB,NM                   
H,B,T,HB, NM  
Male 
Female 
3 3. MIDDLEDOSE OF RKK 
400mg/kg 
           
H,B,T,HB,NM                   
H,B,T,HB, NM 
 
Male 
Female 
4 4. HIGH DOSE OF        RKK  
600mg/kg 
                  
H,B,T,HB,NM                   
H,B,T,HB ,NM  
 
Male 
Female 
The group  no., cage no., sex of the animal and animal no. were identified  as 
indicated below  using cage  label and body marking on the Above 
 
 
Group No 
( C0NCENTRATION/DOSE) 
Animal Marking 
1. CONTROL H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
2. LOW DOSE OF  RKK  
200mg/kg 
H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
3. MIDDLEDOSE OF RKK 
400mg/kg 
H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
4. HIGH DOSE OF  RKK  
600mg/kg 
H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
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8. Husbandry 
8.1 Housing 
The Wister rats were housed in standard polypropylene cages with stainless 
steel top grill. Paddy husk was used as bedding. The paddy husk was changed at least 
twice in a week. From the week before   initiation of the treatment, each cage 
contained a maximum of 10 rat of the differnt sex and treatment group. 
8.2 Environmental conditions 
The animals were kept in a clean environment with 12 hour light and 12 hour 
dark cycles. The air was conditioned at 22±30C and the relative humidity was 
maintained between 30-70% with 100% exhaust facility. The cages corresponding to 
each experimental group were distributed on racks in such a manner that external 
factors, such as environmental conditions, were balanced as far as possible. 
8.3 Feed & feeding schedule 
‘Sai Durga Animal Feed, Bangalore. Feed was provided adlibitum throughout 
the study period, except over night fasting (18-20 hours) prior to dose administration. 
After the substance has been administered, food was with held for a further 3-4 hours. 
 
8.4 Water 
The water was offered adlibitum in bottles. There was periodically analyzed to 
detect the presence of possible contaminants 
8.5 Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
extract was administered orally as single dose using a needle fitted on to a disposable 
syringe of approximate size at the following different doses. 
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Table no -12 Dose level 
 
TEST GROUP 
 
C0NCENTRATION/DOSE TO 
ANIMALS 
(ml/kg body-weight/day) 
 
NUMBER OFANIMALS 
Group-1 1. CONTROL 10 (5MALE and5 FEMALE) 
Group-II 2. LOW DOSE OF  RKK 200mg/kg 10(5MALE and 5 FEMALE) 
 
Group-III 3. MIDDLEDOSE OF RKK 400mg/kg 10(5MALE and 5 FEMALE) 
Group-IV 4. HIGH DOSE OF  RKK 600mg/kg 10(5MALE and 5 FEMALE) 
 
The test item was administered as single dose daily. After single dose 
administration period, all animals were observed for 28 days. 
Dose Preparation 
RKK was added in distilled water and completely dissolved  for oral  
administration. The dose was prepared of a required concentration before dosing by 
dissolving RKK in distilled water. It was mixed well. The preparation for different 
doses was vary in concentrations to allow a constant dosage volume. 
8.6 Administration 
The test item was administered orally to each   rat as single dose using a 
needle fitted on to a disposable syringe of appropriate size at the following different 
doses. The concentration was adjusted according to its body weight. The volume was 
not exceeding 10 ml/kg body weight. Variability in test volume was minimized by 
adjusting the concentration to ensure a constant volume at all dose levels. 
9. OBSERVATIONS  
These observations were also performed on week-ends. The observations 
included   but were not limited to changes in skin and fur, in the eyes and mucous 
membranes, in the respiratory, circulatory, central nervous and autonomous systems, 
somatomotor activity and behavior. 
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9.1. Clinical signs of toxicity  
All the rats were observed at least twice daily with the purpose of recording 
any symptoms of ill- health or behavioral changes. Clinical signs of toxicity daily for 
28 days. 
9.2. Food intake  
Prior to the beginning of treatment, and daily, the food intake of each cage was 
recorded for period of 28 days and the mean weekly intake per rats was calculated. 
9.3. Water intake 
Water intake was checked by visual observation during the Study. In addition, 
the water consumption in each cage was measured daily for a period of 28 days. 
9.4 Bodyweight: 
The body weight of each rat was recorded one week before the start of 
treatment, and during the course of the treatment on the day of initial, 3rd, 7th, 10th, 
14th, 17th, 20th, 24th and 28th days (day of sacrifice). The mean weights for the 
different groups and sexes were calculated from the individual weights. 
Blood Collection   Blood was collected through retro-orbital sinus from all the 
animals of different groups on 28th day. The blood was collected in tubes containing 
Heparin/EDTA as an anticoagulant. Animals were fasted over night prior to the blood 
collection. 
LABORATORY STUDIES  
During the 4th week of treatment, samples of blood were withdrawn from the 
orbital sinus of 6 rats from each group, under light ether anesthesia after fasting for 16 
hours. The blood samples are used to evaluate Hematological   parameters like RBC, 
WBC, and PLATELETS etc….. The collected blood samples also centrifuged 10000 
rpm in 10 minutes to separate the serum. The separated serum used to evaluate 
biochemical parameters like SGOT, SGPT, ALP and BILIRUBIN etc……... 
Hematology  
The following hematological parameters were analysed using Autoanalyser  
Hb   :  Haemoglobin (g %)  
PCV    :  Packed Cell Volume 
WBC   :  White Blood Corpuscles (x103/cmm)  
RBC   :  Red Blood Corpuscles (x106/cmm)  
Blood Platelet count (x103/cmm)  
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Differential WBC count:  
N  :  Neutrophils (%)  
L  :  Lymphocytes (%)  
M  :  Monocytes (%)  
E  :  Eosinophils (%)  
RDW  :  Red Cell Distribution Width. 
MPV  :  Mean Platelet Volume 
 
Clinical Biochemistry:  
The following clinical Bio parameters were analysed using Auto analyser  
Total serum protein (g/dl)  
ALT/SGPT  :  Alanine amino transferase (U/L)  
AST/SGOT  :  Aspartate amino transferase (U/L)  
ALP    :  Alkaline serum phosphatase (U/L)  
CHL    :  Cholesterol (mg/dL)  
HDL    :  High density lipoprotein 
TG    :  Triglyceride 
 
TERMINAL STUDIES  
 Sacrifice and macroscopic examination 
On completion of the 4 weeks of treatment, 18 Wister rats were sacrificed by 
ether inhalation. A full autopsy was performed on all animals which included 
examination of the external surface of the body, all orifices, cranial, thoracic and 
abdominal cavities and their contents both in situ and after evisceration. As the 
number of animals exceeded the number that could be sacrificed in one day, the 
autopsies were carried out over three consecutive days at the end of the treatment 
period.  
Organ weights: 
            After the macroscopic examination the following organs were weighed after 
separating the superficial fat: Brain, Heart, Spleen Kidneys, Testes, Liver, Lungs, 
pancreas and stomach 
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4.5. PHARMOCOLOGICAL STUDY 
4.5.1. CYTOTOXIC PROPERTIES OF RASA KARPOORA KULIGAI 
AGAINST HELA CELL LINE 
Project Title:  In vitro apoptosis study of test drug Rasa karpoora kuligai. 
Aim of the study:  Determination of apoptotic properties of test drug in HeLa cell 
line by DAPI staining. 
 Samples:  KR.2019 
Materials and Methods 
Chemicals 
3-(4,5–dimethyl thiazol–2–yl)–5–diphenyl tetrazolium bromide (MTT), Fetal Bovine 
serum (FBS), Phosphate Buffered Saline (PBS), Dulbecco’s Modified Eagle’s Medium 
(DMEM) and Trypsin were obtained from Sigma Aldrich Co, St Louis, USA. EDTA, Glucose 
and antibiotics from Hi-Media Laboratories Ltd., Mumbai. Dimethyl Sulfoxide (DMSO) and 
Propanol from E.Merck Ltd., Mumbai, India, DAPI from Himedia Mumbai. 
Cell lines and Culture medium 
HeLa cell lines were procured from National Centre for Cell Sciences 
(NCCS), Pune, India. Stock cells were cultured in DMEM supplemented with 10% 
inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 
g/ml) and amphotericin B (5 g/ml) in an humidified atmosphere of 5% CO2 at 37C 
until confluent. The cells were dissociated with TPVG solution (0.2% trypsin, 0.02% 
EDTA, 0.05% glucose in PBS). The stock cultures were grown in 25 cm2 culture 
flasks and all experiments were carried out in 96 microtitre plates (Tarsons India Pvt. 
Ltd., Kolkata, India).  
Preparation of Test samples 
For cytotoxicity studies, weighed test drug was separately dissolved in DMEM 
supplemented with 2% inactivated FBS to obtain a stock solution of 1 mg/ml 
concentration and sterilized by filtration. Serial two fold dilutions were prepared from 
this for carrying out cytotoxic studies. 
Determination of cell viability by MTT Assay 
Principle: The ability of the cells to survive a toxic insult has been the basis of 
most cytotoxicity assays. This assay is based on the assumption that dead cells or their 
products do not reduce tetrazolium. The assay depends both on the number of cells 
present and on the mitochondrial activity per cell. The principle involved is the 
cleavage of tetrazolium salt 3-(4, 5 dimethyl thiazole-2-yl)-2, 5-diphenyl tetrazolium 
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bromide (MTT) into a blue coloured product (formazan) by mitochondrial enzyme 
succinate dehydrogenase. The number of cells was found to be proportional to the 
extent of formazan production by the cells used (Francis and Rita, 1986). 
Procedure: The monolayer cell culture was trypsinized and the cell count was 
adjusted to 1.0 x 105 cells/ml using DMEM containing 10% FBS. Later to each well 
of the 96 well microtitre plate, polymer were placed in triplicates, later 0.1 ml of the 
diluted cell suspension (approximately 10,000 cells) was added. After 4 h, to each 
well 150µl of DMEM supplemented with 2% FBS was added to the wells The plate 
was then incubated at 37o C for 3 days in 5% CO2 atmosphere, and microscopic 
examination was carried out and observations were noted every 24 h interval. After 72 
h, the drug solutions in the wells were discarded and plate was washed with PBS and 
then media containing MTT (5 mg/ml) was added each well. The plates were gently 
shaken and incubated for 3 h at 37o C in 5% CO2 atmosphere. The supernatant was 
removed and 100 l of propanol was added and the plates were gently shaken to 
solubilize the formed formazan. The solubilized formazan was then transferred into 
clean plate and absorbance was measured using a microplate reader at a wavelength 
of 540 nm. The percentage growth inhibition was calculated using the following 
formula and concentration of test drug needed to inhibit cell growth by 50% (CTC50) 
values is generated from the dose-response curves for each cell line. 
 
                                                              Mean OD of individual test group           
                     Mean OD of control group 
 
Determination of Apoptotic property by DAPI staining 
To characterize cell-specific apoptotic process in HeLa cells, analysis of 
chromatin condensation and nuclear fragmentation was done by DAPI staining using 
fluorescence microscopy. After treatment of 70–80% confluent HELA cells with 
varying concentration of sample 1 for 24 hr, cells were quickly washed with ice-cold 
PBS and fixed in ice-chilled acetone: methanol (1:1) mixture for 10 min at 4oC in the 
dark. The cells were washed twice with ice-cold PBS and then incubated for 30 min 
with the DNA-specific fluorochrome, DAPI. The excess DAPI was removed with ice-
cold PBS wash, and the cells were observed and photographed using fluorescence 
microscope at 40Xmagnification. 
     % Growth Inhibition = 100 – X 100 
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4.5.2. ANTIOXIDANT ACTIVITY OF RASA KARPOORA KULIGAI IN 
VITRO METHODS 
4.5.2.1 INVITRO ANTI OXIDANT ACTIVITY RASA KARPOORA KULIGAI 
ON DPPH RADICAL SCAVENGING ACTIVITY 
DPPH ASSAY (2, 2-diphenyl -1-picrylhydrazyl) 
INTRODUCTION 
The radical scavenging activity of different extracts was determined by using 
DPPH assay according to Chang et al[2001].The decrease in the absorption of the 
DPPH solution after the addition of an antioxidant was measured at 517 nm.Ascorbic 
acid (10mg/ml DMSO) was used as reference. 
PRINCIPLE 
1,1-diphenyl-2-picryl hydrazyl is a stable free radical with red colour which 
turns yellow when scavenged. The DPPH assay uses this character to show free 
radical scavenging activity. The scavenging reaction between (DPPH) and an 
antioxidant (H-A) can be written as,  
DPPH + [H-A] →DPPH-H + (A) 
Antioxidants react with DPPH and reduce it to DPPH-H and as consequence 
the absorbance decreases. The degree of discolouration indicates the scavenging 
potential of the antioxidant compounds or extracts in terms of hydrogen donating 
ability. 
REAGENT PREPARATION 
0.1mM DPPH solution was prepared by dissolving 4mg of DPPH in 100ml of 
ethanol.  
PROCEDURE 
Different volumes (1.25-10µl) of plant extracts were made up to 40µl with 
DMSO and 2.96ml DPPH (0.1mM) solution was added. The reaction mixture 
incubated in dark condition at room temperature for 20 minutes. After 20 minutes, the 
absorbance of the mixture was read at 517nm.3ml of DPPH was taken as control. 
 
CALCULATION 
% inhibition = ௖௢௡௧௥௢௟ି௧௘௦௧
௖௢௡௧௥௢௟
ܺ100 
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4.5.2.2 FERRIC REDUCING ANTIOXIDANT POWER (FRAP) RADICAL 
SCAVENGING ACTIVITY ON RASA KARPOORA KULIGAI 
MATERIALS AND METHODS 
Reagent preparation. 
 Reagents included 300 mmol/ - liter acetate buffer, pH 3.6 (3.1 g 
C2H3NaO2r3H2O (Rie- del-de Haen, Germany) and 16 ml C2H4O2 (BDH 
Laboratory Supplies, England) per liter of buffer solution); 10 mmol/liter TPTZ 
(2,4,6-tripyridyl-s-triazine,Fluka Chemicals, Switzerland) in 40 mmol/liter (BDH); 20 
mmol/liter FeCl3r6H2O (BDH). Working FRAP reagent was prepared as required by 
mixing 25 ml acetate buffer, 2.5 ml TPTZ solution, and 2.5 ml FeCl3r6H2O solution.  
Antioxidants. 
Solid L-(/)-ascorbic acid extra pure crystals (Merck, Germany), uric acid, solid 
(BDH), al bumin, solid (bovine serum albumin, fraction V, Sigma), bilirubin 
calibrator solution (Sigma), and Trolox (Aldrich Chemical Co., U.S.A.) were used to 
prepare aqueous antioxidant solutions. DL-a-Tocopherol (Merck) was diluted in 
ethanol (Merck) 
Reagent kits (Hoffman–LaRoche Ltd., Switzerland).Uric acid was measured 
by an enzymatic method, bili- rubin was measured by an alkaline picrate method and 
albumin was measured by a bromocresol green dye-binding method. These tests were 
performed on a CobasFara centrifugal analyzer (Roche) following the manufacturer’s 
instructions and using commercially available calibrators and quality control samples. 
Procedure 
The FRASC assay was performed as described in detail elsewhere (Benzie & 
Strain, 1997, 1999). In brief, reductants (‘antioxidants’) in the sample reduce a ferric– 
tripyridyltriazine complex, present in stoichiometric excess, to the blue coloured 
ferrous form. The change of absorbance at 593 nm over 4 min is proportional to the 
combined (total) FRAP value of the antioxidants in the sample. In the FRASC assay, 
AA(Ascorbic Acid) is selectively destroyed by the addition of ascorbate oxidase to 
one of a pair of sample aliquots. In this case the absorbance change of a sample to 
which ascorbate oxidase was added is subtracted from the absorbance of a matching 
aliquot to which water, rather than ascorbate oxidase was added; the difference is due 
specifically to AA (reduced form only). Change in absorbance (0–1 min for AA and 
0–4 min for FRAP) is converted to mmol/l by comparison with a standard of known 
AA concentration or FRAP value. Aqueous solutions of ferrous ions (iron(II) sulfate 
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(FeSO4.7H2O)) and ascorbic acid (L(1)-AA, extra pure crystals) both from Merck 
(Darmstadt, Germany) are used as calibrators. The FRAP assay has a limit of 
detection of 2mmol/l, and precision is excellent: within- and between-run CV are ,0:5 
and 1:0 % respectively at between 500 and 2000 mmol/l antioxidant– reducing power, 
n.8 in each case. For AA, within- and between-run CV of FRASC are ,5 % at 25, 50, 
100, and 440 mmol/l. All reagents and solutions were prepared in Milli-Q water, 
which was made from a Millipore ultrapure water system (Millipore Corp., Bedford, 
MA, USA). 
FRASC reagents were as follows: 300 mmol/l acetate buffer, pH 3:6, 
prepared by dissolving 3:1 g sodium acetate trihydrate in distilled water, with 16 ml 
glacial acetic acid (BDH Laboratory Supplies, Poole, UK) added and made up to 1 
litre with distilled water; 10 mM-2,4,6 tripyridyl-S-triazine (Fluka Chemicals, Buchs, 
Switzerland) solution in 40 mM-HCl (BDH Laboratory Supplies); 20 mM-FeCl3.6-
H2O (BDH Laboratory Supplies) solution in distilled water. Working FRASC reagent 
was prepared as needed by mixing 10 ml acetate buffer with 1 ml 2,4,6tripyridyl-S-
triazine solution and 1 ml FeCl3.6H2O solution. A 4 IU ascorbic oxidase/ml solution 
(Sigma Chemical Co., St, Louis, MO, USA) was prepared in distilled water, divided 
into portions and stored at 2708C until needed. For FRASC analysis, 100 ml of each 
freshly prepared food extract was mixed with 40 ml ascorbic oxidase solution; a 
matching (paired) 100 ml aliquot of each extract was mixed with 40 ml water; paired 
extracts were immediately loaded on the analyser (CobasFara centrifugal analyser; 
Roche Diagnostics Ltd, Basel, Switzerland). The 0–1 min change in A593 nm 
readings of the paired extracts (tested in parallel) were retrieved and used to calculate 
the AA concentration. The 0–4 min changes in A593 nm of the extracts treated with 
water only (no ascorbic oxidase) were retrieved and used to calculate the FRAP 
values. The FRAP value in mmol/l was calculated by simple comparison of 0–4 min 
change in absorbance at 593 nm of the test sample and that of a Fe21 calibrator, as 
follows: 0–4 min DA593 nm of test sample 0–4 min DA593 nm of standard ½Fe21Š 
standard ðmmol=lÞ: The AA value in mmol/l was calculated by comparison of 0–1 
min change in absorbance at 593 nm of the extract and that of an AA calibrator, as 
follows: 0–1 min DA593 nm ¼ ð0–1 min DA593 nm sample 2 aoÞ 2 ð0–1 min 
DA593 nm sample 1 aoÞ; and AA concentration ðmmol=lÞ ¼ 0–1 min DA593 nm of 
test sample 0–1 min DA593 nm of standard ½AAŠ standard ðmmol=lÞ; where ao is 
ascorbic oxidase. AA was converted from mmol/l extract to mg/kg wet weight of fruit 
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or vegetable by simple calculation based on molecular mass of AA (176), the weight 
of fruit or vegetable extracted and the volume of fluid used for extraction (typically 5 
g and 100 ml respectively). The % contribution of AA (which has a stoichiometric 
value of 2 in the FRAP assay, i.e. 1 mol AA reduces 2 mol Fe31 to Fe21) to the total 
antioxidant capacity (FRAP value) of each fruit or vegetable tested was calculated as 
follows: AA ðmmol=lÞ 2 FRAP value ðmmol=lÞ 100 %.  
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4.5.3. ANTI-INFLAMMATORY ACTIVITYOF SIDDHA FORMULATION 
RASA KARPOORA KULIGAI 
The anti-inflammatory activities of RASA KARPOORA KULIGAI at a dose 
of 200 and 400mg/kg were evaluated using carrageenan-induced paw edema method. 
The inflammation was readily produced in the form of edema with the help of irritant 
such as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea 
weed (Rhodophyceae) and when injected cause the release of prostaglandins by the 
way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                               :  Albino rat (180-200 g) 
Drugs and chemicals    :  Carrageenan (1%w/v), Diclofenac sodium  
(standard),  Carboxy  methyl cellulose (1%w/v), 
Digital plethysmo meter. U G O Basile (Italy) 
Test compounds                :   siddha formulation Rasa karpoora kuligai 
METHOD: 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the siddha formulations test 
Compounds dissolved with 2 ml sterile water given through orally 30 min before the 
carrageenan treatment. The paw volumes of the test compounds, standard and control 
groups were measured at 60,240,360 minutes of carrageenan treatment with the help 
of Digital plethysmometer (Ugo basile, Italy). Mean increase in paw volume was 
measured and the percentage of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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5. MICROBIOLOGICAL ANALYSIS 
ANTI - MICROBIAL STUDIES 
Aim 
To study the Anti-microbial action of “Rasa karpoora kuligai’’ done by 
“Paper disc agar diffusion method” – Kirby – bauyermethod. 
Components of Muller Hinton agar medium 
         Beef extract   -  300gms/lit 
         Agar    -  17 gms/lit 
         Starch    -  1.5 gms/lit 
         Casein Hydrolysate  -  17.5 gms/lit 
         Distilled water  -  1000 ml 
         PH   -  7.6 
Procedure: 
The method of antibacterial activity study is UPS Diffusion Method. 
Antibiotic discs are prepared with known concentration of antibiotic are placed on 
agar plates that has been inoculated with the known pathogenic micro organism. The 
antibiotic diffuses through the agar producing an antibiotic concentration, gradient 
antimicrobial susceptibility is proportional to the diameter of the inhibitory zone 
around the disc. If the microorganism which grows up to the edge of the disc are 
resistant to the antimicrobial agent. The recommended medium in this method is 
Muller Hinton Agar, its PH should be between 7.2-7.6 and should be poured to 
uniform thickness of 4mm in the petri plate (25ml). 
Methodology: 
Muller Hinton Agar plates are prepared and Pseudomonas, Staphylococcus, 
Candida, Escherichia coli, Streptococcus is inoculated separately. 
The prepared disc of Rasa karpoora kuligai are placed over the incubated plate using 
sterile forceps and incubated for 24 hours at 37 degree celcius. The plates after 24 
hours incubation are observed for the zone of inhibition. 
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6. RESULTS AND DISCUSSION 
Many studies have been carried out to bring the efficacy and potency of the 
drug Rasa karpoora kuligai. The study includes literary collections, organoleptic 
character, physicochemical and instrumental analysis, pharmacological studies, and 
toxicological study. The drug Rasa karpoora kuligai has been selected for    Anti-
Cancer, Anti-oxidant, Anti-inflammatory activity in reference with the text 
“GUNAPADAM THATHU JEEVAM”. 
 Literature collections about the drug from various text books were done. Siddha 
literatures related to the drug bring the evidence and importance of its utility in 
treating the cancer.  
 Botanical aspect explains the identification, description, active principle and 
medicinal uses of the plants.  
 Gunapadam review brings the effectiveness of the drug in treating cancer. 
 Pharmaceutical review describes about the kuligai and its properties.  
 The pharmacological review explains about the methodology of Anti-cancer, Anti-
oxidant, Anti-inflammatory activity and the drugs used.  
 Modern and siddha aspect of the disease was also reviewed. 
STANDARDISATION OF THE TEST DRUG 
Standardisation of the drug is more essential to derive the efficacy and potency 
of the drug, which was analysed by the various methods.  The results of 
physicochemical and biochemical analysis have been done and tabulated. 
Pharmacological activity and toxicological results of the drug were derived. The result 
reveals the effectiveness of the trial drug Rasa karpoora kuligai has been proved by 
the following scientific parameters. 
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Table -13.ORGANOLEPTIC CHARACTER 
The following characters have been noted in Rasa karpoora kuligai. 
Table -5. Organoleptic characters 
Colour in day light  Brown 
Smell Pleasant odour  
Taste Bitter, L.Pungent 
Appearance Round 
Touch Hard 
 
Table – 14.Physicochemical properties 
Table 
S.NO 
 
Parameter 
 
Result 
Loss on drying  4.4 % 
Ash content 7.3% 
Acid insoluble ash 2.4% 
Water sol.matter 34.7% 
Alcohol sol.matter 21.1% 
Microbial contamination 
Total bacterial count 
Total fungal count 
 
1.2×104col/g 
2.1×102col/g 
Test for specific Pathogen 
E.coli 
Salamonella spp. 
S.aureus 
Pseudomonas aeruginosa 
 
 
Nil 
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INTERPRETATION: 
Total Ash: Total ash value of plant material indicated the amount of minerals and 
earthy materials present in the plant material. The total inorganic content (ammonium, 
potassium, calcium, chloride, iron, etc.,) present in the drug is measured through the 
Total ash value and it is of 7.3 % for DDC. 
Acid insoluble ash: The acid insoluble ash value of the drug denotes the amount of 
siliceous matter present in the plant. The quality of the drug is better if the acid 
insoluble value is low. It is 2.4% for DDC. 
Water soluble ash: Water-soluble ash is the part of the total ash content, which is 
soluble in water. It is 34.7% for DDC 
Alcohol soluble ash: Alcohol-soluble ash is the part of the total ash content, which is 
soluble in alcohol. It is 21.1% for DDC 
 These are indicating the approximate measure of chemical constituents of crude drug. 
 The percentage of soluble matters present in the drug is determined by the values of 
water extractive and ethanol extractive.  
 Based on the extractive value suitable solvent can be selected. It also gives the 
percentage of drug which will correlate with the metabolism reactions. 
 Water-soluble extractive value plays an important role in evaluation of crude drugs 
 The alcohol-soluble extractive value was also indicative for the same purpose as the 
water-soluble extractive value 
Loss on drying: 
 The total of volatile content and moisture present in the drug was established in loss 
on drying.  
 Moisture content of the drug reveals the stability and its shelf-life.  
 High moisture content can adversely affect the active ingredient of the drug.  
 Thus low moisture content could get maximum stability and better shelf life. 
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THIN LAYER CHROMATOGRAPHY 
Under UV 254 nm and 366 nm 
  
                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 
INTERPRETATION: 
  Under UV 254 nm and 366 nm test related to alkaloids, it shows major spots 
short at Rf 0.86 (violet), 0.86 (blue). 2 major compounds are found. 
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BIO CHEMICAL ANALYSIS: 
Table 7-Result of basic and acidic radical’s studies: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the basic and acidic radical studies of presents the following chemicals. 
 Calcium 
 sulphate 
 Chloride 
 Starch 
 Ferrous iron 
 phosphate 
 Unsaturated compound  
  
Parameter Result 
Test for Calcium Present 
Test for Sulphate Present 
Test for Chloride Present 
Test for carbonate Absent 
Test for Starch Present 
Test for Iron [Ferric] Absent 
Test for Iron [Ferrous]  Present 
Test for Phosphate Present 
Test for Albumin Absent 
Test for  Tannic acid Absent 
Test for  Unsaturation Present 
Test for the Reducing sugar Absent 
Test for Amino acid Absent 
Test for Zinc Absent 
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INTERPRETATION: 
1. Calcium            
Calcium is a major component of bones and teeth. It also is required for the 
clotting of blood to stop bleeding and for normal functioning of the nerves, muscles, 
and heart.Individuals who had a calcium intake of more than 700 mg per day had a 35 
percent to 45 percent reduced risk of cancer of the distal (lower) part of the colon. In a 
study that included more than 61,000 Swedish women, colorectal cancer risk was 
approximately 28 percent lower among individuals who had the highest calcium 
intakes (approximately 800–1000 mg per day).  High intakes of total calcium, dietary 
calcium, and supplemental calcium were associated with an approximately 20 percent 
lower risk of colorectal cancer 
2. Chloride : 
Chloride regulates the acid base balance of the body fluids, by maintaining the 
osmotic pressure of the body fluids. In severe diarrhoea vomiting, large amount of 
water and electrolytes are lost from body. The dehydraction has to be treated by 
administering water and these electrolytes. 
3. Ferrous Iron : 
Iron is easily soluble and readily absorbed from intestine and involved  
4. Starch:  
Starches functions much like dietary fibre. They provide nutrition for the beneficial 
bacteria in the colon, keeping them thriving and health.  Dietary fibre in starch 
reduces effects of haemorrhoids, diverticulosis & controls blood pressure. 
5. Reducing sugar: 
Reducing sugars can react with other parts of the food like aminoacids to change 
colour and taste of the food. 
Reducing sugars like Glucose is essential for brain function and physical 
energy 
6.Phosphate. 
Carcinoma of prostate (CaP), the most common malignancy in men, is also the 
second most common cause of cancer deaths in men.Phosphate reduce the risk for the 
development of prostatic diseases, both benign prostatic hyperplasia and Ca. 
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INSTRUMENTAL ANALYSIS 
ICP-OES (Inductively Coupled Plasma Optical Emission Spectroscopy): 
The drug (Rasa karpoora kuligai) sample was analysed by the Inductively 
Coupled Plasma Optical Emission Spectroscopy (ICP-OES) to detect the trace 
elements and other elements quantitatively. The result of ICP-OES is given on the 
Table. 
Table – 15.ICP-OES of Rasa karpoora kuligai 
S. no Elements Wavelength (nm) Concentration 
1. Al 396.152 BDL 
2. As 188.979 BDL 
3. Ca 315.807 11.160 mg/L 
4. Cd 228.802 BDL 
5. Cu 327.393 BDL 
6. Fe 238.204 BDL 
7. Hg 253.652 BDL 
8. K 766.491 13.801 mg/L 
9. Mg 285.213 BDL 
10. Na 589.592 14.310 mg/L 
11. Ni 231.604 BDL 
12. Pb 220.353 BDL 
13. P 213.617 86.321 mg/L 
14. S 180.731 BDL 
15 Zn 206.200 01.058 mg/L 
 
BDL:Below Detectable Limit 
1% = 10000ppm, 
1ppm = 1/1000000 or 1ppm = 0.0001% 
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Table : 16 The toxic metals and the permissible limits 
Heavy metals  WHO & FDA limits 
Arsenic (As) 10ppm 
Mercury (Hg)  1ppm 
Lead (Pb) 10ppm 
Cadmium (Cd) 0.3ppm 
 
INTERPRETATION: 
 Optical Emission spectrometry is based on the principle that atoms or ions in an 
excited state tend, to revert back to the ground state and in so doing emit characteristic 
wavelength and intensity of that light is proportional to the concentration of that 
particular element in the sample solution. 
 This technique is used for quantitative and qualitative determination of the metals and 
mettaloids, in the biological preparation. 
 The main ingredient of the drug is Mercuric II chloride, but the final product shows 
below detection limit of the Mercury. This results shows Below detection limit(BDL) 
of As(arsenic),Hg(Mercury), Cd (Cadmium), Pb(Lead),  Ni(Nickel), Al(Aluminium), 
Cu (Copper).It is evident that the effectiveness of siddha medicine has been proved by 
the modern scientific way. 
 This result indicates the presence of Calcium, Potassium, Sodium, Phosphorus, Zinc, 
Calcium is a major component of bones and teeth. It also is required for the 
clotting of blood to stop bleeding and for normal functioning of the nerves, muscles, 
and heart.Individuals who had a calcium intake of more than 700 mg per day had a 35 
percent to 45 percent reduced risk of cancer of the distal (lower) part of the colon. In a 
study that included more than 61,000 Swedish women, colorectal cancer risk was 
approximately 28 percent lower among individuals who had the highest calcium 
intakes (approximately 800–1000 mg per day).  High intakes of total calcium, dietary 
calcium, and supplemental calcium were associated with an approximately 20 percent 
lower risk of colorectal cancer  
Potassium is one of the major electrolytes that the body carefully controls for 
proper heart and neuromuscular activity. A high potassium blood level, or 
hyperkalemia, is seen in a variety of medical conditions, including cancer and cancer 
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treatment. Prompt recognition and treatment of hyperkalemia are important to avoid 
potentially life-threatening side effects. 
Sodium is one of the major electrolytes, carefully maintained within a narrow 
normal range and necessary for proper functioning of the body’s systems. Low 
sodium levels, or hyponatremia, occur in a wide variety of medical disorders 
including cancer. Low sodium levels can occur in patients whose cancers produce 
ADH-like hormones, from other cancer complications and different treatment side 
effects. Cancers such as small cell lung carcinoma, pancreatic cancer, lymphoma and 
certain brain tumors can cause due to low sodium level. 
Phosphate. Carcinoma of prostate (CaP), the most common malignancy in 
men, is also the second most common cause of cancer deaths in 
men.Phosphate reduce the risk for the development of prostatic diseases, both benign 
prostatic hyperplasia and Ca. 
Zinc is essential for growth. It has been used in traditional medicine for 
everything from healing wounds to preventing blood clots. 
 It can also help increase the blood flow. 
 It has anti-oxidant properties that protect the cells from damage. 
 It can produce healthy veins and arteries that enhance the blood circulation.  
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Fig : 3 FT IR SPECTROSCOPIC STUDIES OF RASA                  
KARPOORAKULIGAI
 
Graph of FTIR analysis-FI 
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INTERPRETATION 
 FTIR instrumental analysis was done. The test drug was identified to have 13 peaks. 
They are the functional groups present in the trial drug Rasa karpoora kuligai. 
 The above table shows the presence of alcohols,phenols,carboxylic acids,amines, 
aliphatic amines,  aromatic,alkyl halides groups which represents the peak value. 
 PHENOLS:  
Natural phenolic compounds play an important role in cancer prevention and 
treatment. Phenolic compounds from medicine  and dietary plants include phenolic 
acids, flavonoids, tannins, stilbenes, curcuminoids, coumarins, lignans, quinones, and 
others. Various bioactivities of phenolic compounds are responsible for their 
chemopreventive properties (e.g., antioxidant, anticarcinogenic, or antimutagenic and 
anti-inflammatory effects) and also contribute to their inducing apoptosis by arresting 
cell cycle, regulating carcinogen metabolism and ontogenesis expression, inhibiting 
DNA binding and cell adhesion, migration, proliferation or differentiation, and 
blocking signaling pathways 
 AMINES: 
 Acts as a neuro transmitter.Involved in protein synthesis.Amines play an 
important role in reducing abdominal pain, bloating. 
 ALKANES: 
They protect against bacteria and fungal infections. 
 ALCOHOLS: 
Has anti microbial action.Acts as a antiseptic agent. 
 ALDEHYDES: 
Aldehydes normally have Anti-microbial activities.They are readily absorbed  
by the  Gastro intestinal tract. 
 AROMATICS: 
Aromatics are good pain relievers.Has Anti-pyretic,Anti-inflammatory,Auto-
immune activities. 
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SCANNING ELECTRON MICROSCOPE (SEM) 
The above SEM studies of microscopic resolution of 1.00kx and examining 
surface area of 800x800µm2, showed objects of sizes ranging from 238nm to 506nm. 
The surface of the sample grains is uniformly arranged in agglomerates. They are 
micro particles ranging from 238nm, 506nm, 308nm, 341nm, 371nm.  
 
FIG-4.SEM-PICTURE 
 
 
 
SEM PICTURE 24,000 MAGNIFICATION. 
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Fig 4 : SEM PICTURE 40,000 MAGNIFICATION. 
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INTERPRETATION  
Scanning Electron Microscopy (SEM) is the best method to determine the size 
distribution of nanoparticles present in the sample. It has been used for this purpose of 
computer-assisted counting of nanoparticle images. SEM analysis of the 
Rasakarpoorakuligai shows that the uniform distribution of particles presents in the 
entire field. Most of the particles present in the sample is nano size and near nano 
size, average particle size is 4.64µm - 7.51µm.So, very minimal quantity of the 
medicine is enough to treat the disease. 
Siddhars were the great scientist in ancient times. They used nano technology 
for the preparation of Medicines. These Nano particles have beneficial properties that 
can be used to improve drug delivery system. Target cells take up these nano particles 
quickly because of their smaller size, lesser particles enhance the bio absorption and 
bio availability resulting better efficacy of the drug. Larger particles could not enter in 
to the target cell because of their size, resulting they cleared from the body. If a drug 
is cleared too quickly from the body, this could force a patient to use high dose, which 
leads to contraindication of the drugs. The Lesser particles from drug delivery system 
lower the volume of distribution and reduce the effect on non target tissue. In Siddha 
system of medicine adjuvant and detoxification (Purification) is also important factors 
for drug transport. 
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EVALUATION OF ACUTE TOXICITY OF RASA KARPOORA KULIGAI 
Effect of Acute Toxicity (14 Days) of RASA KARPOORA 
KULIGAI 
Table: Shows Physical and behavioral examinations. 
Table 18 Physical and behavioral examinations. 
Group no. Dose(mg/kg Observation 
sign 
No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table-19 Home cage activity 
Functional and 
Behavioural 
observation 
Observation 5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral closure Normal 3 3 3 3 3 
Approach response Normal 3 3 3 3 3 
Touch response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch response Normal 3 3 3 3 3 
 
 
 
 
129 
 
Table-20 Hand held observation 
Functional and 
Behavioral observation 
O
bs
er
va
tio
n 
Control 5  
mg/ kg  
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
1750 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
 n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral closure Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary reflex Normal 3 3 3 3 3 3 
Abdominal tone Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
 
Table-21 DOSE CONCENTRATION- 2000mg/kg 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness N - N - N - 
2 Grooming A - A - A - 
3 Touch response P - P - P - 
4 Torch response P - P - P - 
5 Pain response A - A - A - 
6 Tremors A Present A Present A Present 
7 Convulsion A Present A Present A Present 
8 Righting reflux A Present A Present A Present 
9 Gripping 
strength 
P - P - P - 
 
 
130 
 
 
Table-22 Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 1750(mg/kg) 0 of 3 
Group-VI 2000(mg/kg) 3 of 3 
 
RESULT:  
From acute toxicity study it was observed that the administration of RASA 
KARPOORA KULIGAI at a dose of 2000mg/kg, to a rats. Immediately after the 
administration the RASA KARPOORA KULIGAI at a dose of 2000mg/kg to 
develop hyperactivity, righting reflux, tremors and convulsion and death the RASA 
KARPOORA KULIGAI at a dose of 2000mg/kg to produce drug-related toxicity and 
mortality . From acute toxicity study it was observed that the administration of RASA 
KARPOORA KULIGAI at a dose of 1750 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 
RASA KARPOORA KULIGAI is 1750 mg/kg. 
 
10 Pinna reflux P - P - P - 
11 Corneal reflux P - P - P - 
12 Writhing A - A - A - 
13 Pupils N - N - N - 
14 Urination N - N - N - 
15 Salivation A - A - A - 
16 Skin colour N - N - N - 
17 Lacrimation A - A - A - 
18 Hyper activity A Present A present A Present 
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INTERPRETATION: 
RASA KARPOORA KULIGAI was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 1750 mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot study 
and literature review. All animals were observed daily once for any abnormal clinical 
signs. Weekly body weight and food consumption were recorded. No mortality was 
observed during the entire period of the study. Data obtained in this study indicated 
no significance physical and behavioural signs of any toxicity due to administration of 
RASA KARPOORA KULIGAI at the doses of 5mg/kg, 50mg/kg, 300mg/kg, 
1000mg/kg and 1750 mg/kg to rats.  At the 14th day, all animals were observed for 
functional and behavioral examination. In functional and behavioral examination, 
home cage activity, hand held activity were observed. Home cage activities like Body 
position, Respiration, Clonic involuntary movement, Tonic involuntary movement, 
Palpebral closure, Approach response, Touch response, Pinna reflex, Sound 
responses, Tail pinch response were observed. Handheld activities like Reactivity, 
Handling, Palpebral closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, 
abdominal tone, Limb tone were observed. Functional and behavioral examination 
was normal in all treated groups. Food consumption of all treated animals was found 
normal as compared to normal group. 
  
 
 
132 
 
SUB-ACUTE TOXICITY  RESULTS 
Table : 23 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF RASA 
KARPOORA KULIGAION BODY WEIGHT IN GRAM 
 
GROUP CONTROL RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
 400mg/kg 
RKK. HIGE 
DOSE 
600mg/kg 
0,DAY 126.667±1.42984 117.5±0.718795 98.3333±0.954521 95.8333±1.7966 
7th DAY 132.667±1.42984 123.5±0.921955 104±1.06458 101.667±1.72562 
14th DAY 138.5±1.40831 131±1.41421 110.167±1.27584 107.333±1.7062 
21st  DAY 144.5±1.40831 137±1.52753 116±1.18322 113±1.59165 
28th  DAY 150.333±1.52023 143.5±1.82117 121.667±1.22927 118.667±1.68655 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by 
one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group. 
Fig : 5 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF RASA 
Table : 24 KARPOORA KULIGAI 
ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
GROUP CONTROL 
RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. HIGE 
DOSE 
600mg/kg 
BRAIN 1.256±0.2052 1.232±0.1547 1.499±0.2023 1.159±0.2025 
HEART 0.8727±0.04385 0.8323±0.06207 0.738±0.03329 0.6877±0.02028 
LIVER 6.019±0.359 8.448±0.652 6.706±0.07517 5.779±0.338 
LUNGS 1.447±0.1242 0.9353±0.03152 1.671±0.1854 1.278±0.2453 
 
KIDNEY 
L 0.7613±0.03038 0.8533±0.06263 0.8533±0.05191 0.7467±0.02533 
R 0.7453±0.03374 0.8287±0.06534 0.721±0.01721 0.7333±0.02809 
TESTIS 3.095±0.1521 2.517±0.1654 3.295±0.08581 3.11±0.1176 
UTERUS 0.736±0.02501 0.9607±0.05447 0.985±0.03436 1.214±0.306 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated 
by one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Fig : 6 
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Tabel : 25 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF RASA 
KARPOORA KULIGAI ON HAEMATOLOGICAL PARAMETERS 
 
GROUP CONTROL RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDDLE 
DOSE 
400mg/kg 
RKK. HIGH 
DOSE 
600mg/kg 
RBC (X10^6/µL) 4.573±0.1139 5.39±0.3035 4.853±0.6894 5.8±0.3617 
 
WBC(X10^3/µL) 
 
12.5±1.531 
 
11.47±0.5783 
 
13±1.007 
 
11.43±0.3756 
 
 
HB (g/dl) 
 
10.5±0.5859 
 
13.2±0.8963 
 
11.83±1.683 
 
14.03±0.809 
 
 
PCV % 
 
32.2±1.833 
 
40.6±2.689 
 
36.17±4.725 
 
43.1±2.427 
 
 
POLYMORPHS (%) 
 
7.333±0.6667 
 
10±1 
 
8±3.055 
 
7±1.155 
 
 
LYMPHOCYTES (%) 
 
85.33±2.028 
 
81.33±1.856 
 
79.33±3.528 
 
85.67±2.963 
 
 
MONOCYTES (%) 
 
5±0.5774 
 
3±0.5774 
 
3.333±0.6667 
 
3.333±0.3333 
 
 
EOSINOPHILS (%) 
 
3.333±0.3333 
 
4.333±0.3333 
 
4.667±0.8819 
 
4.333±0.3333 
 
 
MCH (Pg) 
 
23.6±0.611 
 
24.93±0.4702 
 
24.83±0.6566 
 
25.77±0.3283 
 
 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by 
one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Table : 26 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF RASA 
KARPOORA KULIGAI ON BIOCHEMICAL PARAMETERS 
GROUP CONTROL RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. HIGH 
DOSE 
600mg/kg 
SGOT(units/min/liter/
mg protein) 97.2±6.835 116.1±11.08 98.37±10.16 91.5±3.523 
SGPT(units/min/liter/
mg protein) 44.77±8.151 90.73±17.71 45.3±5.852 48.6±6.012 
ALP 
(units/min/liter/mg 
protein) 
210.1±69.74 
 
175.9±11.87 
 
169.9±27.35 
 
186.6±24.95 
 
 
 
EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF RASA KARPOORA 
KULIGAI ON BIOCHEMICAL PARAMETERS 
GROUP CONTROL RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. 
HIGH 
DOSE 
600mg/kg 
TOTAL 
BILIRUBIN 
(mg/dl) 
1.303±0.2452 1.453±0.2822 0.8193±0.3371 0.99±0.194 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by 
one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Table : 26 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF RASA KARPOORA 
KULIGAI  ON BIOCHEMICAL  PARAMETERS 
 
GROUP CONTROL 
RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. HIGH 
DOSE 600mg/kg 
 
CREATININE (mg/dl) 
 
0.6133±0.03844 
 
0.58±0.08327 
 
0.4767±0.0441 
 
0.5867±0.02028 
 
 
URIC ACID (mg/dl) 
 
1.747±0.2761 
 
1.74±0.155 
 
2.06±0.6612 
 
1.983±0.2924 
 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by 
one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group.  
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Table : 27 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF RASA 
KARPOORA KULIGAI ON FOOD INTAKE IN GRAM 
GROUP CONTROL 
RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. HIGE 
DOSE 
600mg/kg 
1st DAY 42±4.53137 38±4.64758 54.6667±6.23253 40.6667±4.20053 
7th DAY 35.1667±4.13454 39±6.90411 44.5±3.30404 60.6667±7.82588 
14th DAY 42±4.14729 42.6667±5.92546 47±7.49667 47.3333±8.40106 
21st  DAY 52±5.83095 41.1667±6.5341 42.6667±9.04311 34.6667±5.71936 
28th  DAY 50.5±4.62421 47.3333±6.27517 37.3333±5.3831 42.1667±6.42089 
 
              Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated 
by one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
Table : 28 Effect of Sub- Acute Dose (28 Days) Of RASA KARPOORA 
KULIGAI On Water Intake in ml 
GROUP CONTROL RKK. LOW 
DOSE 
200mg/kg 
RKK.MIDLE 
DOSE 
400mg/kg 
RKK. HIGE 
DOSE 
600mg/kg 
1st DAY 98.3333±13.5195 89.1667±14.3421 102.5±21.6699 67.5±7.6103 
7th DAY 82.5±11.7438 100.833±12.6765 76.6667±9.80363 81.6667±14.4145 
14th DAY 58.3333±8.72417 90.8333±14.2838 80±13.9642 89.1667±8.88976 
21st  DAY 91.6667±12.4944 80±8.46562 65.8333±9.43545 89.1667±8.79552 
28th  DAY 82.5±11.3835 88.3333±11.4504 75±8.85061 65±7.52773 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated 
by one way ANOVA followed by dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
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Fig : 9 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF RASA KARPOORA 
KULIGAI  
ON FOOD INTAKE IN GRAM. 
 
 
 
Fig : 9  Effect of Sub- Acute Dose (28 Days) Of RASA KARPOORA KULIGAI  
On Water Intake in ml 
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Table : 29 EFFECT OF SUB ACUTE DOSES (28 DAY) OF RASA 
KARPOORA KULIGAI 
ON ELECTROLYTES:- 
 
Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by 
one way ANOVA followed by dunnett’s (n=6); NS- non significant, *p<0.05, 
**p<0.01, ***p<0.001, calculated by comparing treated groupswith control group.  
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Fig : 11 
GROUP CONTROL RKK. LOW 
DOSE 200mg/kg 
RKK.MIDLE 
DOSE 400mg/kg 
RKK. HIGE 
DOSE 600mg/kg 
Sodium (mg/dl) 4.5±0.6455 4.25±0.6292 6±0.7071 6.75±0.75 
Calcium (mg/dl) 1.575±0.137689 3.15±0.170783*** 4.2±0.163299*** 6.175±0.19311*** 
Phosphorus (U/L) 0.273±0.022517 0.3005±0.019615ns 0.35625±0.030491ns 5.033±0.32452* 
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RESULTS: 
CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
Body weight: 
Results of body weight determination of animals Table-1 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (%of body weight) are recorded in Table 
No.4 Comparison of organ weights of treated animals with respective control animals 
on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 
revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; however, the increase 
or decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in 
Table 2 revealed the following significant changes in the values of hepatic serum 
enzymes studied. When compared with those of respective control. However, the 
increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison 
with control and treated animal. 
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INTERPRETATION 
1)  All the animals from control and all the treated dose groups up to 600 mg/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with 
control and treated animal. 
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Table : 30 PHARMACOLOGICAL STUDY RESULT 
CYTOTOXIC PROPERTIES OF RASA KARPOORA KULIGAI AGAINST 
HELA CELL LINE. 
Results: 
Table -------: Cytotoxic properties of Raskarpoorakuligai against HeLa cell line. 
Sl. No 
Name of  
Test sample 
Test Concn. 
( µg/ml) 
% Cytotoxicity 
CTC50 
( µg/ml) 
1 RKK 
62.5 
125 
250 
500 
1000 
 
6.32±1.3 
40.12±0.2 
66.84±1.0 
93.22±0.1 
94.02±0.2 
 
164.77±1.6 
 
FIG: 12 Graphical representation of cytotoxic effect of Raskarpoorakuligai on HeLa 
cell line 
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INTERPRETATION 
Apoptosis is considered a vital component of various processes including normal 
cell turn over, proper development and functioning of the immune system, hormone-
dependent atrophy, embryonic development and chemical-induced cell death. 
Inappropriate apoptosis (either too little or too much) is a factor in many human 
conditions including neurodegenerative diseases, ischemic damage, autoimmune 
disorders and many types of cancer. The ability to modulate the life or death of a cell is 
recognized for its immense therapeutic potential. 
Cytotoxicity activity: 
The cytotoxicity study was carried out for Herbomineral drug 
Raskarpoorakuligai. These extract was screened for its cytotoxicity against HeLa cell 
lines at different concentrations to determine the IC50 (50% growth inhibition) by MTT 
assay. Results are tabulated in Table --- and graphically represented in Fig. ---. The 
percentage growth inhibition was found to be increasing with different concentration of 
test compound.Rasakarpoorakuligai effect on HeLa cell line at the concentration 
increased from 62.5 to 1000µg/ml, percentage of inhibition increased from 6.32 % to 
94.02% and the IC50 value on HeLa cell line was 164.77µg/ml. Highest percentage of 
inhibition(94.02%)obtained at the concentration of 1000µg/ml. The results suggested that 
the Rasakarpoorakuligai inhibited the proliferation of human cervical cancer HeLa cells. 
Furtherstudies are needed to explore the intracellular mechanism. 
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RESULTS 
Table : 31 ANTIOXIDANT ACTIVITY OF RASA KARPOORA KULIGAI IN 
IN VITRO METHODS 
DPPH FREE RADICAL SCAVENGING ACTIVITY OF RASA KARPOORA 
KULIGAI 
Si.No Concentration 
Ascorbic acid (Standard) 
 
RKK 
Absorbance %  inhibition 
Absorbanc
e 
%  
inhibition 
1 10 1.626 18 % 0.994 50 % 
2 20 1.514 24 % 0.825 54 % 
3 40 1.492 25 % 0.778 56 % 
4 60 1.316 34 % 0.620 69 % 
5 80 1.214 39 % 0.585 71 % 
 
6 
100 0.988 50 % 0.438 78 % 
Ic 50 values  Ic50= 64.98  Ic50 =12.70 
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INTERPRETATION 
Antioxidants are slow down the oxidative damage of our body. Antioxidants 
act as a freeradical scavengers. Preventing and repairing damages. Health problems 
such as Heart diseases, cancer and degenerative disorders are all exacerbated by 
oxidative damage. TheAntioxidant activity of the drug RasakarpooraKuligai (RKK) 
was tested by DPPH assay. The results showed that there was a concentration 
dependent Antioxidant activity of crude extract of RasakarpooraKuligai (RKK). At 
the concentration increased from 10 to 100 μg/ml, percentage of inhibition increased 
from 50 % to 78 %. At a concentration of 100 μg/mlthere was an increased percentage 
of inhibition (78 %) in scavenging the free radicals  (DPPH). The IC50 value was 
obtained at 12.70 μg/ml.It showed that RasakarpooraKuligai (RKK) is having 
significant anti oxidant activity 
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Table : 32 FRAP RADICAL SCAVENGING ACTIVITY ON RASA 
KARPOORA KULIGAI 
TABLE NO: 
Si.No Concentration Ascorbic acid (Standard) 
 
RKK 
Absorbance %  inhibition Absorbance %  inhibition 
1 10 0.286 67 % 0.254 64 % 
2 20 0.354 59 % 0.343 51 % 
3 40 0.462 47 % 0.470 42 % 
4 60 0.566 35 % 0.588 39 % 
5 80 0.622 28 % 0.771 23 % 
 
6 
100 0.768 11 % 0.982 42 % 
Ic 50 values  Ic50= 26.97  Ic50 =23.45 
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Fig : 14 Percentage of inhibition at different concentration 
 
 
 
Percentage of inhibition at different concentration 
 
 
 
 
 
y = -11x + 79.66
R² = 0.989
y = -5.628x + 63.2
R² = 0.601
0
10
20
30
40
50
60
70
80
10 20 40 60 80 100
%
 in
hi
bi
tio
n
concentration (µg/ml)
FRAP radical scavenging activity
STD (Ascorbic acid)
RKK
0
10
20
30
40
50
60
70
80
10 20 40 60 80 100
%
 in
hi
bi
tio
n
concentration (µg/ml)
FRAP radical scavenging activity
STD (Ascorbic acid)
RKK
 
 
153 
 
INTERPRETATION 
 Many chronic diseases are associated with increased oxidative stress caused 
by an imbalance between free-radical production and the antioxidant level. 
Antioxidants, which are abundant in Siddha medicines, they are free-radical 
scavengers that either reduce the formation of or neutralize free radicals.  
The extracts were screened for their potential antioxidant activities using Ferric 
reducing antioxidant power (FRAP) The DPPH radical scavenging activities were 
well proved and correlated with the ferric reducing antioxidant capacity of the 
extracts. Interestingly, The Test drug showed the highest hydroxyl radical scavenging 
activity of 64% at concentration of 10μg/ml extract. The results showed that there was 
a concentration dependent Antioxidant activity of crude extract of 
RasakarpooraKuligai (RKK). At the concentration increased from 10 to 100 
μg/ml,percentage of inhibition increased from 42 % to 64 %. At a concentration of 10 
μg/mlthere was an increased percentage of inhibition in scavenging the free radicals  
(64%). The IC50 value was obtained at 23.75 μg/ml. It showed that 
RasakarpooraKuligai (RKK) is having significant FRAP radical scavenginganti 
oxidant activity. 
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TABLE No.33 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION RKK 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.20±0.96 - 
Group II 
   Std 
10mg/kg 
I.P.Diclofenac 
sodium 
1.70±0.40 67.30%*a 
Group III 
   RKK 
200mg/kg.Orally. 2.06±0.48 60.38%*a 
Group IV 
   RKK 
400mg/kg.Orally.  1.90±0.52 63.46%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
 
INTERPRETATION 
Anti- inflammatory activity 
Both doses of  siddha formulation RKK at 200mg/kg and 400mg/kg were tested for 
their Anti- inflammatory activity by using carrageenan Induced rat paw edema 
method and the results are tabulated in table no 1.  The results reveals that   both 
doses of siddha formulation at 200mg/kg and 400mg/kg doses possesses significant 
Anti- inflammatory activity when compared to control group at p<0.01. 
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ANTI – MICROBIAL ACTIVITY 
Table -34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No. Microorganisms Susceptibility Zone of Inhibition (mm) 
Control 100 µgm Sample 
1. Escherichia coli Sensitive 19 17 
2. Klebsiella pneumonia Moderately 
sensitive 14 13 
3. Staphylococcus aureus Sensitive 16 14 
4. Streptococcus mutans Moderately 
sensitive 12 12 
5. Pseudomonas.aerugina Moderately 
sensitive 16 9 
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INTERPRETATION: 
It was observed that anti microbial studies of  showed that it is sensitive Rasa 
karpoora kuligai  against Escherichia coli,Staphylococcus aureus and moderately 
sensitive against Streptococcus mutans,pseudomona  aerugina when compared to the 
standard drug (Amikacin) which was evident from the zone inhibition.The herbo 
mineral drug DDC showed inhibition of the growth of the micro organism at 
100mg/ml concentration for the organism.Our result confirmed the traditional use of 
RKK  has Anti microbial activity. 
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7.SUMMARY 
The test drug RASA KARPOORA KULIGAI is selected from the text, 
GUNAPADAM THATHU JEEVAM for the evaluation of safety, efficacy and 
therapeutic potency in CERVICAL CANCER (yoni putru). 
Aim of the dissertation is to rule out the anti cancer, anti-oxidant, anti-
inflammatory properties of the test drug Rasa karpoora kuligai by universal accepted 
scientific methods. 
The review of the literatures and lateral research reveals  pepper, garlic, betel 
leaf, mother milk  that, are having anti cancer, anti-oxidant, anti-inflammatory 
activities . 
The test drug was prepared properly by the given procedure all the ingredients 
were identified and authenticated by the experts  
             The preparation of trial drug was standardized primarily by physicochemical 
and biochemical analysis   
             The physicochemical analysis the drug shows brown in colour with pleasant 
odour and bitter mixed light pungent in taste. 
 As per the siddha literature diseases are caused due to changes in mukkutram, 
in cancer disease the kapam is affected; to treat kapha  the drug must be in suitable 
taste that lower the effect of kapam.  
             In physiochemical analysis the total Ash value of test drug is 7.3% which 
shows the total inorganic content (ammonium, potassium, calcium, chloride, iron) 
present in the drug. These contents are having important role in physiological 
functions of the body. 
              Biochemical analysis shows the presence of calcium, sulphate, chloride, 
starch, phosphate, ferrous iron these compounds are protect the body from the risk of  
cancer. 
              In instrumental analysis the ICP-OES result shows the  toxic heavy metals 
such as  As, Hg,  Cd, Pb, Al, Cu, Ni  are in Below Detection Limit(BDL)   . The main 
ingredient of the drug is mercuric II chloride, but the final product Rkk shows below 
detection limit of the mercury. It is evident that the effectiveness of  SUDDHI 
(purification) of  siddha medicine has been proved by the modern scientific way. 
                               The FTIR instrumental analysis shows the presence of phenols, alcohol, 
amines, aliphatic amines, carboxylic acids, aromatic and alkyl halides groups. From 
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these phenol compounds are responsible for the anti-oxidant activity of  the test drug 
and other remaining compounds are responsible for the  anti microbial and anti 
inflammatory activity.  
                                SEM analysis of the Rasa karpoora kuligai shows that the uniform 
distribution of particles presents in the entire field. Most of the particles present in the 
sample is nano size and near nano size, average particle size is 4.64µm - 7.51µm 
which increase the efficacy and bio availability of the test drug.  So, very minimal 
quantity of the medicine is enough to treat the disease.  
                The acute toxicity study shows that Rasa karpoora kuligai did not produce 
any toxic effect at dose of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 1750 mg/kg 
to rats.     So No-Observed-Adverse-Effect-Level (NOAEL) of Rasa karpoora kuligai 
is 1750 mg/kg  
                  In sub acute toxicity study test drug Rasa karpoora kuligai can be 
considered safe, as it did not cause either any lethality or adverse changes with 
general behaviour of rats and also there were no observable detrimental effects (200 
to 600 mg/kg body weight)over a period of 28 days. Our results have demonstrated 
that the Rasa karpoora kuligai  is relatively safe when administered orally in rats     
In the anti cancer study the  Cytotoxicty  properties of rasa karpoora kuligai against 
hela cell line the percentage growth inhibition was found to be increasing with 
different concentration of test compound.Rasakarpoorakuligai effect on HeLa cell 
line at the concentration increased from 62.5 to 1000µg/ml, percentage of inhibition 
increased from 6.32 % to 94.02% and the IC50 value on HeLa cell line was 
164.77µg/ml. Highest percentage of inhibition(94.02%)obtained at the concentration 
of 1000µg/ml. The results suggested that the Rasakarpoorakuligai significantly 
inhibited the proliferation of human cervical cancer HeLa cells.  
From the results of DPPH Assay, FRAP radical scavenging methods, it is 
found that displayed significant antioxidant activity which might be due to its 
chemical constituent.  This suggests that it is useful to prevent the oxidative stress 
induced damage seen in cancer .Thus it may act as prophylactic as well as curative 
drug in treating cancer.  
              In pharmacological study the anti inflammatory activity of Rasa karpoora 
kuligai results reveals that   both doses of  RKK at 200mg/kg and 400mg/kg doses 
possesses significant Anti- inflammatory activity when compared to control group. 
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               Antimicrobial studies show, antimicrobial activity against the E.coli, 
Pseudomonas aeruginesae, Klebisella pneumonia, streptococcus and stapylo coccus 
which compared to standard drug(Amikacin). The test drug inhibits the growth of the 
micro organisms effectively. This is mainly due to the phytochemical constituents 
present in the Rkk. 
                     It has been summarized that Rasa karpoora kuligai is very effective in 
treating cervical cancer(yoni putru) without causing any adverse effects. 
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8. CONCLUSION 
Management of cancer with a holistic approach, devoid of any side effects is 
now the major challenge to the medical system. This work highlights Rasa karpoora 
kuligai as novel anti cancer agent which provide a basis for the traditional use of it 
and proves that it could provide a cost effective and holistic remedy, without any side 
effects. From the literature review, physiochemical, pharmacological, 
microbiological, phytochemical, Instrumental analysis support the traditional use of 
Rasa karpoora kuligai in Siddha system of medicine for the treatment of cervical 
cancer ( yoni putru ). 
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9. FUTURE SCOPE 
Pre clinical evaluation of the drug Rasa karpoora kuligai has been done by 
physio chemical, biochemical, Instrumental, pharmacological, toxicological, 
antimicrobial procedures.In future,the drug has to be validated by further studies and 
should be used for patients. 
The active principle which is responsible for the activity of  Rasa karpoora 
kuligai  has to be find out, through modern scientific analysis.  Having made up of 
nano particles, holds extra promise for the treatment of cancer.   
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